

PI Aksenov M, Carney JM, Hensley K, Butterfield DA;  
XX  
DR WPI; 1999-034120/03.  
XX  
PT Process for treating synthetic amyloid beta peptides - by organic solvent  
PT treatment, useful for studying neurotoxicity.  
XX  
PS Claim 5; Col 9-10; 14pp; English.  
XX  
CC Sequences AAW81466 to AAW81476 represent synthetic amyloid beta (Abeta)  
CC peptides. The invention provides a process for treating a synthetic Abeta  
CC peptide that comprises dissolving the peptide in a deoxygenated solvent  
CC selected from trifluoroethanol, hexafluorocyclohexane, dimethyl  
CC sulphoxide, morpholinopropanesulphonic acid, dimethylformamide and  
CC acetonitrile to a concentration of 0.01-10 mg/ml, incubating the solution  
CC at 20-65 deg. C for 0.5-4 hour, and removing the solvent by "evaporative  
CC deposition" in 5-10 minutes. Synthetic amyloid beta peptides are useful  
CC as research tools for studying neurotoxicity resulting from Abeta peptide  
CC -enhanced free-radical production. The treatment increases the activity  
CC of the synthetic Abeta peptides in tests to determine free-radical  
CC generating capacity and glutamine synthetase inactivation  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 2; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 73  
AAB35591  
ID AAB35591 standard; peptide; 28 AA.  
XX  
AC AAB35591;  
XX  
DT 15-FEB-2001 (first entry)  
XX  
DE Human clone D1N B(1-28) amyloid B peptide.  
XX  
KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.  
XX  
OS Homo sapiens.  
XX  
PN US6136548-A.  
XX  
PD 24-OCT-2000.  
XX  
PF 02-SEP-1999; 99US-00388890.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.

XX  
PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.  
XX  
PI Anderson S;  
XX  
DR WPI; 2001-030939/04.  
XX  
PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving  
PT thrombolytic therapy or treating vascular hemorrhaging, by determining  
PT whether t-PA binds to fibrin but not to a beta amyloid peptide.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 74  
AAB35595  
ID AAB35595 standard; peptide; 28 AA.  
XX  
AC AAB35595;  
XX  
DT 15-FEB-2001 (first entry)  
XX  
DE Human clone D7Q B(1-28) amyloid B peptide.  
XX  
KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.  
XX  
OS Homo sapiens.  
XX  
PN US6136548-A.  
XX  
PD 24-OCT-2000.  
XX  
PF 02-SEP-1999; 99US-00388890.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.  
XX

PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.  
XX  
PI Anderson S;  
XX  
DR WPI; 2001-030939/04.  
XX  
PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving  
PT thrombolytic therapy or treating vascular hemorrhaging, by determining  
PT whether t-PA binds to fibrin but not to a beta amyloid peptide.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 75  
AAB35594  
ID AAB35594 standard; peptide; 28 AA.  
XX  
AC AAB35594;  
XX  
DT 15-FEB-2001 (first entry)  
XX  
DE Human clone H6Q B(1-28) amyloid B peptide.  
XX  
KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.  
XX  
OS Homo sapiens.  
XX  
PN US6136548-A.  
XX  
PD 24-OCT-2000.  
XX  
PF 02-SEP-1999; 99US-00388890.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.  
XX  
PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.

XX  
PI Anderson S;  
XX  
DR WPI; 2001-030939/04.  
XX  
PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving  
PT thrombolytic therapy or treating vascular hemorrhaging, by determining  
PT whether t-PA binds to fibrin but not to a beta amyloid peptide.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 76  
AAB35592  
ID AAB35592 standard; peptide; 28 AA.  
XX  
AC AAB35592;  
XX  
DT 15-FEB-2001 (first entry)  
XX  
DE Human clone E3Q B(1-28) amyloid B peptide.  
XX  
KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.  
XX  
OS Homo sapiens.  
XX  
PN US6136548-A.  
XX  
PD 24-OCT-2000.  
XX  
PF 02-SEP-1999; 99US-00388890.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.  
XX  
PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.  
XX

PI Anderson S;  
XX  
DR WPI; 2001-030939/04.  
XX  
PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving  
PT thrombolytic therapy or treating vascular hemorrhaging, by determining  
PT whether t-PA binds to fibrin but not to a beta amyloid peptide.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 77  
AAB35593  
ID AAB35593 standard; peptide; 28 AA.  
XX  
AC AAB35593;  
XX  
DT 15-FEB-2001 (first entry)  
XX  
DE Human clone R5Q B(1-28) amyloid B peptide.  
XX  
KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.  
XX  
OS Homo sapiens.  
XX  
PN US6136548-A.  
XX  
PD 24-OCT-2000.  
XX  
PF 02-SEP-1999; 99US-00388890.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.  
XX  
PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.  
XX  
PI Anderson S;

XX  
DR WPI; 2001-030939/04.  
XX  
PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving  
PT thrombolytic therapy or treating vascular hemorrhaging, by determining  
PT whether t-PA binds to fibrin but not to a beta amyloid peptide.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 78  
AAB35597  
ID AAB35597 standard; peptide; 28 AA.  
XX  
AC AAB35597;  
XX  
DT 15-FEB-2001 (first entry)  
XX  
DE Human clone H13Q B(1-28) amyloid B peptide.  
XX  
KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.  
XX  
OS Homo sapiens.  
XX  
PN US6136548-A.  
XX  
PD 24-OCT-2000.  
XX  
PF 02-SEP-1999; 99US-00388890.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.  
XX  
PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.  
XX  
PI Anderson S;  
XX

DR WPI; 2001-030939/04.  
XX  
PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving  
PT thrombolytic therapy or treating vascular hemorrhaging, by determining  
PT whether t-PA binds to fibrin but not to a beta amyloid peptide.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 79  
AAB35596  
ID AAB35596 standard; peptide; 28 AA.  
XX  
AC AAB35596;  
XX  
DT 15-FEB-2001 (first entry)  
XX  
DE Human clone E11Q B(1-28) amyloid B peptide.  
XX  
KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.  
XX  
OS Homo sapiens.  
XX  
PN US6136548-A.  
XX  
PD 24-OCT-2000.  
XX  
PF 02-SEP-1999; 99US-00388890.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.  
XX  
PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.  
XX  
PI Anderson S;  
XX  
DR WPI; 2001-030939/04.

XX  
PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving  
PT thrombolytic therapy or treating vascular hemorrhaging, by determining  
PT whether t-PA binds to fibrin but not to a beta amyloid peptide.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 80  
AAB35598  
ID AAB35598 standard; peptide; 28 AA.  
XX  
AC AAB35598;  
XX  
DT 15-FEB-2001 (first entry)  
XX  
DE Human clone H14Q B(1-28) amyloid B peptide.  
XX  
KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.  
XX  
OS Homo sapiens.  
XX  
PN US6136548-A.  
XX  
PD 24-OCT-2000.  
XX  
PF 02-SEP-1999; 99US-00388890.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.  
XX  
PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.  
XX  
PI Anderson S;  
XX  
DR WPI; 2001-030939/04.  
XX

PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving  
PT thrombolytic therapy or treating vascular hemorrhaging, by determining  
PT whether t-PA binds to fibrin but not to a beta amyloid peptide.

XX

PS Example 3; Col 26; 23pp; English.

XX

CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism

XX

SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 81

AAB36202

ID AAB36202 standard; peptide; 28 AA.

XX

AC AAB36202;

XX

DT 15-FEB-2001 (first entry)

XX

DE Human clone K28Q B(1-28) amyloid B peptide.

XX

KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.

XX

OS Homo sapiens.

XX

PN US6136548-A.

XX

PD 24-OCT-2000.

XX

PF 02-SEP-1999; 99US-00388890.

XX

PR 22-NOV-1994; 94US-00347144.

PR 22-NOV-1995; 95WO-US015007.

PR 26-JUL-1996; 96US-00686959.

XX

PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.

XX

PI Anderson S;

XX

DR WPI; 2001-030939/04.

XX

PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving

PT thrombolytic therapy or treating vascular hemorrhaging, by determining  
PT whether t-PA binds to fibrin but not to a beta amyloid peptide.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 82  
AAB35590  
ID AAB35590 standard; peptide; 28 AA.  
XX  
AC AAB35590;  
XX  
DT 15-FEB-2001 (first entry)  
XX  
DE Human clone B(1-28) amyloid B peptide.  
XX  
KW Beta-amyloid; amyloid deposit; Alzheimer's disease; thrombolytic therapy;  
KW acute cardiovascular disease; therapy.  
XX  
OS Homo sapiens.  
XX  
PN US6136548-A.  
XX  
PD 24-OCT-2000.  
XX  
PF 02-SEP-1999; 99US-00388890.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.  
XX  
PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.  
XX  
PI Anderson S;  
XX  
DR WPI; 2001-030939/04.  
XX  
PT Identifying mutant tissue-type plasminogen activator (t-PA) for improving  
PT thrombolytic therapy or treating vascular hemorrhaging, by determining

PT whether t-PA binds to fibrin but not to a beta amyloid peptide.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention describes a method for identifying mutant  
CC derivatives of tissue-type plasminogen activator, which involves  
CC determining whether or not they bind to beta-amyloid peptides and fibrin.  
CC Mutants will only bind to the latter. These mutants are useful in  
CC improved thrombolytic therapies, in the treatment of Alzheimer's disease  
CC and in the treatment of acute cardiovascular disease, which may be caused  
CC by myocardial infarction, stroke, ischaemia and pulmonary embolism  
XX  
SQ Sequence 28 AA;  
  
Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 83  
AAB91816  
ID AAB91816 standard; peptide; 28 AA.  
XX  
AC AAB91816;  
XX  
DT 22-JUN-2001 (first entry)  
XX  
DE Amyloid beta-protein fragment peptide SEQ ID NO:992.  
XX  
KW Protection; endogenous therapeutic peptide; peptidase; conjugation;  
KW blood component; modification; succinimidyl; maleimido group; amino;  
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200069900-A2.  
XX  
PD 23-NOV-2000.  
XX  
PF 17-MAY-2000; 2000WO-US013576.  
XX  
PR 17-MAY-1999; 99US-0134406P.  
PR 10-SEP-1999; 99US-0153406P.  
PR 15-OCT-1999; 99US-0159783P.  
XX  
PA (CONJ-) CONJUCHEM INC.  
XX  
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;  
XX  
DR WPI; 2001-112059/12.  
XX  
PT Modifying and attaching therapeutic peptides to albumin prevents

PT peptidase degradation, useful for increasing length of in vivo activity.  
XX  
PS Disclosure; Page 519; 733pp; English.  
XX  
CC The present invention describes a modified therapeutic peptide (I)  
CC comprising a therapeutically active amino acid region (III) and a  
CC reactive group (II) (e.g. succinimidyl and maleimido groups) attached to  
CC a less therapeutically active amino acid region (IV), which covalently  
CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.  
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth  
CC factors and neurotransmitters, to protect them from peptidase activity in  
CC vivo for the treatment of various disorders. Endogenous therapeutic  
CC peptides are not suitable as drug candidates as they require frequent  
CC administration due to rapid degradation by peptidases in the body.  
CC Modifying and attaching therapeutic peptides to albumin prevents or  
CC reduces the action of peptidases to increase length of activity (half  
CC life) and specificity as bonding to large molecules decreases  
CC intracellular uptake and interference with physiological processes.  
CC AAB90829 to AAB92441 represent peptides which can be used in the  
CC exemplification of the present invention  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
Db 16 KLVFFAED 23

RESULT 84  
AAB91789  
ID AAB91789 standard; peptide; 28 AA.

XX  
AC AAB91789;  
XX  
DT 22-JUN-2001 (first entry)  
XX  
DE Amyloid beta-protein fragment peptide SEQ ID NO:965.  
XX  
KW Protection; endogenous therapeutic peptide; peptidase; conjugation;  
KW blood component; modification; succinimidyl; maleimido group; amino;  
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.  
XX

OS Homo sapiens.  
OS Synthetic.

XX  
PN WO200069900-A2.

XX  
PD 23-NOV-2000.

XX  
PF 17-MAY-2000; 2000WO-US013576.  
XX

PR 17-MAY-1999; 99US-0134406P.

PR 10-SEP-1999; 99US-0153406P.  
PR 15-OCT-1999; 99US-0159783P.  
XX  
PA (CONJ-) CONJUCHEM INC.  
XX  
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;  
XX  
DR WPI; 2001-112059/12.  
XX  
PT Modifying and attaching therapeutic peptides to albumin prevents  
PT peptidase degradation, useful for increasing length of in vivo activity.  
XX  
PS Disclosure; Page 509; 733pp; English.  
XX  
CC The present invention describes a modified therapeutic peptide (I)  
CC comprising a therapeutically active amino acid region (III) and a  
CC reactive group (II) (e.g. succinimidyl and maleimido groups) attached to  
CC a less therapeutically active amino acid region (IV), which covalently  
CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.  
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth  
CC factors and neurotransmitters, to protect them from peptidase activity in  
CC vivo for the treatment of various disorders. Endogenous therapeutic  
CC peptides are not suitable as drug candidates as they require frequent  
CC administration due to rapid degradation by peptidases in the body.  
CC Modifying and attaching therapeutic peptides to albumin prevents or  
CC reduces the action of peptidases to increase length of activity (half  
CC life) and specificity as bonding to large molecules decreases  
CC intracellular uptake and interference with physiological processes.  
CC AAB90829 to AAB92441 represent peptides which can be used in the  
CC exemplification of the present invention  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 85  
AAB91827  
ID AAB91827 standard; peptide; 28 AA.  
XX  
AC AAB91827;  
XX  
DT 22-JUN-2001 (first entry)  
XX  
DE Amyloid beta-protein fragment peptide SEQ ID NO:1003.  
XX  
KW Protection; endogenous therapeutic peptide; peptidase; conjugation;  
KW blood component; modification; succinimidyl; maleimido group; amino;  
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.  
XX

OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200069900-A2.  
XX  
PD 23-NOV-2000.  
XX  
PF 17-MAY-2000; 2000WO-US013576.  
XX  
PR 17-MAY-1999; 99US-0134406P.  
PR 10-SEP-1999; 99US-0153406P.  
PR 15-OCT-1999; 99US-0159783P.  
XX  
PA (CONJ-) CONJUCHEM INC.  
XX  
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;  
XX  
DR WPI; 2001-112059/12.  
XX  
PT Modifying and attaching therapeutic peptides to albumin prevents  
PT peptidase degradation, useful for increasing length of in vivo activity.  
XX  
PS Disclosure; Page 523; 733pp; English.  
XX  
CC The present invention describes a modified therapeutic peptide (I)  
CC comprising a therapeutically active amino acid region (III) and a  
CC reactive group (II) (e.g. succinimidyl and maleimido groups) attached to  
CC a less therapeutically active amino acid region (IV), which covalently  
CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.  
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth  
CC factors and neurotransmitters, to protect them from peptidase activity in  
CC vivo for the treatment of various disorders. Endogenous therapeutic  
CC peptides are not suitable as drug candidates as they require frequent  
CC administration due to rapid degradation by peptidases in the body.  
CC Modifying and attaching therapeutic peptides to albumin prevents or  
CC reduces the action of peptidases to increase length of activity (half  
CC life) and specificity as bonding to large molecules decreases  
CC intracellular uptake and interference with physiological processes.  
CC AAB90829 to AAB92441 represent peptides which can be used in the  
CC exemplification of the present invention  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 86  
AAB91783  
ID AAB91783 standard; peptide; 28 AA.  
XX

AC AAB91783;  
XX  
DT 22-JUN-2001 (first entry)  
XX  
DE Amyloid beta-protein fragment peptide SEQ ID NO:959.  
XX  
KW Protection; endogenous therapeutic peptide; peptidase; conjugation;  
KW blood component; modification; succinimidyl; maleimido group; amino;  
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO200069900-A2.  
XX  
PD 23-NOV-2000.  
XX  
PF 17-MAY-2000; 2000WO-US013576.  
XX  
PR 17-MAY-1999; 99US-0134406P.  
PR 10-SEP-1999; 99US-0153406P.  
PR 15-OCT-1999; 99US-0159783P.  
XX  
PA (CONJ-) CONJUCHEM INC.  
XX  
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;  
XX  
DR WPI; 2001-112059/12.  
XX  
PT Modifying and attaching therapeutic peptides to albumin prevents  
PT peptidase degradation, useful for increasing length of in vivo activity.  
XX  
PS Disclosure; Page 507; 733pp; English.  
XX  
CC The present invention describes a modified therapeutic peptide (I)  
CC comprising a therapeutically active amino acid region (III) and a  
CC reactive group (II) (e.g. succinimidyl and maleimido groups) attached to  
CC a less therapeutically active amino acid region (IV), which covalently  
CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.  
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth  
CC factors and neurotransmitters, to protect them from peptidase activity in  
CC vivo for the treatment of various disorders. Endogenous therapeutic  
CC peptides are not suitable as drug candidates as they require frequent  
CC administration due to rapid degradation by peptidases in the body.  
CC Modifying and attaching therapeutic peptides to albumin prevents or  
CC reduces the action of peptidases to increase length of activity (half  
CC life) and specificity as bonding to large molecules decreases  
CC intracellular uptake and interference with physiological processes.  
CC AAB90829 to AAB92441 represent peptides which can be used in the  
CC exemplification of the present invention  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 87

AAB91800

ID AAB91800 standard; peptide; 28 AA.

XX

AC AAB91800;

XX

DT 22-JUN-2001 (first entry)

XX

DE Amyloid beta-protein fragment peptide SEQ ID NO:976.

XX

KW Protection; endogenous therapeutic peptide; peptidase; conjugation;  
KW blood component; modification; succinimidyl; maleimido group; amino;  
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.

XX

OS Homo sapiens.

OS Synthetic.

XX

PN WO200069900-A2.

XX

PD 23-NOV-2000.

XX

PF 17-MAY-2000; 2000WO-US013576.

XX

PR 17-MAY-1999; 99US-0134406P.

PR 10-SEP-1999; 99US-0153406P.

PR 15-OCT-1999; 99US-0159783P.

XX

PA (CONJ-) CONJUCHEM INC.

XX

PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;

XX

DR WPI; 2001-112059/12.

XX

PT Modifying and attaching therapeutic peptides to albumin prevents  
PT peptidase degradation, useful for increasing length of in vivo activity.

XX

PS Disclosure; Page 513; 733pp; English.

XX

CC The present invention describes a modified therapeutic peptide (I)  
CC comprising a therapeutically active amino acid region (III) and a  
CC reactive group (II) (e.g. succinimidyl and maleimido groups) attached to  
CC a less therapeutically active amino acid region (IV), which covalently  
CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.  
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth  
CC factors and neurotransmitters, to protect them from peptidase activity in  
CC vivo for the treatment of various disorders. Endogenous therapeutic  
CC peptides are not suitable as drug candidates as they require frequent  
CC administration due to rapid degradation by peptidases in the body.  
CC Modifying and attaching therapeutic peptides to albumin prevents or  
CC reduces the action of peptidases to increase length of activity (half

CC life) and specificity as bonding to large molecules decreases  
CC intracellular uptake and interference with physiological processes.  
CC AAB90829 to AAB92441 represent peptides which can be used in the  
CC exemplification of the present invention

XX

SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 88

AAB49396

ID AAB49396 standard; peptide; 28 AA.

XX

AC AAB49396;

XX

DT 06-MAR-2001 (first entry)

XX

DE Human amyloid peptide protein fragment SEQ ID NO: 11.

XX

KW Human; immunogenic peptide; immune response; monophosphoryl lipid A;  
KW antigen; infection; cancer; amyloid deposition.

XX

OS Homo sapiens.

XX

PN WO200069456-A2.

XX

PD 23-NOV-2000.

XX

PF 12-MAY-2000; 2000WO-US013156.

XX

PR 13-MAY-1999; 99US-0133963P.

XX

PA (AMCY ) AMERICAN CYANAMID CO.

XX

PI Hagen M;

XX

DR WPI; 2001-024946/03.

XX

PT Antigenic composition having an antigen (e.g. viral protein) and an  
PT adjuvant, useful for enhancing humoral and cellular immune response in a  
PT host or as a prophylaxis against virus, bacterium, parasite, cancer cell  
PT or allergen.

XX

PS Disclosure; Page 40; 129pp; English.

XX

CC The present invention provides an antigenic composition comprising an  
CC antigen with a 3-O-deacylated monophosphoryl lipid A or monophosphoryl  
CC lipid A adjuvant. The presence of the adjuvant causes an increased immune  
CC response. The antigen may be from a pathogenic bacterium, fungus, virus  
CC or parasite, a cancer cell, an allergen or from amyloid peptide protein.

CC The composition can be used in the prevention and treatment of infection,  
CC cancer and diseases caused by amyloid deposition. It is particularly  
CC useful against HIV, Neisseria gonorrhoeae and respiratory syncytial virus  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 89

AAE21439

ID AAE21439 standard; peptide; 28 AA.

XX

AC AAE21439;

XX

DT 16-JUL-2002 (first entry)

XX

DE Human beta-amyloid peptide #2.

XX

KW Recombinant polynucleotide; rPN; DNA-dependent RNA polymerase; human;

KW positive-strand RNA virus; psRNAV; recombinant protein synthesis;

KW cancer immunotherapy; subunit vaccine; gene therapy; A beta peptide;

KW beta-amyloid peptide.

XX

OS Homo sapiens.

XX

PN WO200218585-A2.

XX

PD 07-MAR-2002.

XX

PF 28-AUG-2001; 2001WO-US041888.

XX

PR 29-AUG-2000; 2000US-0228906P.

XX

PA (AMCY ) AMERICAN CYANAMID CO.

XX

PI Kovacs GR, Vasilakis N, Kowalski J, Zamb T, Gangolli SS;

XX

DR WPI; 2002-315540/35.

XX

PT New recombinant polynucleotides encoding positive-strand RNA virus

PT structural proteins useful for creating virus-based (e.g. poxvirus)

PT replicon particle packaging systems for use in recombinant protein

PT synthesis or gene therapy.

XX

PS Disclosure; Page 32; 99pp; English.

XX

CC The invention relates to recombinant polynucleotides (designated rPN)  
CC which comprise encoding a DNA-dependent RNA polymerase, positive-strand  
CC RNA virus (psRNAV) structural protein, and/or a replicon-like psRNAV  
CC helper RNA sequence and/or heterologous promoters operatively linked to

CC sequences encoding at least one foreign polypeptide, psRNAV capsid and/or  
CC psRNAV glycoprotein. The recombinant polynucleotides and vectors are  
CC useful for creating virus-based (e.g. poxvirus) replicon particle  
CC packaging systems. They are also particularly useful in subunit vaccine  
CC gene delivery, gene therapy, cancer immunotherapy and recombinant protein  
CC synthesis. The present sequence is human beta-amyloid peptide also  
CC referred to as A beta peptide which serves as fragment of foreign  
CC polypeptide of the invention

XX

SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 5; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 90

ABB76030

ID ABB76030 standard; peptide; 28 AA.

XX

AC ABB76030;

XX

DT 12-JUL-2002 (first entry)

XX

DE Beta amyloid peptide fragment.

XX

KW Beta amyloid; Alzheimer's disease; amyloidogenic disease; amyloidosis;  
KW human; mucin-binding protein; vaccine; gene therapy;  
KW Streptococcus pneumoniae.

XX

OS Homo sapiens.

XX

PN WO200228351-A2.

XX

PD 11-APR-2002.

XX

PF 04-OCT-2001; 2001WO-US031269.

XX

PR 04-OCT-2000; 2000US-0237888P.

PR 07-FEB-2001; 2001US-0267104P.

XX

PA (AMHP ) AMERICAN HOME PROD CORP.

PA (UYNY ) UNIV NEW YORK STATE RES FOUND.

XX

PI Green BA, Masi AW, Reddy MS;

XX

DR WPI; 2002-383318/41.

XX

PT Mucin binding proteins, useful in the induction of an immune response to,  
PT and in the diagnosis of, pneumococcal infections.

XX

PS Disclosure; Page 19; 71pp; English.

XX

CC The present sequence is a fragment of the human beta amyloid peptide (see  
CC also ABB76029), which is derived from amyloid peptide protein implicated  
CC in Alzheimer's disease, amyloidosis and amyloidogenic disease.  
CC Administration of the beta amyloid peptide induces an immune response  
CC against the beta amyloid component of an amyloid deposit. The beta  
CC amyloid may be linked to unrelated moieties, in the present case to the  
CC mucin-binding protein (see ABB76025 and ABB76026) of Streptococcus  
CC pneumoniae. Heterologous nucleotide sequences of the present invention  
CC may include the expression of beta amyloid peptide, or fragments of it,  
CC making use of the normal route of infection of pneumococcal bacteria.  
CC These enter the body through the respiratory tract to infect a variety of  
CC tissues and cells, including the meninges

XX

SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 5; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8

|||||||

Db 16 KLVFFAED 23

RESULT 91

AAO18476

ID AAO18476 standard; peptide; 28 AA.

XX

AC AAO18476;

XX

DT 11-OCT-2002 (first entry)

XX

DE Human beta-amyloid protein production inhibitor related peptide.

XX

KW Human; beta-amyloid; beta-AP; amyloid production inhibitor; nootropic;  
KW neuroprotective; intramolecular bridge; Alzheimer's disease;  
KW amyloidogenesis.

XX

OS Unidentified.

XX

PN WO200255552-A2.

XX

PD 18-JUL-2002.

XX

PF 21-DEC-2001; 2001WO-EP015181.

XX

PR 13-JAN-2001; 2001DE-01001430.

XX

PA (FRAU ) FRAUNHOFER GES FOERDERUNG ANGEWANDTEN.

XX

PI Kapurniotu A, Bernhagen J, Brunner H;

XX

DR WPI; 2002-575427/61.

XX

PT New cyclic peptide, useful for treatment, prevention and diagnosis of  
PT Alzheimer's disease, is an intramolecularly bridged forms of beta-  
PT amyloid.

XX  
PS Example 2; Fig 3; 44pp; German.  
XX  
CC The present invention relates to polypeptides capable of modulating  
CC amyloidogenesis, comprising beta-amyloid with at least one intramolecular  
CC bridge. These polypeptides can be used in the prevention and treatment of  
CC diseases associated with amyloid formation, particularly Alzheimer's  
CC disease. The present sequence is a peptide shownn in the exemplification  
CC of the invention  
XX  
SQ Sequence 28 AA;  
  
Query Match 100.0%; Score 40; DB 5; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23  
  
RESULT 92  
AAU76484  
ID AAU76484 standard; protein; 28 AA.  
XX  
AC AAU76484;  
XX  
DT 21-MAY-2002 (first entry)  
XX  
DE Amino acids 1-29 of human beta-amyloid peptide protein (APP).  
XX  
KW Influenza haemagglutinin A protein; vesicular stomatitis virus;  
KW G protein; VSV; antiviral; antibacterial; antifungal; antiparasitic;  
KW immunostimulant; virus-like particle; VLP; immunogenic; vaccine; APP;  
KW haemagglutinin; HA; neuraminidase; NA; beta-amyloid peptide protein.  
XX  
OS Homo sapiens.  
XX  
PN WO200200885-A2.  
XX  
PD 03-JAN-2002.  
XX  
PF 21-JUN-2001; 2001WO-US019890.  
XX  
PR 23-JUN-2000; 2000US-0213656P.  
PR 17-APR-2001; 2001US-0284411P.  
XX  
PA (AMCY ) AMERICAN CYANAMID CO.  
XX  
PI Galarza JM, Latham TE;  
XX  
DR WPI; 2002-205932/26.  
XX  
PT Production of influenza virus-like particles (VLPs) composed of one  
PT matrix protein (M1) and structural proteins of influenza, useful in  
PT immunogenic compositions against new influenza variants.  
XX

PS Disclosure; Page 35; 90pp; English.

XX

CC The invention relates to production of influenza virus-like particles (VLPs) composed of one matrix protein and further including structural proteins of influenza, comprising constructing one or more recombinant DNA encoding the matrix protein and one structural protein, and transfecting these into host cells which can then express the VLP. The VLPs produced can be used in immunogenic compositions against new influenza variants. The VLPs can also incorporate non-influenza peptides which can be used in immunogenic compositions against other pathogenic micro-organisms such as bacteria, fungi or parasites. The ability to replace surface glycoproteins with different sub-types of haemagglutinin (HA) and neuraminidase (NA) would permit the updating of formulations with new antigenic variants of these proteins. The present sequence represents amino acids 1-29 of human beta-amyloid peptide used as a non-influenza peptide in an immunogenic composition of the invention. Note: The patent specification obtained from the patent office had claim numbers 28 to 38 missing, but none of the pages were missing

XX

SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 5; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 93

ABB04910

ID ABB04910 standard; peptide; 28 AA.

XX

AC ABB04910;

XX

DT 14-MAR-2002 (first entry)

XX

DE Human amyloid beta protein (beta-A4) peptide 1-28 SEQ ID NO:1.

XX

KW Human; amyloid beta protein; beta-A4; memory enhancement; learning.

XX

OS Homo sapiens.

XX

PN US6320024-B1.

XX

PD 20-NOV-2001.

XX

PF 09-MAR-1999; 99US-00264709.

XX

PR 07-FEB-1997; 97US-00797782.

XX

PA (ROBE/) ROBERTS E.

XX

PI Roberts E;

XX

DR WPI; 2002-096566/13..

XX  
PT New peptide compound useful for design of substances that enhance memory.  
XX  
PS Disclosure; Col 1; 30pp; English.  
XX  
CC The present invention describes a novel peptide compound comprising Lys-His-Tyr-beta-alanine, which has a memory modulating effect. The peptide has nootropic activity. The peptide can be used for the development of topographic models useful to design and synthesise memory-enhancing and life-quality improving substances. The peptide compound restores the balance between excitatory and inhibitory systems in the brain, which is required for optimal acquisition and retention of learning and helps to correct defects in the balance that arise as a result of aging, infections and injury. The substances exert recyberneticising effects on nervous system function and has more prolonged desired effects at lower doses than the peptide structures. The substances mimic the action of active peptides without having a peptide structure and do not subject to degradation of peptide-splitting enzymes in the gut or other tissues. The present sequence represents a human amyloid beta protein (beta-A4) peptide, which is used in the exemplification of the present invention  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 5; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 94  
AAE26081  
ID AAE26081 standard; peptide; 28 AA.  
XX  
AC AAE26081;  
XX  
DT 14-NOV-2002 (first entry)  
XX  
DE Beta amyloid peptide.  
XX  
KW Antigenic composition; cancer; aminoalkyl glucosamine phosphate compound; AGP; immune response; cytotoxic T lymphocyte; allergic response; tumour; amyloid deposition; vaccine; antifungal; antibacterial; antiparasitic; cytostatic; immunostimulant; virucide; beta amyloid peptide.  
XX  
OS Unidentified.  
XX  
PN WO200238177-A2.  
XX  
PD 16-MAY-2002.  
XX  
PF 08-NOV-2001; 2001WO-US046943.  
XX  
PR 10-NOV-2000; 2000US-0247100P.  
PR 18-OCT-2001; 2001US-0330345P.

XX  
PA (AMCY ) AMERICAN CYANAMID CO.  
XX  
PI Hagen M;  
XX  
DR WPI; 2002-636409/68.  
XX  
PT Antigenic composition for use in enhancing immune response of antigen,  
PT has selected antigen, and combination of adjuvant comprising an  
PT aminoalkyl glucosamine phosphate compound, and cytokine or lymphokine.  
XX  
PS Disclosure; Page 19-20; 94pp; English.  
XX  
CC The invention relates to an antigenic composition comprising a selected  
CC antigen from a pathogenic virus, bacterium, fungus or parasite, or from a  
CC cancer or tumour cell, or from an allergen, or from a self molecule; and  
CC an combination of adjuvant comprising an aminoalkyl glucosamine phosphate  
CC compound (AGP), or its derivative or analogue, and a cytokine or  
CC lymphokine, or an agonist to it. The invention is useful for increasing  
CC the ability of an antigenic composition (enhancing immune response)  
CC containing a selected antigen from a pathogenic virus, bacterium, fungus  
CC or parasite to elicit an immune response especially cytotoxic T  
CC lymphocytes; a selected antigen a cancer or tumour cell to elicit  
CC therapeutic or prophylactic anti-cancer effect; a selected allergen to  
CC moderate an allergic response; or a selected antigen from a molecule or  
CC its portion representing those produced by a host in an undesired manner,  
CC amount or location so as to reduce an undesired effect, in a vertebrate  
CC host. The invention is useful for increasing the ability of an antigenic  
CC composition to prevent or treat disease characterised by amyloid  
CC deposition in a vertebrate host. The invention is useful as a vaccine.  
CC The present sequence is beta amyloid peptide  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 5; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 95  
AAM50910  
ID AAM50910 standard; protein; 28 AA.  
XX  
AC AAM50910;  
XX  
DT 07-MAY-2002 (first entry)  
XX  
DE Beta amyloid protein amino acid residues 1-28.  
XX  
KW Beta amyloid protein; beta/A4; amyloidosis; Alzheimer's disease;  
KW amyloid deposition; human; animal model.  
XX  
OS Homo sapiens.

XX  
PN US6340783-B1.  
XX  
PD 22-JAN-2002.  
XX  
PF 03-OCT-1996; 96US-00723661.  
XX  
PR 23-SEP-1992; 92US-00950417.  
PR 23-OCT-1992; 92US-00969734.  
PR 05-JUN-1995; 95US-00461216.  
XX  
PA (UNIW ) UNIV WASHINGTON.  
XX  
PI Snow AD;  
XX  
DR WPI; 2002-146857/19.  
XX  
PT Rodent models for studying amyloid deposition in Alzheimer's disease and  
PT for identifying candidate therapeutic agents.  
XX  
PS Disclosure; Col 67; 78pp; English.  
XX  
CC The present sequence is that of a protein comprising amino acids 1-28 of  
CC beta amyloid protein (or beta/A4). The invention provides a method for  
CC producing a rodent (especially rat) model of Alzheimer's disease, which  
CC involves infusing a proteoglycan and a beta-amyloid protein into the  
CC brain (preferably the hippocampus) of the rodent for a time sufficient to  
CC allow co-deposition, and detecting the amyloid deposit in the brain  
CC tissue using staining techniques (Congo Red or thioflavin S) for  
CC fibrillar amyloid. The beta amyloid protein is preferably comprised of 39  
CC -43 amino acids. The present peptide has the ability to self-aggregate  
CC and fold into a specific beta-pleated sheet. This can be observed using  
CC Congo Red staining. Inhibition of staining indicates that an inhibitor  
CC has altered the secondary structure of the amyloid protein. In an in vivo  
CC assay for selecting a candidate therapeutic for inhibiting fibrillar  
CC amyloid deposition/persistence in the brain, the candidate reagent is  
CC administered to a rodent in an infusate comprising beta/A4 peptide and  
CC perlecan by continuous infusion for at least 1 week into the hippocampus.  
CC The candidate reagent is selected as a candidate therapeutic for  
CC congophilic and fibrillar beta/A4 amyloid deposition in the brain if the  
CC infusate diminishes Congo Red and thioflavin S staining indicative of  
CC amyloid deposition adjacent to the infusion site as compared to a control  
CC rodent receiving an infusate not comprising the candidate reagent. The  
CC rodent model is used to study the process of amyloidosis that occurs in  
CC Alzheimer's disease, and to identify therapeutic agents (e.g. heparin,  
CC heparan sulfate glycosaminoglycans and related macromolecules and heparin  
CC binding peptides) that may be used for the treatment of Alzheimer's and  
CC other amyloidosis diseases  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 5; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||

RESULT 96  
ABB77991  
ID ABB77991 standard; peptide; 28 AA.  
XX  
AC ABB77991;  
XX  
DT 22-OCT-2002 (first entry)  
XX  
DE Fragment of beta-amyloid peptide of amyloid peptide protein (APP).  
XX  
KW Surface associated pneumoprotective protein; PPP; pneumococcal bacteria;  
KW immunity; otitis media; rhinosinusitis; bacteremia; meningitis;  
KW pneumonia; lower respiratory tract infection; amyloid peptide protein;  
KW APP.  
XX  
OS Homo sapiens.  
XX  
PN WO200253761-A2.  
XX  
PD 11-JUL-2002.  
XX  
PF 28-DEC-2001; 2001WO-US049650.  
XX  
PR 28-DEC-2000; 2000US-0258841P.  
XX  
PA (AMHP ) WYETH.  
XX  
PI Green BA, Masi AW;  
XX  
DR WPI; 2002-583625/62.  
XX  
PT Novel isolated 20 kDa Streptococcus pneumoniae surface associated  
PT pneumoprotective protein having ability to reduce colonization of  
PT pneumococcal bacteria, useful for eliciting immunity from otitis media,  
PT pneumonia.  
XX  
PS Disclosure; Page 27; 91pp; English.  
XX  
CC The present sequence represents a fragment of beta amyloid peptide of  
CC amyloid peptide protein (APP). This peptide may be co-expressed with a  
CC Streptococcus pneumoniae surface associated pneumoprotective protein  
CC (PPP), in the course of the invention. The PPP has a molecular weight of  
CC 20 kilo daltons (kDa), which is determined using a 10-20% sodium  
CC dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The PPP has  
CC the ability to reduce colonization of pneumococcal bacteria. The PPP is  
CC useful for screening for a compound which induces an immune response in a  
CC mammal infected with pneumococcal bacteria. It is also useful for  
CC diagnosing pneumococcal bacterial infection, and for eliciting protective  
CC immunity from a disease e.g., otitis media, rhinosinusitis, bacteremia,  
CC meningitis, pneumonia, or lower respiratory tract infection, caused by S.  
CC pneumoniae. The PPP nucleic acid sequences can be used for a variety of  
CC diagnostic applications. These nucleic acids sequences can be used to  
CC prepare relatively short DNA and RNA sequences that have the ability to  
CC specifically hybridize to the nucleic acid sequences encoding PPP

CC protein. The nucleic acids are also useful as probes and primers  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 5; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
Db 16 KLVFFAED 23

RESULT 97  
AAE35672  
ID AAE35672 standard; peptide; 28 AA.  
XX  
AC AAE35672;  
XX  
DT 17-JUN-2003 (first entry)  
XX  
DE Human beta amyloid peptide (residues 1-28).  
XX  
KW Immunogen; helper T cell; Th epitope; amyloid beta; Alzheimer's disease;  
KW Abeta; AD; brain tissue plaque; immunoneutralisation; neuroprotective;  
KW vaccine; nootropic; human.  
XX  
OS Homo sapiens.  
XX  
PN WO200296350-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 02-APR-2002; 2002WO-US010293.  
XX  
PR 25-MAY-2001; 2001US-00865294.  
XX  
PA (UNBI-) UNITED BIOMEDICAL INC.  
XX  
PI Wang CY;  
XX  
DR WPI; 2003-201258/19.  
XX  
PT Novel peptide immunogen comprising a helper T cell epitope, an N-terminal  
PT fragment of amyloid beta peptide linked to the epitope, and optionally a  
PT spacer, useful for preventing or treating Alzheimer's disease.  
XX  
PS Claim 6; Page 38; 77pp; English.  
XX  
CC The present invention relates to a novel peptide immunogen comprising a  
CC helper T cell (Th) epitope, an N-terminal fragment of amyloid beta  
CC (Abeta) peptide (residues 1-42) linked to the epitope and optionally a  
CC spacer consisting of at least an amino acid to separate the immunogenic  
CC domains. Sequences of the invention are useful for preventing or treating  
CC Alzheimer's disease (AD) in a mammal, to produce antibodies to Abeta  
CC peptide that is cross-reactive to soluble Abeta peptides and brain tissue  
CC plaques formed from it. They are useful for eliciting a site-directed

CC mutagenesis against the main functional/regulatory site of the Abeta peptide and for generating antibodies, which are highly cross-reactive to the soluble Abeta peptide and the amyloid plaques formed in the brain of Alzheimer's disease patients. The sequences are useful for induction of accelerated clearance of amyloid plaques and immunoneutralisation of the soluble Abeta derived toxins in the brain to prevent and treat Alzheimer's disease. They are also useful as vaccines. The present sequence is human beta amyloid peptide (residues 1-28) used in the exemplification of the invention

XX

SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 6; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 98

AAE33794

ID AAE33794 standard; peptide; 28 AA.

XX

AC AAE33794;

XX

DT 16-APR-2003 (first entry)

XX

DE Beta-amyloid precursor protein fragment.

XX

KW Immunogenic; cholera toxin; CT; toxicity; Alzheimer's disease; cancer; allergy; autoimmune disease; beta-amyloid precursor protein; therapy; amyloid deposition.

XX

OS Unidentified.

XX

PN WO200298369-A2.

XX

PD 12-DEC-2002.

XX

PF 05-JUN-2002; 2002WO-US021008.

XX

PR 07-JUN-2001; 2001US-0296531P.

XX

PA (AMCY ) AMERICAN CYANAMID CO.

PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.

XX

PI Green BA, Holmes RK, Jobling MG, Zhu D;

XX

DR WPI; 2003-140543/13.

XX

PT Novel immunogenic, mutant cholera holotoxin useful for enhancing immune response of vertebrate host to antigen, comprises amino sequence of subunit A of wild-type cholera toxin.

XX

PS Disclosure; Col 87; 44pp; English.

XX

CC The invention relates to an immunogenic, mutant cholera holotoxin (CT-  
CC CRM) comprising an amino sequence of subunit A of the wild-type cholera  
CC toxin (CT), where the mutant CT-CRM has reduced toxicity compared to the  
CC wild-type CT. Mutant CT-CRM is useful for prevention and/or treatment of  
CC diseases caused by pathogenic bacteria, fungus, virus or parasite or  
CC diseases such as allergy, autoimmune disease, Alzheimer's disease or  
CC cancer or diseases caused by amyloid deposition in a vertebrate host. The  
CC present sequence is beta-amyloid precursor protein fragment, used in the  
CC invention

XX

SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 6; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 16 KLVFFAED 23

RESULT 99

ABG72238

ID ABG72238 standard; peptide; 28 AA.

XX

AC ABG72238;

XX

DT 27-FEB-2003 (first entry)

XX

DE Mutant H6Q of human beta(1-28) peptide of amyloid beta peptide.

XX

KW Plasmin-mediated proteolysis; beta-amyloid peptide; brain cell;  
KW brain tissue; tissue plasminogen activator; t-PA; Alzheimer's disease;  
KW vascular haemorrhaging; thrombolytic therapy; neurological disorder;  
KW nerve cell; neuroprotective; nootropic; beta(1-28) peptide;  
KW amyloid beta peptide; mutant; mutein.

XX

OS Homo sapiens.

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Misc-difference 6

FT /note= "Substitution of wild-type His to Gln"

XX

PN US6471960-B1.

XX

PD 29-OCT-2002.

XX

PF 13-SEP-2000; 2000US-00660954.

XX

PR 22-NOV-1994; 94US-00347144.

PR 22-NOV-1995; 95WO-US015007.

PR 26-JUL-1996; 96US-00686959.

PR 02-SEP-1999; 99US-00388890.

XX

PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.

XX  
PI Anderson S;  
XX  
DR WPI; 2003-138240/13.  
XX  
PT Increasing plasmin-mediated proteolysis of beta-amyloid peptides in brain  
PT cells or tissues for treating Alzheimer's disease, by contacting the  
PT cells with tissue plasminogen activator to proteolyze the peptides.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention relates to a method for increasing plasmin-mediated  
CC proteolysis of beta-amyloid peptides in brain cells or tissues. The  
CC method comprises contacting brain cells or tissues with a purified tissue  
CC plasminogen activator (t-PA) so that beta-amyloid peptides in the brain  
CC cells or tissues are proteolysed. The method is useful for increasing  
CC plasmin-mediated proteolysis of beta-amyloid peptides in brain cells or  
CC tissues which are found in patients diagnosed with Alzheimer's disease.  
CC The method is useful for preventing or treating vascular haemorrhaging  
CC such as that incident to thrombolytic therapy, or characteristic of  
CC Alzheimer's disease and other neurological disorders. Administration of t  
CC -PA to nerve cells comprises a therapy for Alzheimer's disease. ABG72235-  
CC ABG72246 represent mutants of human beta(1-28) peptide of amyloid beta  
CC peptide  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 6; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 100  
ABG72246  
ID ABG72246 standard; peptide; 28 AA.  
XX  
AC ABG72246;  
XX  
DT 27-FEB-2003 (first entry)  
XX  
DE Mutant K28Q of human beta(1-28) peptide of amyloid beta peptide.  
XX  
KW Plasmin-mediated proteolysis; beta-amyloid peptide; brain cell;  
KW brain tissue; tissue plasminogen activator; t-PA; Alzheimer's disease;  
KW vascular haemorrhaging; thrombolytic therapy; neurological disorder;  
KW nerve cell; neuroprotective; nootropic; beta(1-28) peptide;  
KW amyloid beta peptide; mutant; mutein.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 28

FT /note= "Substitution of wild-type Lys to Gln"  
XX  
PN US6471960-B1.  
XX  
PD 29-OCT-2002.  
XX  
PF 13-SEP-2000; 2000US-00660954.  
XX  
PR 22-NOV-1994; 94US-00347144.  
PR 22-NOV-1995; 95WO-US015007.  
PR 26-JUL-1996; 96US-00686959.  
PR 02-SEP-1999; 99US-00388890.  
XX  
PA (RUTF ) UNIV RUTGERS STATE NEW JERSEY.  
XX  
PI Anderson S;  
XX  
DR WPI; 2003-138240/13.  
XX  
PT Increasing plasmin-mediated proteolysis of beta-amyloid peptides in brain  
PT cells or tissues for treating Alzheimer's disease, by contacting the  
PT cells with tissue plasminogen activator to proteolyze the peptides.  
XX  
PS Example 3; Col 26; 23pp; English.  
XX  
CC The present invention relates to a method for increasing plasmin-mediated  
CC proteolysis of beta-amyloid peptides in brain cells or tissues. The  
CC method comprises contacting brain cells or tissues with a purified tissue  
CC plasminogen activator (t-PA) so that beta-amyloid peptides in the brain  
CC cells or tissues are proteolysed. The method is useful for increasing  
CC plasmin-mediated proteolysis of beta-amyloid peptides in brain cells or  
CC tissues which are found in patients diagnosed with Alzheimer's disease.  
CC The method is useful for preventing or treating vascular haemorrhaging  
CC such as that incident to thrombolytic therapy, or characteristic of  
CC Alzheimer's disease and other neurological disorders. Administration of t  
CC -PA to nerve cells comprises a therapy for Alzheimer's disease. ABG72235-  
CC ABG72246 represent mutants of human beta(1-28) peptide of amyloid beta  
CC peptide  
XX  
SQ Sequence 28 AA;

Query Match 100.0%; Score 40; DB 6; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.12;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

Search completed: February 28, 2004, 08:51:58  
Job time : 119.5 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 28, 2004, 08:48:49 ; Search time 28.5 Seconds  
(without alignments)  
14.492 Million cell updates/sec

Title: US-09-668-314C-73  
Perfect score: 40  
Sequence: 1 KLVFFAED 8

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 1000 summaries

Database : Issued\_Patents\_AA:  
1: /cgn2\_6/ptodata/2/iaa/5A\_COMB.pep:  
2: /cgn2\_6/ptodata/2/iaa/5B\_COMB.pep:  
3: /cgn2\_6/ptodata/2/iaa/6A\_COMB.pep:  
4: /cgn2\_6/ptodata/2/iaa/6B\_COMB.pep:  
5: /cgn2\_6/ptodata/2/iaa/PCTUS\_COMB.pep:  
6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

%

Result	Query					Description
No.	Score	Match	Length	DB	ID	
1	40	100.0	8	2	US-08-630-645-1	Sequence 1, Appli
2	40	100.0	8	4	US-08-766-596A-1	Sequence 1, Appli
3	40	100.0	8	5	PCT-US96-10220-1	Sequence 1, Appli
4	40	100.0	9	4	US-08-766-596A-64	Sequence 64, Appli
5	40	100.0	10	3	US-08-970-833-3	Sequence 3, Appli
6	40	100.0	11	2	US-08-630-645-14	Sequence 14, Appli
7	40	100.0	11	4	US-08-766-596A-14	Sequence 14, Appli
8	40	100.0	11	5	PCT-US96-10220-14	Sequence 14, Appli
9	40	100.0	14	4	US-09-594-366-5	Sequence 5, Appli
10	40	100.0	15	2	US-08-612-785B-14	Sequence 14, Appli
11	40	100.0	15	2	US-08-612-785B-37	Sequence 37, Appli

12	40	100.0	15	4	US-08-617-267C-14	Sequence 14, Appl
13	40	100.0	15	4	US-08-766-596A-56	Sequence 56, Appl
14	40	100.0	15	4	US-08-766-596A-57	Sequence 57, Appl
15	40	100.0	15	4	US-08-766-596A-58	Sequence 58, Appl
16	40	100.0	15	4	US-08-766-596A-63	Sequence 63, Appl
17	40	100.0	15	4	US-08-766-596A-65	Sequence 65, Appl
18	40	100.0	17	4	US-09-264-709A-2	Sequence 2, Appli
19	40	100.0	17	4	US-09-594-366-3	Sequence 3, Appli
20	40	100.0	19	3	US-08-970-833-11	Sequence 11, Appl
21	40	100.0	20	3	US-08-970-833-10	Sequence 10, Appl
22	40	100.0	26	1	US-08-304-585-7	Sequence 7, Appli
23	40	100.0	28	1	US-08-346-849-4	Sequence 4, Appli
24	40	100.0	28	1	US-08-302-808-7	Sequence 7, Appli
25	40	100.0	28	2	US-08-609-090-2	Sequence 2, Appli
26	40	100.0	28	2	US-08-986-948-7	Sequence 7, Appli
27	40	100.0	28	2	US-08-293-284A-4	Sequence 4, Appli
28	40	100.0	28	2	US-08-461-216-2	Sequence 2, Appli
29	40	100.0	28	3	US-09-388-890-2	Sequence 2, Appli
30	40	100.0	28	3	US-09-388-890-3	Sequence 3, Appli
31	40	100.0	28	3	US-09-388-890-4	Sequence 4, Appli
32	40	100.0	28	3	US-09-388-890-5	Sequence 5, Appli
33	40	100.0	28	3	US-09-388-890-6	Sequence 6, Appli
34	40	100.0	28	3	US-09-388-890-7	Sequence 7, Appli
35	40	100.0	28	3	US-09-388-890-8	Sequence 8, Appli
36	40	100.0	28	3	US-09-388-890-9	Sequence 9, Appli
37	40	100.0	28	3	US-09-388-890-10	Sequence 10, Appl
38	40	100.0	28	3	US-09-388-890-14	Sequence 14, Appl
39	40	100.0	28	4	US-09-264-709A-1	Sequence 1, Appli
40	40	100.0	28	4	US-08-723-661B-2	Sequence 2, Appli
41	40	100.0	28	4	US-09-660-954-2	Sequence 2, Appli
42	40	100.0	28	4	US-09-660-954-3	Sequence 3, Appli
43	40	100.0	28	4	US-09-660-954-4	Sequence 4, Appli
44	40	100.0	28	4	US-09-660-954-5	Sequence 5, Appli
45	40	100.0	28	4	US-09-660-954-6	Sequence 6, Appli
46	40	100.0	28	4	US-09-660-954-7	Sequence 7, Appli
47	40	100.0	28	4	US-09-660-954-8	Sequence 8, Appli
48	40	100.0	28	4	US-09-660-954-9	Sequence 9, Appli
49	40	100.0	28	4	US-09-660-954-10	Sequence 10, Appl
50	40	100.0	28	4	US-09-660-954-14	Sequence 14, Appl
51	40	100.0	28	4	US-08-898-300-4	Sequence 4, Appli
52	40	100.0	30	2	US-08-609-090-3	Sequence 3, Appli
53	40	100.0	33	2	US-08-609-090-4	Sequence 4, Appli
54	40	100.0	34	2	US-08-475-579A-4	Sequence 4, Appli
55	40	100.0	35	1	US-08-304-585-6	Sequence 6, Appli
56	40	100.0	35	2	US-08-612-785B-16	Sequence 16, Appl
57	40	100.0	35	2	US-08-612-785B-36	Sequence 36, Appl
58	40	100.0	35	2	US-08-612-785B-38	Sequence 38, Appl
59	40	100.0	35	2	US-08-612-785B-40	Sequence 40, Appl
60	40	100.0	35	4	US-08-617-267C-16	Sequence 16, Appl
61	40	100.0	36	2	US-08-609-090-6	Sequence 6, Appli
62	40	100.0	38	1	US-08-302-808-1	Sequence 1, Appli
63	40	100.0	38	2	US-07-737-371E-68	Sequence 68, Appl
64	40	100.0	38	2	US-08-986-948-1	Sequence 1, Appli
65	40	100.0	39	1	US-08-304-585-5	Sequence 5, Appli
66	40	100.0	39	1	US-08-302-808-2	Sequence 2, Appli
67	40	100.0	39	2	US-08-609-090-7	Sequence 7, Appli
68	40	100.0	39	2	US-08-682-245A-1	Sequence 1, Appli

69	40	100.0	39	2	US-08-986-948-2	Sequence 2, Appli
70	40	100.0	40	1	US-07-744-767A-1	Sequence 1, Appli
71	40	100.0	40	1	US-08-235-400-2	Sequence 2, Appli
72	40	100.0	40	1	US-08-476-464A-2	Sequence 2, Appli
73	40	100.0	40	1	US-08-304-585-1	Sequence 1, Appli
74	40	100.0	40	1	US-08-302-808-3	Sequence 3, Appli
75	40	100.0	40	2	US-08-433-734-1	Sequence 1, Appli
76	40	100.0	40	2	US-08-609-090-8	Sequence 8, Appli
77	40	100.0	40	2	US-07-737-371E-69	Sequence 69, Appli
78	40	100.0	40	2	US-08-682-245A-2	Sequence 2, Appli
79	40	100.0	40	2	US-08-986-948-3	Sequence 3, Appli
80	40	100.0	40	2	US-08-461-216-1	Sequence 1, Appli
81	40	100.0	40	3	US-08-959-148-1	Sequence 1, Appli
82	40	100.0	40	4	US-09-242-724-22	Sequence 22, Appli
83	40	100.0	40	4	US-08-723-661B-1	Sequence 1, Appli
84	40	100.0	40	4	US-09-062-365-3	Sequence 3, Appli
85	40	100.0	40	4	US-09-133-866-1	Sequence 1, Appli
86	40	100.0	40	5	PCT-US92-06700-1	Sequence 1, Appli
87	40	100.0	41	1	US-08-302-808-4	Sequence 4, Appli
88	40	100.0	41	2	US-08-682-245A-3	Sequence 3, Appli
89	40	100.0	41	2	US-08-986-948-4	Sequence 4, Appli
90	40	100.0	42	1	US-07-744-767A-2	Sequence 2, Appli
91	40	100.0	42	1	US-08-179-574-1	Sequence 1, Appli
92	40	100.0	42	1	US-08-271-162-5	Sequence 5, Appli
93	40	100.0	42	1	US-08-347-144-1	Sequence 1, Appli
94	40	100.0	42	1	US-08-462-859A-19	Sequence 19, Appli
95	40	100.0	42	1	US-08-123-659A-19	Sequence 19, Appli
96	40	100.0	42	1	US-08-464-247A-19	Sequence 19, Appli
97	40	100.0	42	1	US-08-464-248A-19	Sequence 19, Appli
98	40	100.0	42	1	US-08-476-464A-1	Sequence 1, Appli
99	40	100.0	42	1	US-08-304-585-2	Sequence 2, Appli
100	40	100.0	42	1	US-08-302-808-5	Sequence 5, Appli
101	40	100.0	42	1	US-08-268-348A-1	Sequence 1, Appli
102	40	100.0	42	1	US-08-268-348A-2	Sequence 2, Appli
103	40	100.0	42	1	US-08-268-348A-3	Sequence 3, Appli
104	40	100.0	42	1	US-08-268-348A-4	Sequence 4, Appli
105	40	100.0	42	1	US-08-268-348A-5	Sequence 5, Appli
106	40	100.0	42	1	US-08-268-348A-6	Sequence 6, Appli
107	40	100.0	42	2	US-08-433-734-2	Sequence 2, Appli
108	40	100.0	42	2	US-08-609-090-9	Sequence 9, Appli
109	40	100.0	42	2	US-07-737-371E-72	Sequence 72, Appli
110	40	100.0	42	2	US-08-422-333-4	Sequence 4, Appli
111	40	100.0	42	2	US-08-682-245A-4	Sequence 4, Appli
112	40	100.0	42	2	US-08-986-948-5	Sequence 5, Appli
113	40	100.0	42	3	US-08-717-551A-2	Sequence 2, Appli
114	40	100.0	42	3	US-09-388-890-1	Sequence 1, Appli
115	40	100.0	42	3	US-09-005-215-20	Sequence 20, Appli
116	40	100.0	42	4	US-09-242-724-23	Sequence 23, Appli
117	40	100.0	42	4	US-08-922-930-2	Sequence 2, Appli
118	40	100.0	42	4	US-09-660-954-1	Sequence 1, Appli
119	40	100.0	42	4	US-08-923-055-2	Sequence 2, Appli
120	40	100.0	42	4	US-08-922-889-2	Sequence 2, Appli
121	40	100.0	42	4	US-09-731-460-1	Sequence 1, Appli
122	40	100.0	42	4	US-09-133-866-2	Sequence 2, Appli
123	40	100.0	42	5	PCT-US92-06700-2	Sequence 2, Appli
124	40	100.0	42	5	PCT-US93-00325-1	Sequence 1, Appli
125	40	100.0	42	5	PCT-US95-08302-5	Sequence 5, Appli

126	40	100.0	42	6	5220013-12	Patent No. 5220013
127	40	100.0	42	6	5220013-14	Patent No. 5220013
128	40	100.0	42	6	5223482-12	Patent No. 5223482
129	40	100.0	43	1	US-08-235-400-1	Sequence 1, Appli
130	40	100.0	43	1	US-08-437-067-1	Sequence 1, Appli
131	40	100.0	43	1	US-08-302-808-6	Sequence 6, Appli
132	40	100.0	43	1	US-08-079-511-1	Sequence 1, Appli
133	40	100.0	43	1	US-08-467-607-1	Sequence 1, Appli
134	40	100.0	43	2	US-08-404-831-1	Sequence 1, Appli
135	40	100.0	43	2	US-08-602-264A-3	Sequence 3, Appli
136	40	100.0	43	2	US-08-469-362-1	Sequence 1, Appli
137	40	100.0	43	2	US-08-612-785B-1	Sequence 1, Appli
138	40	100.0	43	2	US-08-475-579A-1	Sequence 1, Appli
139	40	100.0	43	2	US-08-850-392-1	Sequence 1, Appli
140	40	100.0	43	2	US-07-737-371E-70	Sequence 70, Appli
141	40	100.0	43	2	US-08-986-948-6	Sequence 6, Appli
142	40	100.0	43	2	US-08-975-977-1	Sequence 1, Appli
143	40	100.0	43	2	US-08-817-423-1	Sequence 1, Appli
144	40	100.0	43	2	US-08-920-162A-1	Sequence 1, Appli
145	40	100.0	43	3	US-08-461-018A-3	Sequence 3, Appli
146	40	100.0	43	3	US-08-976-191-1	Sequence 1, Appli
147	40	100.0	43	3	US-08-976-179-1	Sequence 1, Appli
148	40	100.0	43	3	US-09-216-958-3	Sequence 3, Appli
149	40	100.0	43	3	US-09-356-931-1	Sequence 1, Appli
150	40	100.0	43	3	US-08-733-202-1	Sequence 1, Appli
151	40	100.0	43	4	US-08-703-675C-1	Sequence 1, Appli
152	40	100.0	43	4	US-09-390-692-1	Sequence 1, Appli
153	40	100.0	43	4	US-08-617-267C-1	Sequence 1, Appli
154	40	100.0	43	4	US-09-303-655-1	Sequence 1, Appli
155	40	100.0	43	4	US-08-294-819-1	Sequence 1, Appli
156	40	100.0	43	4	US-09-408-283-1	Sequence 1, Appli
157	40	100.0	43	4	US-09-280-966-1	Sequence 1, Appli
158	40	100.0	43	4	US-09-032-019-1	Sequence 1, Appli
159	40	100.0	43	4	US-09-481-980A-1	Sequence 1, Appli
160	40	100.0	43	4	US-09-594-366-1	Sequence 1, Appli
161	40	100.0	43	4	US-08-665-649-1	Sequence 1, Appli
162	40	100.0	43	4	US-09-519-019A-1	Sequence 1, Appli
163	40	100.0	43	4	US-09-915-342-1	Sequence 1, Appli
164	40	100.0	43	4	US-08-996-422-1	Sequence 1, Appli
165	40	100.0	43	4	US-09-984-834-1	Sequence 1, Appli
166	40	100.0	43	4	US-09-027-258-2	Sequence 2, Appli
167	40	100.0	44	6	5223482-14	Patent No. 5223482
168	40	100.0	47	2	US-08-609-090-10	Sequence 10, Appli
169	40	100.0	48	4	US-09-560-883-1	Sequence 1, Appli
170	40	100.0	52	2	US-08-609-090-11	Sequence 11, Appli
171	40	100.0	53	3	US-09-173-887-5	Sequence 5, Appli
172	40	100.0	53	4	US-09-294-987-1	Sequence 1, Appli
173	40	100.0	53	4	US-09-797-543-5	Sequence 5, Appli
174	40	100.0	59	1	US-08-484-969-3	Sequence 3, Appli
175	40	100.0	59	1	US-08-472-627-3	Sequence 3, Appli
176	40	100.0	59	1	US-08-388-463-3	Sequence 3, Appli
177	40	100.0	63	1	US-08-462-859A-4	Sequence 4, Appli
178	40	100.0	63	1	US-08-123-659A-4	Sequence 4, Appli
179	40	100.0	63	1	US-08-464-247A-4	Sequence 4, Appli
180	40	100.0	63	1	US-08-464-248A-4	Sequence 4, Appli
181	40	100.0	67	4	US-09-027-258-1	Sequence 1, Appli
182	40	100.0	97	6	5187153-8	Patent No. 5187153

183	40	100.0	97	6	5220013-8	Patent No. 5220013
184	40	100.0	97	6	5223482-8	Patent No. 5223482
185	40	100.0	99	2	US-08-422-333-3	Sequence 3, Appli
186	40	100.0	99	3	US-08-339-708A-4	Sequence 4, Appli
187	40	100.0	99	3	US-08-339-708A-8	Sequence 8, Appli
188	40	100.0	100	6	5187153-10	Patent No. 5187153
189	40	100.0	100	6	5220013-10	Patent No. 5220013
190	40	100.0	100	6	5223482-10	Patent No. 5223482
191	40	100.0	103	2	US-08-404-831-2	Sequence 2, Appli
192	40	100.0	103	2	US-08-612-785B-2	Sequence 2, Appli
193	40	100.0	103	2	US-08-475-579A-2	Sequence 2, Appli
194	40	100.0	103	2	US-08-920-162A-2	Sequence 2, Appli
195	40	100.0	103	3	US-08-339-708A-10	Sequence 10, Appli
196	40	100.0	103	3	US-08-339-708A-12	Sequence 12, Appli
197	40	100.0	103	3	US-09-356-931-2	Sequence 2, Appli
198	40	100.0	103	4	US-08-703-675C-2	Sequence 2, Appli
199	40	100.0	103	4	US-08-617-267C-2	Sequence 2, Appli
200	40	100.0	103	4	US-09-519-019A-2	Sequence 2, Appli
201	40	100.0	105	2	US-08-729-345-1	Sequence 1, Appli
202	40	100.0	108	6	5187153-14	Patent No. 5187153
203	40	100.0	108	6	5220013-18	Patent No. 5220013
204	40	100.0	108	6	5223482-16	Patent No. 5223482
205	40	100.0	117	2	US-08-729-345-3	Sequence 3, Appli
206	40	100.0	117	4	US-09-422-569-10	Sequence 10, Appli
207	40	100.0	133	1	US-08-268-348A-8	Sequence 8, Appli
208	40	100.0	133	1	US-08-268-348A-10	Sequence 10, Appli
209	40	100.0	264	1	US-07-990-893-5	Sequence 5, Appli
210	40	100.0	487	1	US-08-462-859A-9	Sequence 9, Appli
211	40	100.0	487	1	US-08-123-659A-9	Sequence 9, Appli
212	40	100.0	487	1	US-08-464-247A-9	Sequence 9, Appli
213	40	100.0	487	1	US-08-464-248A-9	Sequence 9, Appli
214	40	100.0	492	1	US-08-462-859A-7	Sequence 7, Appli
215	40	100.0	492	1	US-08-123-659A-7	Sequence 7, Appli
216	40	100.0	492	1	US-08-464-247A-7	Sequence 7, Appli
217	40	100.0	492	1	US-08-464-248A-7	Sequence 7, Appli
218	40	100.0	506	2	US-08-659-984A-21	Sequence 21, Appli
219	40	100.0	506	3	US-08-660-531-21	Sequence 21, Appli
220	40	100.0	506	4	US-09-054-334-4	Sequence 4, Appli
221	40	100.0	537	1	US-08-453-552-4	Sequence 4, Appli
222	40	100.0	537	2	US-08-710-637-4	Sequence 4, Appli
223	40	100.0	537	5	PCT-US93-00907-4	Sequence 4, Appli
224	40	100.0	656	1	US-08-371-930-23	Sequence 23, Appli
225	40	100.0	656	5	PCT-US94-01712-23	Sequence 23, Appli
226	40	100.0	676	1	US-08-371-930-24	Sequence 24, Appli
227	40	100.0	676	5	PCT-US94-01712-24	Sequence 24, Appli
228	40	100.0	694	1	US-08-339-152A-18	Sequence 18, Appli
229	40	100.0	694	2	US-08-007-999B-5	Sequence 5, Appli
230	40	100.0	694	2	US-08-689-276A-5	Sequence 5, Appli
231	40	100.0	695	1	US-08-371-930-27	Sequence 27, Appli
232	40	100.0	695	1	US-08-123-702-2	Sequence 2, Appli
233	40	100.0	695	1	US-08-339-152A-30	Sequence 30, Appli
234	40	100.0	695	2	US-08-104-165-1	Sequence 1, Appli
235	40	100.0	695	3	US-08-464-250-1	Sequence 1, Appli
236	40	100.0	695	4	US-08-464-250-1	Sequence 1, Appli
237	40	100.0	695	4	US-09-458-481B-4	Sequence 4, Appli
238	40	100.0	695	4	US-09-458-481B-5	Sequence 5, Appli
239	40	100.0	695	4	US-09-458-481B-6	Sequence 6, Appli

240	40	100.0	695	4	US-09-458-481B-7	Sequence 7, Appli
241	40	100.0	695	4	US-09-458-481B-8	Sequence 8, Appli
242	40	100.0	695	4	US-09-548-372D-10	Sequence 10, Appli
243	40	100.0	695	4	US-09-548-372D-12	Sequence 12, Appli
244	40	100.0	695	4	US-09-548-372D-14	Sequence 14, Appli
245	40	100.0	695	4	US-09-548-367D-10	Sequence 10, Appli
246	40	100.0	695	4	US-09-548-367D-12	Sequence 12, Appli
247	40	100.0	695	4	US-09-548-367D-14	Sequence 14, Appli
248	40	100.0	695	4	US-09-551-853D-10	Sequence 10, Appli
249	40	100.0	695	4	US-09-551-853D-12	Sequence 12, Appli
250	40	100.0	695	4	US-09-551-853D-14	Sequence 14, Appli
251	40	100.0	695	4	US-09-415-099-6	Sequence 6, Appli
252	40	100.0	695	5	PCT-US94-01712-27	Sequence 27, Appli
253	40	100.0	695	6	5218100-2	Patent No. 5218100
254	40	100.0	697	4	US-09-548-372D-16	Sequence 16, Appli
255	40	100.0	697	4	US-09-548-372D-18	Sequence 18, Appli
256	40	100.0	697	4	US-09-548-372D-20	Sequence 20, Appli
257	40	100.0	697	4	US-09-548-367D-16	Sequence 16, Appli
258	40	100.0	697	4	US-09-548-367D-18	Sequence 18, Appli
259	40	100.0	697	4	US-09-548-367D-20	Sequence 20, Appli
260	40	100.0	697	4	US-09-551-853D-16	Sequence 16, Appli
261	40	100.0	697	4	US-09-551-853D-18	Sequence 18, Appli
262	40	100.0	697	4	US-09-551-853D-20	Sequence 20, Appli
263	40	100.0	751	1	US-08-123-702-4	Sequence 4, Appli
264	40	100.0	751	2	US-08-104-165-2	Sequence 2, Appli
265	40	100.0	751	2	US-08-422-333-2	Sequence 2, Appli
266	40	100.0	751	2	US-08-422-333-21	Sequence 21, Appli
267	40	100.0	751	3	US-08-464-250-2	Sequence 2, Appli
268	40	100.0	751	4	US-08-464-250-2	Sequence 2, Appli
269	40	100.0	751	4	US-08-832-867-5	Sequence 5, Appli
270	40	100.0	751	4	US-09-548-372D-57	Sequence 57, Appli
271	40	100.0	751	4	US-09-548-367D-57	Sequence 57, Appli
272	40	100.0	751	4	US-09-551-853D-57	Sequence 57, Appli
273	40	100.0	751	6	5187153-2	Patent No. 5187153
274	40	100.0	751	6	5220013-2	Patent No. 5220013
275	40	100.0	751	6	5223482-2	Patent No. 5223482
276	40	100.0	753	4	US-09-548-372D-61	Sequence 61, Appli
277	40	100.0	753	4	US-09-548-367D-61	Sequence 61, Appli
278	40	100.0	753	4	US-09-551-853D-61	Sequence 61, Appli
279	40	100.0	770	1	US-08-133-248-8	Sequence 8, Appli
280	40	100.0	770	1	US-08-231-940-1	Sequence 1, Appli
281	40	100.0	770	2	US-08-641-774-1	Sequence 1, Appli
282	40	100.0	770	2	US-08-104-165-3	Sequence 3, Appli
283	40	100.0	770	3	US-08-464-250-3	Sequence 3, Appli
284	40	100.0	770	4	US-08-464-250-3	Sequence 3, Appli
285	40	100.0	770	4	US-09-548-372D-55	Sequence 55, Appli
286	40	100.0	770	4	US-09-548-367D-55	Sequence 55, Appli
287	40	100.0	770	4	US-09-551-853D-55	Sequence 55, Appli
288	40	100.0	770	4	US-08-665-649-3	Sequence 3, Appli
289	40	100.0	772	4	US-09-548-372D-59	Sequence 59, Appli
290	40	100.0	772	4	US-09-548-367D-59	Sequence 59, Appli
291	40	100.0	772	4	US-09-551-853D-59	Sequence 59, Appli
292	40	100.0	1024	4	US-09-522-666-2	Sequence 2, Appli
293	37	92.5	28	3	US-09-388-890-12	Sequence 12, Appli
294	37	92.5	28	4	US-09-660-954-12	Sequence 12, Appli
295	37	92.5	28	6	5187153-28	Patent No. 5187153
296	37	92.5	40	1	US-08-304-585-8	Sequence 8, Appli

297	37	92.5	63	1	US-08-462-859A-3	Sequence 3, Appli
298	37	92.5	63	1	US-08-123-659A-3	Sequence 3, Appli
299	37	92.5	63	1	US-08-464-247A-3	Sequence 3, Appli
300	37	92.5	63	1	US-08-464-248A-3	Sequence 3, Appli
301	37	92.5	99	3	US-08-339-708A-6	Sequence 6, Appli
302	36	90.0	28	3	US-09-388-890-11	Sequence 11, Appli
303	36	90.0	28	4	US-09-660-954-11	Sequence 11, Appli
304	35	87.5	9	4	US-08-766-596A-54	Sequence 54, Appli
305	35	87.5	12	1	US-08-302-808-11	Sequence 11, Appli
306	35	87.5	12	2	US-08-986-948-11	Sequence 11, Appli
307	35	87.5	14	4	US-09-458-481B-13	Sequence 13, Appli
308	35	87.5	15	4	US-08-766-596A-59	Sequence 59, Appli
309	34	85.0	7	1	US-08-127-904-14	Sequence 14, Appli
310	34	85.0	7	4	US-09-264-709A-13	Sequence 13, Appli
311	34	85.0	7	5	PCT-US94-10475-14	Sequence 14, Appli
312	34	85.0	9	4	US-08-766-596A-51	Sequence 51, Appli
313	34	85.0	15	4	US-08-766-596A-60	Sequence 60, Appli
314	34	85.0	15	4	US-08-766-596A-61	Sequence 61, Appli
315	34	85.0	15	4	US-08-766-596A-62	Sequence 62, Appli
316	34	85.0	28	3	US-09-388-890-13	Sequence 13, Appli
317	34	85.0	28	4	US-09-660-954-13	Sequence 13, Appli
318	33	82.5	9	4	US-08-766-596A-50	Sequence 50, Appli
319	33	82.5	17	3	US-09-102-451-2	Sequence 2, Appli
320	33	82.5	43	3	US-08-339-141A-1	Sequence 1, Appli
321	33	82.5	43	5	PCT-US95-14659-1	Sequence 1, Appli
322	32	80.0	28	2	US-08-461-216-4	Sequence 4, Appli
323	31	77.5	7	4	US-09-747-408-18	Sequence 18, Appli
324	31	77.5	7	4	US-09-747-408-19	Sequence 19, Appli
325	31	77.5	8	3	US-08-970-833-4	Sequence 4, Appli
326	31	77.5	11	1	US-08-302-808-12	Sequence 12, Appli
327	31	77.5	11	2	US-08-986-948-12	Sequence 12, Appli
328	31	77.5	11	4	US-09-264-709A-3	Sequence 3, Appli
329	31	77.5	41	1	US-07-819-361-1	Sequence 1, Appli
330	31	77.5	49	1	US-08-123-702-45	Sequence 45, Appli
331	30	75.0	9	4	US-08-766-596A-52	Sequence 52, Appli
332	30	75.0	9	4	US-08-766-596A-53	Sequence 53, Appli
333	30	75.0	15	4	US-08-766-596A-55	Sequence 55, Appli
334	30	75.0	43	6	5187153-12	Patent No. 5187153
335	30	75.0	370	3	US-09-251-373-2	Sequence 2, Appli
336	30	75.0	370	4	US-09-622-439-4	Sequence 4, Appli
337	30	75.0	370	4	US-09-622-439-24	Sequence 24, Appli
338	30	75.0	533	4	US-09-508-370A-6	Sequence 6, Appli
339	30	75.0	659	4	US-09-252-991A-17731	Sequence 17731, A
340	30	75.0	1294	4	US-09-473-717-2	Sequence 2, Appli
341	30	75.0	1305	4	US-08-864-785-3	Sequence 3, Appli
342	30	75.0	1353	3	US-08-894-173-2	Sequence 2, Appli
343	30	75.0	1353	3	US-09-398-193-2	Sequence 2, Appli
344	30	75.0	1353	3	US-09-398-193-99	Sequence 99, Appli
345	30	75.0	1353	4	US-09-473-717-3	Sequence 3, Appli
346	29	72.5	6	2	US-08-612-785B-9	Sequence 9, Appli
347	29	72.5	6	2	US-08-612-785B-27	Sequence 27, Appli
348	29	72.5	6	4	US-08-703-675C-32	Sequence 32, Appli
349	29	72.5	6	4	US-08-703-675C-40	Sequence 40, Appli
350	29	72.5	6	4	US-08-617-267C-9	Sequence 9, Appli
351	29	72.5	6	4	US-08-617-267C-27	Sequence 27, Appli
352	29	72.5	6	4	US-09-747-408-3	Sequence 3, Appli
353	29	72.5	6	4	US-09-747-408-11	Sequence 11, Appli

354	29	72.5	7	2	US-08-612-785B-7	Sequence 7, Appli
355	29	72.5	7	4	US-08-703-675C-30	Sequence 30, Appli
356	29	72.5	7	4	US-08-617-267C-7	Sequence 7, Appli
357	29	72.5	7	4	US-09-747-408-2	Sequence 2, Appli
358	29	72.5	8	2	US-08-612-785B-5	Sequence 5, Appli
359	29	72.5	8	4	US-08-703-675C-28	Sequence 28, Appli
360	29	72.5	8	4	US-08-617-267C-5	Sequence 5, Appli
361	29	72.5	8	4	US-09-095-106A-44	Sequence 44, Appli
362	29	72.5	9	4	US-09-747-408-20	Sequence 20, Appli
363	29	72.5	300	4	US-09-543-681A-7926	Sequence 7926, Ap
364	29	72.5	352	4	US-09-205-815B-42	Sequence 42, Appli
365	29	72.5	539	1	US-08-464-340A-13	Sequence 13, Appli
366	29	72.5	858	4	US-09-275-252A-6	Sequence 6, Appli
367	28	70.0	25	2	US-08-930-605-20	Sequence 20, Appli
368	28	70.0	97	4	US-09-543-681A-4351	Sequence 4351, Ap
369	28	70.0	130	4	US-09-732-210-1623	Sequence 1623, Ap
370	28	70.0	149	4	US-09-585-173B-6	Sequence 6, Appli
371	28	70.0	169	4	US-09-540-236-2416	Sequence 2416, Ap
372	28	70.0	193	1	US-08-616-368A-9	Sequence 9, Appli
373	28	70.0	193	1	US-08-616-368A-10	Sequence 10, Appli
374	28	70.0	193	2	US-08-739-485-7	Sequence 7, Appli
375	28	70.0	193	3	US-09-054-298-9	Sequence 9, Appli
376	28	70.0	193	3	US-09-054-298-10	Sequence 10, Appli
377	28	70.0	193	3	US-08-818-655-9	Sequence 9, Appli
378	28	70.0	193	3	US-08-818-655-10	Sequence 10, Appli
379	28	70.0	193	4	US-09-305-839-9	Sequence 9, Appli
380	28	70.0	193	4	US-09-305-839-10	Sequence 10, Appli
381	28	70.0	232	4	US-09-489-039A-12731	Sequence 12731, A
382	28	70.0	244	4	US-09-328-352-7894	Sequence 7894, Ap
383	28	70.0	258	4	US-09-107-532A-6273	Sequence 6273, Ap
384	28	70.0	378	4	US-09-673-395A-618	Sequence 618, App
385	28	70.0	383	4	US-09-585-173B-8	Sequence 8, Appli
386	28	70.0	428	4	US-09-134-001C-5059	Sequence 5059, Ap
387	28	70.0	470	2	US-08-377-440A-1	Sequence 1, Appli
388	28	70.0	470	3	US-09-440-530-1	Sequence 1, Appli
389	28	70.0	728	4	US-09-508-824-10	Sequence 10, Appli
390	28	70.0	750	4	US-09-585-173B-12	Sequence 12, Appli
391	28	70.0	754	4	US-09-585-173B-51	Sequence 51, Appli
392	28	70.0	755	4	US-09-585-173B-4	Sequence 4, Appli
393	28	70.0	869	4	US-09-252-991A-22290	Sequence 22290, A
394	28	70.0	1037	4	US-09-543-681A-7677	Sequence 7677, Ap
395	28	70.0	3898	3	US-08-750-717-2	Sequence 2, Appli
396	27	67.5	6	4	US-09-747-408-1	Sequence 1, Appli
397	27	67.5	6	4	US-09-747-408-10	Sequence 10, Appli
398	27	67.5	7	3	US-08-970-833-5	Sequence 5, Appli
399	27	67.5	8	1	US-08-133-248-1	Sequence 1, Appli
400	27	67.5	108	4	US-09-107-532A-5688	Sequence 5688, Ap
401	27	67.5	186	4	US-09-134-000C-4177	Sequence 4177, Ap
402	27	67.5	231	4	US-09-489-039A-10800	Sequence 10800, A
403	27	67.5	258	3	US-09-053-197A-7	Sequence 7, Appli
404	27	67.5	258	4	US-09-085-761A-7	Sequence 7, Appli
405	27	67.5	262	4	US-09-489-039A-8063	Sequence 8063, Ap
406	27	67.5	267	4	US-09-134-001C-3936	Sequence 3936, Ap
407	27	67.5	294	4	US-09-252-991A-20737	Sequence 20737, A
408	27	67.5	304	4	US-09-198-452A-9	Sequence 9, Appli
409	27	67.5	309	4	US-09-345-473E-37	Sequence 37, Appli
410	27	67.5	310	2	US-08-695-355-4	Sequence 4, Appli

411	27	67.5	310	3	US-09-063-869-4	Sequence 4, Appli
412	27	67.5	335	4	US-09-134-000C-4450	Sequence 4450, Ap
413	27	67.5	424	4	US-09-252-991A-26486	Sequence 26486, A
414	27	67.5	505	4	US-09-489-039A-8637	Sequence 8637, Ap
415	27	67.5	517	4	US-09-328-352-6214	Sequence 6214, Ap
416	27	67.5	542	4	US-09-252-991A-25862	Sequence 25862, A
417	27	67.5	644	4	US-09-107-532A-7277	Sequence 7277, Ap
418	27	67.5	658	4	US-08-953-040-9	Sequence 9, Appli
419	27	67.5	770	1	US-08-445-135-2	Sequence 2, Appli
420	27	67.5	904	3	US-09-198-484-2	Sequence 2, Appli
421	27	67.5	915	4	US-09-907-794A-34	Sequence 34, Appli
422	27	67.5	915	4	US-09-905-125A-34	Sequence 34, Appli
423	27	67.5	915	4	US-09-902-775A-34	Sequence 34, Appli
424	27	67.5	930	4	US-08-953-040-2	Sequence 2, Appli
425	27	67.5	956	2	US-08-897-443-3	Sequence 3, Appli
426	27	67.5	1381	4	US-09-808-701A-25	Sequence 25, Appli
427	27	67.5	1713	3	US-08-600-982-24	Sequence 24, Appli
428	27	67.5	1713	5	PCT-US94-10261A-24	Sequence 24, Appli
429	26	65.0	6	4	US-09-747-408-9	Sequence 9, Appli
430	26	65.0	6	4	US-09-747-408-17	Sequence 17, Appli
431	26	65.0	25	3	US-09-059-369-4	Sequence 4, Appli
432	26	65.0	35	2	US-08-612-785B-15	Sequence 15, Appli
433	26	65.0	35	4	US-08-617-267C-15	Sequence 15, Appli
434	26	65.0	41	3	US-08-924-330A-6	Sequence 6, Appli
435	26	65.0	41	3	US-09-138-721-6	Sequence 6, Appli
436	26	65.0	43	2	US-08-404-831-3	Sequence 3, Appli
437	26	65.0	43	2	US-08-612-785B-3	Sequence 3, Appli
438	26	65.0	43	2	US-08-475-579A-3	Sequence 3, Appli
439	26	65.0	43	4	US-08-617-267C-3	Sequence 3, Appli
440	26	65.0	61	4	US-09-621-976-6803	Sequence 6803, Ap
441	26	65.0	84	4	US-09-134-001C-5031	Sequence 5031, Ap
442	26	65.0	103	4	US-09-732-210-1746	Sequence 1746, Ap
443	26	65.0	112	4	US-09-134-000C-5151	Sequence 5151, Ap
444	26	65.0	116	4	US-09-489-039A-7246	Sequence 7246, Ap
445	26	65.0	120	4	US-09-198-452A-1016	Sequence 1016, Ap
446	26	65.0	124	4	US-09-489-039A-12368	Sequence 12368, A
447	26	65.0	140	3	US-09-196-388-2	Sequence 2, Appli
448	26	65.0	176	4	US-09-134-000C-3485	Sequence 3485, Ap
449	26	65.0	189	1	US-08-233-788A-45	Sequence 45, Appli
450	26	65.0	193	2	US-08-765-536-1	Sequence 1, Appli
451	26	65.0	193	5	PCT-US95-08401-1	Sequence 1, Appli
452	26	65.0	197	2	US-08-756-387B-11	Sequence 11, Appli
453	26	65.0	197	3	US-08-788-954-2	Sequence 2, Appli
454	26	65.0	197	4	US-09-285-873-11	Sequence 11, Appli
455	26	65.0	197	4	US-09-816-095-5	Sequence 5, Appli
456	26	65.0	197	4	US-09-944-277A-11	Sequence 11, Appli
457	26	65.0	253	5	PCT-US96-01314-52	Sequence 52, Appli
458	26	65.0	255	4	US-09-328-352-5808	Sequence 5808, Ap
459	26	65.0	257	1	US-07-869-933-11	Sequence 11, Appli
460	26	65.0	257	2	US-08-756-387B-2	Sequence 2, Appli
461	26	65.0	257	3	US-09-103-663-11	Sequence 11, Appli
462	26	65.0	257	4	US-09-285-873-2	Sequence 2, Appli
463	26	65.0	257	4	US-08-897-956A-1	Sequence 1, Appli
464	26	65.0	257	4	US-09-944-277A-2	Sequence 2, Appli
465	26	65.0	291	4	US-10-083-624-2	Sequence 2, Appli
466	26	65.0	295	1	US-08-295-657-3	Sequence 3, Appli
467	26	65.0	323	4	US-09-816-095-2	Sequence 2, Appli

468	26	65.0	324	4	US-09-816-095-4	Sequence 4, Appli
469	26	65.0	334	4	US-09-205-258-348	Sequence 348, App
470	26	65.0	347	3	US-09-059-369-2	Sequence 2, Appli
471	26	65.0	357	4	US-09-107-532A-5132	Sequence 5132, Ap
472	26	65.0	367	4	US-09-491-577-62	Sequence 62, Appl
473	26	65.0	452	4	US-09-323-872A-15	Sequence 15, Appl
474	26	65.0	452	4	US-09-072-433-12	Sequence 12, Appl
475	26	65.0	469	4	US-09-328-352-5007	Sequence 5007, Ap
476	26	65.0	477	3	US-08-704-711A-20	Sequence 20, Appl
477	26	65.0	477	3	US-08-448-489-15	Sequence 15, Appl
478	26	65.0	477	3	US-08-281-313-1	Sequence 9, Appli
479	26	65.0	477	4	US-09-521-220-20	Sequence 20, Appl
480	26	65.0	477	4	US-09-391-104-21	Sequence 21, Appl
481	26	65.0	486	4	US-09-252-991A-16751	Sequence 16751, A
482	26	65.0	493	4	US-09-508-370A-7	Sequence 7, Appli
483	26	65.0	494	4	US-09-328-352-7729	Sequence 7729, Ap
484	26	65.0	506	4	US-09-328-352-5523	Sequence 5523, Ap
485	26	65.0	511	1	US-08-480-604A-20	Sequence 20, Appl
486	26	65.0	511	2	US-08-405-496A-20	Sequence 20, Appl
487	26	65.0	511	3	US-08-646-695-5	Sequence 5, Appli
488	26	65.0	511	3	US-08-915-136-20	Sequence 20, Appl
489	26	65.0	511	4	US-08-957-310-20	Sequence 20, Appl
490	26	65.0	511	4	US-09-217-967-1	Sequence 1, Appli
491	26	65.0	511	4	US-10-011-366-20	Sequence 20, Appl
492	26	65.0	511	4	US-09-084-517-20	Sequence 20, Appl
493	26	65.0	511	5	PCT-US96-06053-5	Sequence 5, Appli
494	26	65.0	512	3	US-09-149-922-2	Sequence 2, Appli
495	26	65.0	515	4	US-09-489-039A-11600	Sequence 11600, A
496	26	65.0	517	4	US-09-391-104-32	Sequence 32, Appl
497	26	65.0	519	3	US-09-211-704A-7	Sequence 7, Appli
498	26	65.0	579	3	US-08-704-711A-1	Sequence 1, Appli
499	26	65.0	579	4	US-09-521-220-1	Sequence 1, Appli
500	26	65.0	582	3	US-08-704-711A-2	Sequence 2, Appli
501	26	65.0	582	3	US-08-448-489-1	Sequence 1, Appli
502	26	65.0	582	3	US-09-211-704A-9	Sequence 9, Appli
503	26	65.0	582	4	US-09-521-220-2	Sequence 2, Appli
504	26	65.0	582	4	US-09-391-104-28	Sequence 28, Appl
505	26	65.0	608	1	US-08-480-604A-21	Sequence 21, Appl
506	26	65.0	608	2	US-08-405-496A-21	Sequence 21, Appl
507	26	65.0	608	3	US-08-915-136-21	Sequence 21, Appl
508	26	65.0	608	4	US-08-957-310-21	Sequence 21, Appl
509	26	65.0	608	4	US-10-011-366-21	Sequence 21, Appl
510	26	65.0	608	4	US-09-084-517-21	Sequence 21, Appl
511	26	65.0	609	1	US-08-480-604A-30	Sequence 30, Appl
512	26	65.0	609	3	US-08-915-136-30	Sequence 30, Appl
513	26	65.0	609	4	US-09-084-517-30	Sequence 30, Appl
514	26	65.0	618	3	US-09-299-378-4	Sequence 4, Appli
515	26	65.0	737	4	US-09-252-991A-22539	Sequence 22539, A
516	26	65.0	768	1	US-08-454-455-4	Sequence 4, Appli
517	26	65.0	769	1	US-08-454-455-6	Sequence 6, Appli
518	26	65.0	773	4	US-09-252-991A-19916	Sequence 19916, A
519	26	65.0	822	4	US-09-328-352-5754	Sequence 5754, Ap
520	26	65.0	862	4	US-09-751-687-9	Sequence 9, Appli
521	26	65.0	862	4	US-09-751-687-12	Sequence 12, Appl
522	26	65.0	864	4	US-09-751-687-18	Sequence 18, Appl
523	26	65.0	919	2	US-08-788-674-4	Sequence 4, Appli
524	26	65.0	943	4	US-09-252-991A-20094	Sequence 20094, A

525	26	65.0	978	4	US-08-897-956A-3	Sequence 3, Appli
526	26	65.0	979	4	US-09-323-872A-55	Sequence 55, Appli
527	26	65.0	979	4	US-09-072-433-9	Sequence 9, Appli
528	26	65.0	1045	1	US-07-596-467-6	Sequence 6, Appli
529	26	65.0	1045	1	US-07-934-374-6	Sequence 6, Appli
530	26	65.0	1045	1	US-07-783-861C-6	Sequence 6, Appli
531	26	65.0	1144	1	US-08-147-812-5	Sequence 5, Appli
532	26	65.0	1144	2	US-08-319-866-12	Sequence 12, Appli
533	26	65.0	1144	3	US-09-123-708-2	Sequence 2, Appli
534	26	65.0	1144	3	US-09-123-624-2	Sequence 2, Appli
535	26	65.0	1144	4	US-09-661-258-5	Sequence 5, Appli
536	26	65.0	2366	1	US-08-480-604A-10	Sequence 10, Appli
537	26	65.0	2366	2	US-08-405-496A-10	Sequence 10, Appli
538	26	65.0	2366	3	US-08-915-136-10	Sequence 10, Appli
539	26	65.0	2366	4	US-08-957-310-10	Sequence 10, Appli
540	26	65.0	2366	4	US-10-011-366-10	Sequence 10, Appli
541	26	65.0	2366	4	US-09-084-517-10	Sequence 10, Appli
542	26	65.0	2475	3	US-09-413-814-48	Sequence 48, Appli
543	26	65.0	3200	2	US-08-477-451-8	Sequence 8, Appli
544	25	62.5	5	1	US-08-127-904-15	Sequence 15, Appli
545	25	62.5	5	2	US-08-612-785B-10	Sequence 10, Appli
546	25	62.5	5	3	US-08-970-833-2	Sequence 2, Appli
547	25	62.5	5	4	US-08-703-675C-46	Sequence 46, Appli
548	25	62.5	5	4	US-09-242-724-25	Sequence 25, Appli
549	25	62.5	5	4	US-09-242-724-26	Sequence 26, Appli
550	25	62.5	5	4	US-08-617-267C-10	Sequence 10, Appli
551	25	62.5	5	4	US-09-264-709A-28	Sequence 28, Appli
552	25	62.5	5	4	US-09-095-106A-1	Sequence 1, Appli
553	25	62.5	5	4	US-09-747-408-8	Sequence 8, Appli
554	25	62.5	5	4	US-09-747-408-16	Sequence 16, Appli
555	25	62.5	5	5	PCT-US94-10475-15	Sequence 15, Appli
556	25	62.5	6	2	US-08-612-785B-8	Sequence 8, Appli
557	25	62.5	6	2	US-08-612-785B-31	Sequence 31, Appli
558	25	62.5	6	3	US-08-664-379B-19	Sequence 19, Appli
559	25	62.5	6	4	US-08-703-675C-31	Sequence 31, Appli
560	25	62.5	6	4	US-08-703-675C-44	Sequence 44, Appli
561	25	62.5	6	4	US-09-242-724-24	Sequence 24, Appli
562	25	62.5	6	4	US-09-242-724-27	Sequence 27, Appli
563	25	62.5	6	4	US-09-242-724-30	Sequence 30, Appli
564	25	62.5	6	4	US-09-242-724-31	Sequence 31, Appli
565	25	62.5	6	4	US-09-242-724-33	Sequence 33, Appli
566	25	62.5	6	4	US-08-617-267C-8	Sequence 8, Appli
567	25	62.5	6	4	US-08-617-267C-31	Sequence 31, Appli
568	25	62.5	6	4	US-08-617-267C-43	Sequence 43, Appli
569	25	62.5	6	4	US-09-095-106A-5	Sequence 5, Appli
570	25	62.5	6	4	US-09-747-408-4	Sequence 4, Appli
571	25	62.5	6	4	US-09-747-408-12	Sequence 12, Appli
572	25	62.5	6	4	US-09-747-408-24	Sequence 24, Appli
573	25	62.5	7	2	US-08-612-785B-6	Sequence 6, Appli
574	25	62.5	7	4	US-08-703-675C-29	Sequence 29, Appli
575	25	62.5	7	4	US-08-617-267C-6	Sequence 6, Appli
576	25	62.5	7	4	US-09-095-106A-11	Sequence 11, Appli
577	25	62.5	8	4	US-09-095-106A-8	Sequence 8, Appli
578	25	62.5	8	4	US-09-535-852-1789	Sequence 1789, Ap
579	25	62.5	9	4	US-09-264-709A-4	Sequence 4, Appli
580	25	62.5	9	4	US-09-095-106A-6	Sequence 6, Appli
581	25	62.5	10	4	US-09-095-106A-2	Sequence 2, Appli

582	25	62.5	11	3	US-08-970-833-8	Sequence 8, Appli
583	25	62.5	11	4	US-08-766-596A-68	Sequence 68, Appl
584	25	62.5	15	2	US-08-612-785B-4	Sequence 4, Appli
585	25	62.5	15	4	US-08-617-267C-4	Sequence 4, Appli
586	25	62.5	37	4	US-09-330-914A-10	Sequence 10, Appl
587	25	62.5	50	1	US-08-178-477B-5	Sequence 5, Appli
588	25	62.5	52	4	US-09-621-976-5552	Sequence 5552, Ap
589	25	62.5	56	4	US-09-621-976-5720	Sequence 5720, Ap
590	25	62.5	72	4	US-09-328-352-5060	Sequence 5060, Ap
591	25	62.5	72	4	US-09-540-236-2558	Sequence 2558, Ap
592	25	62.5	79	4	US-09-328-352-6081	Sequence 6081, Ap
593	25	62.5	84	4	US-09-543-681A-5500	Sequence 5500, Ap
594	25	62.5	84	4	US-09-540-236-2290	Sequence 2290, Ap
595	25	62.5	104	4	US-09-489-039A-13207	Sequence 13207, A
596	25	62.5	131	4	US-09-328-352-6689	Sequence 6689, Ap
597	25	62.5	134	4	US-09-107-532A-5878	Sequence 5878, Ap
598	25	62.5	151	4	US-09-328-352-5879	Sequence 5879, Ap
599	25	62.5	154	4	US-09-134-001C-3635	Sequence 3635, Ap
600	25	62.5	154	4	US-09-543-681A-4706	Sequence 4706, Ap
601	25	62.5	160	1	US-08-264-003B-3	Sequence 3, Appli
602	25	62.5	160	3	US-08-842-234-3	Sequence 3, Appli
603	25	62.5	172	4	US-09-489-039A-10016	Sequence 10016, A
604	25	62.5	185	3	US-09-475-316A-15	Sequence 15, Appl
605	25	62.5	185	4	US-09-704-640-15	Sequence 15, Appl
606	25	62.5	189	3	US-08-816-346-8	Sequence 8, Appli
607	25	62.5	189	3	US-09-335-411-8	Sequence 8, Appli
608	25	62.5	198	4	US-09-328-352-4951	Sequence 4951, Ap
609	25	62.5	201	3	US-08-816-346-6	Sequence 6, Appli
610	25	62.5	201	3	US-09-335-411-6	Sequence 6, Appli
611	25	62.5	203	4	US-09-134-001C-3696	Sequence 3696, Ap
612	25	62.5	212	4	US-08-311-731A-15	Sequence 15, Appl
613	25	62.5	220	4	US-09-252-991A-30727	Sequence 30727, A
614	25	62.5	224	1	US-08-265-086-4	Sequence 4, Appli
615	25	62.5	227	1	US-08-265-086-2	Sequence 2, Appli
616	25	62.5	227	2	US-08-801-740-5	Sequence 5, Appli
617	25	62.5	227	3	US-08-801-740-5	Sequence 5, Appli
618	25	62.5	227	4	US-08-916-442-3	Sequence 3, Appli
619	25	62.5	227	4	US-09-731-924A-3	Sequence 3, Appli
620	25	62.5	227	4	US-09-317-641-3	Sequence 3, Appli
621	25	62.5	230	4	US-09-198-452A-313	Sequence 313, App
622	25	62.5	240	4	US-09-252-991A-30656	Sequence 30656, A
623	25	62.5	266	4	US-09-198-452A-250	Sequence 250, App
624	25	62.5	271	2	US-07-637-865-2	Sequence 2, Appli
625	25	62.5	285	4	US-09-134-000C-4197	Sequence 4197, Ap
626	25	62.5	293	4	US-09-134-001C-5374	Sequence 5374, Ap
627	25	62.5	302	4	US-09-489-039A-7616	Sequence 7616, Ap
628	25	62.5	302	4	US-09-489-039A-10388	Sequence 10388, A
629	25	62.5	312	4	US-09-328-352-8015	Sequence 8015, Ap
630	25	62.5	339	4	US-09-463-962-2	Sequence 2, Appli
631	25	62.5	341	4	US-09-328-352-5966	Sequence 5966, Ap
632	25	62.5	342	4	US-09-540-236-2385	Sequence 2385, Ap
633	25	62.5	351	4	US-09-252-991A-29992	Sequence 29992, A
634	25	62.5	353	4	US-09-134-001C-4640	Sequence 4640, Ap
635	25	62.5	378	4	US-09-491-577-12	Sequence 12, Appl
636	25	62.5	393	3	US-09-377-557-14	Sequence 14, Appl
637	25	62.5	394	3	US-09-385-028-8	Sequence 8, Appli
638	25	62.5	394	4	US-09-726-614-8	Sequence 8, Appli

639	25	62.5	394	4	US-09-385-040-8	Sequence 8, Appli
640	25	62.5	414	4	US-09-134-001C-3357	Sequence 3357, Ap
641	25	62.5	415	4	US-09-328-352-6516	Sequence 6516, Ap
642	25	62.5	425	4	US-09-489-039A-8209	Sequence 8209, Ap
643	25	62.5	427	4	US-09-328-352-5205	Sequence 5205, Ap
644	25	62.5	431	4	US-09-540-236-3536	Sequence 3536, Ap
645	25	62.5	453	2	US-08-599-171A-27	Sequence 27, Appl
646	25	62.5	453	2	US-08-646-590B-27	Sequence 27, Appl
647	25	62.5	453	3	US-09-069-226-27	Sequence 27, Appl
648	25	62.5	453	3	US-09-412-184-27	Sequence 27, Appl
649	25	62.5	457	4	US-09-489-039A-8037	Sequence 8037, Ap
650	25	62.5	472	2	US-08-622-166A-2	Sequence 2, Appli
651	25	62.5	472	2	US-08-622-166A-4	Sequence 4, Appli
652	25	62.5	476	4	US-09-252-991A-26249	Sequence 26249, A
653	25	62.5	492	4	US-09-252-991A-20751	Sequence 20751, A
654	25	62.5	497	3	US-09-377-557-10	Sequence 10, Appl
655	25	62.5	502	4	US-09-489-039A-13376	Sequence 13376, A
656	25	62.5	534	4	US-09-508-370A-5	Sequence 5, Appli
657	25	62.5	554	4	US-09-540-236-2663	Sequence 2663, Ap
658	25	62.5	576	4	US-09-252-991A-26023	Sequence 26023, A
659	25	62.5	583	4	US-09-328-352-5822	Sequence 5822, Ap
660	25	62.5	596	3	US-09-135-232-2	Sequence 2, Appli
661	25	62.5	596	4	US-09-863-549-2	Sequence 2, Appli
662	25	62.5	615	4	US-09-107-532A-6507	Sequence 6507, Ap
663	25	62.5	619	4	US-09-540-236-2377	Sequence 2377, Ap
664	25	62.5	625	4	US-09-134-001C-4504	Sequence 4504, Ap
665	25	62.5	643	4	US-09-328-352-5146	Sequence 5146, Ap
666	25	62.5	655	4	US-09-228-986-70	Sequence 70, Appl
667	25	62.5	671	3	US-09-121-321-16	Sequence 16, Appl
668	25	62.5	671	3	US-08-933-803A-16	Sequence 16, Appl
669	25	62.5	678	1	US-08-288-408-5	Sequence 5, Appli
670	25	62.5	678	3	US-08-655-782-5	Sequence 5, Appli
671	25	62.5	719	4	US-09-328-352-6274	Sequence 6274, Ap
672	25	62.5	771	2	US-08-742-753-2	Sequence 2, Appli
673	25	62.5	797	4	US-09-198-452A-636	Sequence 636, App
674	25	62.5	797	4	US-09-540-236-2813	Sequence 2813, Ap
675	25	62.5	806	3	US-08-945-983-2	Sequence 2, Appli
676	25	62.5	816	4	US-09-328-352-6677	Sequence 6677, Ap
677	25	62.5	867	4	US-09-107-532A-4393	Sequence 4393, Ap
678	25	62.5	884	2	US-08-474-067-8	Sequence 8, Appli
679	25	62.5	884	2	US-08-474-068A-8	Sequence 8, Appli
680	25	62.5	884	2	US-08-472-481-7	Sequence 7, Appli
681	25	62.5	886	4	US-09-134-001C-4496	Sequence 4496, Ap
682	25	62.5	947	2	US-08-500-857A-4	Sequence 4, Appli
683	25	62.5	951	3	US-08-816-346-58	Sequence 58, Appl
684	25	62.5	951	3	US-09-335-411-58	Sequence 58, Appl
685	25	62.5	952	2	US-08-788-674-5	Sequence 5, Appli
686	25	62.5	952	3	US-08-816-346-4	Sequence 4, Appli
687	25	62.5	952	3	US-09-335-411-4	Sequence 4, Appli
688	25	62.5	955	2	US-08-500-857A-10	Sequence 10, Appl
689	25	62.5	967	3	US-08-816-346-56	Sequence 56, Appl
690	25	62.5	967	3	US-09-335-411-56	Sequence 56, Appl
691	25	62.5	968	3	US-08-816-346-2	Sequence 2, Appli
692	25	62.5	968	3	US-09-335-411-2	Sequence 2, Appli
693	25	62.5	1007	4	US-09-252-991A-26494	Sequence 26494, A
694	25	62.5	1014	4	US-09-134-000C-6265	Sequence 6265, Ap
695	25	62.5	1233	4	US-09-328-352-7874	Sequence 7874, Ap

696	25	62.5	1333	4	US-09-347-878-20	Sequence 20, Appl
697	25	62.5	1360	4	US-09-489-039A-7193	Sequence 7193, Ap
698	25	62.5	1388	4	US-09-543-681A-7349	Sequence 7349, Ap
699	25	62.5	2787	3	US-09-245-041-15	Sequence 15, Appl
700	25	62.5	2958	3	US-08-894-344C-2	Sequence 2, Appl
701	24	60.0	5	2	US-08-612-785B-11	Sequence 11, Appl
702	24	60.0	5	2	US-08-920-162A-3	Sequence 3, Appl
703	24	60.0	5	2	US-08-920-162A-16	Sequence 16, Appl
704	24	60.0	5	2	US-08-920-162A-33	Sequence 33, Appl
705	24	60.0	5	2	US-08-920-162A-34	Sequence 34, Appl
706	24	60.0	5	3	US-09-356-931-3	Sequence 3, Appl
707	24	60.0	5	3	US-09-356-931-16	Sequence 16, Appl
708	24	60.0	5	3	US-09-356-931-33	Sequence 33, Appl
709	24	60.0	5	3	US-09-356-931-34	Sequence 34, Appl
710	24	60.0	5	4	US-08-703-675C-3	Sequence 3, Appl
711	24	60.0	5	4	US-08-703-675C-16	Sequence 16, Appl
712	24	60.0	5	4	US-08-703-675C-45	Sequence 45, Appl
713	24	60.0	5	4	US-08-617-267C-11	Sequence 11, Appl
714	24	60.0	5	4	US-09-519-019A-4	Sequence 4, Appl
715	24	60.0	6	4	US-09-747-408-7	Sequence 7, Appl
716	24	60.0	6	4	US-09-747-408-15	Sequence 15, Appl
717	24	60.0	14	4	US-09-443-199C-1217	Sequence 1217, Ap
718	24	60.0	22	1	US-08-103-445-13	Sequence 13, Appl
719	24	60.0	22	1	US-08-461-690B-13	Sequence 13, Appl
720	24	60.0	41	2	US-08-896-605A-1	Sequence 1, Appl
721	24	60.0	41	2	US-08-896-501A-1	Sequence 1, Appl
722	24	60.0	42	3	US-08-924-330A-7	Sequence 7, Appl
723	24	60.0	42	3	US-09-138-721-7	Sequence 7, Appl
724	24	60.0	52	2	US-08-856-444-3	Sequence 3, Appl
725	24	60.0	59	4	US-09-205-258-754	Sequence 754, App
726	24	60.0	61	4	US-09-149-476-492	Sequence 492, App
727	24	60.0	61	4	US-09-621-976-4382	Sequence 4382, Ap
728	24	60.0	61	4	US-09-621-976-5938	Sequence 5938, Ap
729	24	60.0	62	4	US-09-543-681A-6108	Sequence 6108, Ap
730	24	60.0	66	4	US-09-205-258-759	Sequence 759, App
731	24	60.0	72	4	US-09-107-532A-3822	Sequence 3822, Ap
732	24	60.0	74	4	US-09-194-468A-19	Sequence 19, Appl
733	24	60.0	74	4	US-09-194-468A-25	Sequence 25, Appl
734	24	60.0	80	4	US-09-589-733C-23	Sequence 23, Appl
735	24	60.0	81	4	US-09-543-681A-5801	Sequence 5801, Ap
736	24	60.0	86	4	US-09-732-210-749	Sequence 749, App
737	24	60.0	92	4	US-09-134-000C-3911	Sequence 3911, Ap
738	24	60.0	100	4	US-09-732-210-1745	Sequence 1745, Ap
739	24	60.0	102	2	US-08-480-473B-50	Sequence 50, Appl
740	24	60.0	102	3	US-08-915-213-50	Sequence 50, Appl
741	24	60.0	102	3	US-09-235-217-50	Sequence 50, Appl
742	24	60.0	108	4	US-09-194-468A-20	Sequence 20, Appl
743	24	60.0	108	4	US-09-194-468A-26	Sequence 26, Appl
744	24	60.0	115	4	US-09-107-532A-7171	Sequence 7171, Ap
745	24	60.0	116	4	US-09-673-395A-522	Sequence 522, App
746	24	60.0	118	3	US-09-245-041-127	Sequence 127, App
747	24	60.0	122	4	US-09-489-039A-12288	Sequence 12288, A
748	24	60.0	123	3	US-09-188-930-170	Sequence 170, App
749	24	60.0	123	4	US-09-312-283C-170	Sequence 170, App
750	24	60.0	125	4	US-09-134-001C-5034	Sequence 5034, Ap
751	24	60.0	128	3	US-09-188-930-316	Sequence 316, App
752	24	60.0	128	4	US-09-312-283C-316	Sequence 316, App

753	24	60.0	134	4	US-09-621-976-4537	Sequence 4537, Appl
754	24	60.0	138	3	US-08-586-039B-37	Sequence 37, Appl
755	24	60.0	138	4	US-09-699-769-37	Sequence 37, Appl
756	24	60.0	151	3	US-08-680-506-11	Sequence 11, Appl
757	24	60.0	153	4	US-09-107-532A-5003	Sequence 5003, Ap
758	24	60.0	153	4	US-09-489-039A-12639	Sequence 12639, A
759	24	60.0	155	4	US-09-107-532A-7084	Sequence 7084, Ap
760	24	60.0	158	3	US-08-586-039B-39	Sequence 39, Appl
761	24	60.0	158	4	US-09-699-769-39	Sequence 39, Appl
762	24	60.0	161	4	US-09-134-000C-4260	Sequence 4260, Ap
763	24	60.0	163	3	US-09-053-197A-26	Sequence 26, Appl
764	24	60.0	163	3	US-09-053-197A-28	Sequence 28, Appl
765	24	60.0	163	4	US-09-085-761A-26	Sequence 26, Appl
766	24	60.0	163	4	US-09-085-761A-28	Sequence 28, Appl
767	24	60.0	163	4	US-09-489-039A-13539	Sequence 13539, A
768	24	60.0	166	5	PCT-US93-02869-4	Sequence 4, Appli
769	24	60.0	166	5	PCT-US93-02869-8	Sequence 8, Appli
770	24	60.0	166	5	PCT-US93-02869-9	Sequence 9, Appli
771	24	60.0	166	5	PCT-US93-02869-10	Sequence 10, Appli
772	24	60.0	171	2	US-08-934-959-2	Sequence 2, Appli
773	24	60.0	173	2	US-08-245-511-6	Sequence 6, Appli
774	24	60.0	173	2	US-08-245-511-25	Sequence 25, Appli
775	24	60.0	173	2	US-08-600-993A-6	Sequence 6, Appli
776	24	60.0	173	2	US-08-600-993A-25	Sequence 25, Appli
777	24	60.0	173	4	US-09-107-532A-3763	Sequence 3763, Ap
778	24	60.0	176	4	US-09-091-097-2	Sequence 2, Appli
779	24	60.0	177	4	US-09-091-097-19	Sequence 19, Appli
780	24	60.0	186	4	US-09-198-452A-498	Sequence 498, App
781	24	60.0	187	4	US-09-328-352-5117	Sequence 5117, Ap
782	24	60.0	187	4	US-09-489-039A-13483	Sequence 13483, A
783	24	60.0	193	2	US-08-896-605A-2	Sequence 2, Appli
784	24	60.0	193	2	US-08-896-501A-2	Sequence 2, Appli
785	24	60.0	193	3	US-08-832-180-9	Sequence 9, Appli
786	24	60.0	193	4	US-09-597-576-2	Sequence 2, Appli
787	24	60.0	193	4	US-09-194-468A-18	Sequence 18, Appli
788	24	60.0	193	4	US-09-194-468A-24	Sequence 24, Appli
789	24	60.0	198	4	US-09-252-991A-19680	Sequence 19680, A
790	24	60.0	201	2	US-08-484-126-5	Sequence 5, Appli
791	24	60.0	201	4	US-09-374-909-5	GENERAL INFORMA
792	24	60.0	203	2	US-08-531-525-21	Sequence 21, Appli
793	24	60.0	203	2	US-08-718-270A-21	Sequence 21, Appli
794	24	60.0	207	2	US-08-531-525-22	Sequence 22, Appli
795	24	60.0	207	2	US-08-718-270A-22	Sequence 22, Appli
796	24	60.0	208	4	US-09-134-001C-4007	Sequence 4007, Ap
797	24	60.0	210	4	US-09-328-352-4775	Sequence 4775, Ap
798	24	60.0	213	4	US-09-252-991A-16947	Sequence 16947, A
799	24	60.0	213	4	US-09-543-681A-5663	Sequence 5663, Ap
800	24	60.0	219	3	US-08-975-628-2	Sequence 2, Appli
801	24	60.0	219	4	US-09-427-774-2	Sequence 2, Appli
802	24	60.0	221	2	US-08-861-269-6	Sequence 6, Appli
803	24	60.0	221	2	US-09-134-596-6	Sequence 6, Appli
804	24	60.0	221	3	US-09-293-273-6	Sequence 6, Appli
805	24	60.0	222	4	US-09-194-468A-17	Sequence 17, Appli
806	24	60.0	228	4	US-09-194-468A-23	Sequence 23, Appli
807	24	60.0	230	4	US-09-107-532A-4717	Sequence 4717, Ap
808	24	60.0	233	4	US-09-886-319A-12	Sequence 12, Appli
809	24	60.0	234	4	US-09-543-681A-5274	Sequence 5274, Ap

810	24	60.0	237	4	US-09-252-991A-23500	Sequence 23500, A
811	24	60.0	248	4	US-09-198-452A-721	Sequence 721, App
812	24	60.0	255	4	US-09-489-039A-13166	Sequence 13166, A
813	24	60.0	257	4	US-09-634-238-353	Sequence 353, App
814	24	60.0	262	4	US-09-543-681A-5824	Sequence 5824, Ap
815	24	60.0	265	4	US-09-489-039A-14115	Sequence 14115, A
816	24	60.0	270	4	US-09-134-000C-5024	Sequence 5024, Ap
817	24	60.0	278	4	US-09-149-476-454	Sequence 454, App
818	24	60.0	278	4	US-09-134-000C-4596	Sequence 4596, Ap
819	24	60.0	279	4	US-09-543-681A-7858	Sequence 7858, Ap
820	24	60.0	284	2	US-08-215-089-7	Sequence 7, Appli
821	24	60.0	284	5	PCT-US95-03384-7	Sequence 7, Appli
822	24	60.0	285	4	US-09-198-452A-855	Sequence 855, App
823	24	60.0	289	4	US-09-252-991A-27680	Sequence 27680, A
824	24	60.0	292	4	US-09-107-532A-6875	Sequence 6875, Ap
825	24	60.0	298	4	US-09-328-352-5270	Sequence 5270, Ap
826	24	60.0	304	4	US-09-107-532A-5424	Sequence 5424, Ap
827	24	60.0	309	4	US-08-952-736A-10	Sequence 10, Appl
828	24	60.0	312	1	US-08-915-003-2	Sequence 2, Appli
829	24	60.0	312	2	US-08-642-247-2	Sequence 2, Appli
830	24	60.0	313	4	US-09-134-001C-4371	Sequence 4371, Ap
831	24	60.0	313	4	US-09-700-397-4	Sequence 4, Appli
832	24	60.0	317	4	US-10-043-238-1	Sequence 1, Appli
833	24	60.0	317	4	US-10-043-238-3	Sequence 3, Appli
834	24	60.0	318	3	US-08-680-506-3	Sequence 3, Appli
835	24	60.0	320	4	US-09-043-302-4	Sequence 4, Appli
836	24	60.0	320	4	US-09-043-302-7	Sequence 7, Appli
837	24	60.0	325	4	US-09-972-784-4	Sequence 4, Appli
838	24	60.0	325	4	US-09-107-532A-6542	Sequence 6542, Ap
839	24	60.0	329	4	US-09-543-681A-4491	Sequence 4491, Ap
840	24	60.0	330	4	US-09-252-991A-29761	Sequence 29761, A
841	24	60.0	341	4	US-09-198-452A-293	Sequence 293, App
842	24	60.0	343	2	US-08-856-444-2	Sequence 2, Appli
843	24	60.0	344	4	US-09-700-397-3	Sequence 3, Appli
844	24	60.0	347	4	US-09-328-352-7050	Sequence 7050, Ap
845	24	60.0	348	3	US-09-315-794-42	Sequence 42, Appl
846	24	60.0	348	3	US-09-389-341-42	Sequence 42, Appl
847	24	60.0	350	2	US-08-852-481-2	Sequence 2, Appli
848	24	60.0	353	4	US-09-107-532A-7032	Sequence 7032, Ap
849	24	60.0	354	4	US-09-570-856B-34	Sequence 34, Appl
850	24	60.0	364	4	US-09-134-000C-3748	Sequence 3748, Ap
851	24	60.0	367	4	US-09-252-991A-29742	Sequence 29742, A
852	24	60.0	375	4	US-09-622-439-2	Sequence 2, Appli
853	24	60.0	377	4	US-09-622-439-22	Sequence 22, Appl
854	24	60.0	379	4	US-08-311-731A-268	Sequence 268, App
855	24	60.0	385	4	US-09-644-907B-2	Sequence 2, Appli
856	24	60.0	386	4	US-09-489-039A-7965	Sequence 7965, Ap
857	24	60.0	388	4	US-09-134-000C-6113	Sequence 6113, Ap
858	24	60.0	390	3	US-08-977-865-2	Sequence 2, Appli
859	24	60.0	393	4	US-09-134-001C-5594	Sequence 5594, Ap
860	24	60.0	397	4	US-09-543-681A-6180	Sequence 6180, Ap
861	24	60.0	398	4	US-09-543-681A-7046	Sequence 7046, Ap
862	24	60.0	401	4	US-08-858-207A-344	Sequence 344, App
863	24	60.0	401	4	US-09-489-039A-12882	Sequence 12882, A
864	24	60.0	411	4	US-09-328-352-7452	Sequence 7452, Ap
865	24	60.0	419	4	US-09-328-352-7115	Sequence 7115, Ap
866	24	60.0	420	3	US-09-213-053-4	Sequence 4, Appli

867	24	60.0	421	4	US-09-107-532A-4030	Sequence 4030, Ap
868	24	60.0	427	4	US-09-199-637A-107	Sequence 107, App
869	24	60.0	429	4	US-09-194-468A-45	Sequence 45, Appl
870	24	60.0	431	2	US-08-928-613-2	Sequence 2, Appli
871	24	60.0	431	3	US-09-193-524-2	Sequence 2, Appli
872	24	60.0	431	4	US-09-107-532A-5796	Sequence 5796, Ap
873	24	60.0	432	4	US-09-252-991A-23312	Sequence 23312, A
874	24	60.0	433	2	US-09-139-424-4	Sequence 4, Appli
875	24	60.0	433	3	US-08-706-216-4	Sequence 4, Appli
876	24	60.0	433	4	US-09-650-284B-4	Sequence 4, Appli
877	24	60.0	438	4	US-09-134-000C-4100	Sequence 4100, Ap
878	24	60.0	446	4	US-09-134-000C-3908	Sequence 3908, Ap
879	24	60.0	447	4	US-08-836-687B-39	Sequence 39, Appl
880	24	60.0	448	3	US-09-143-954-4	Sequence 4, Appli
881	24	60.0	448	4	US-09-134-000C-3794	Sequence 3794, Ap
882	24	60.0	449	3	US-08-680-506-7	Sequence 7, Appli
883	24	60.0	449	4	US-09-489-039A-8009	Sequence 8009, Ap
884	24	60.0	452	1	US-08-205-719-3	Sequence 3, Appli
885	24	60.0	453	4	US-09-134-000C-4191	Sequence 4191, Ap
886	24	60.0	455	4	US-09-198-452A-1028	Sequence 1028, Ap
887	24	60.0	456	3	US-08-879-565-12	Sequence 12, Appli
888	24	60.0	456	3	US-08-431-517F-8	Sequence 8, Appli
889	24	60.0	456	3	US-08-431-517F-12	Sequence 12, Appli
890	24	60.0	457	3	US-09-143-954-2	Sequence 2, Appli
891	24	60.0	467	4	US-09-328-352-5725	Sequence 5725, Ap
892	24	60.0	468	4	US-09-328-352-8129	Sequence 8129, Ap
893	24	60.0	471	4	US-09-242-913B-16	Sequence 16, Appli
894	24	60.0	472	4	US-09-252-991A-26992	Sequence 26992, A
895	24	60.0	476	3	US-08-704-711A-21	Sequence 21, Appli
896	24	60.0	476	3	US-08-448-489-14	Sequence 14, Appli
897	24	60.0	476	4	US-09-521-220-21	Sequence 21, Appli
898	24	60.0	476	4	US-09-391-104-22	Sequence 22, Appli
899	24	60.0	477	1	US-07-847-562-2	Sequence 2, Appli
900	24	60.0	477	1	US-08-240-328-2	Sequence 2, Appli
901	24	60.0	477	2	US-08-990-849-2	Sequence 2, Appli
902	24	60.0	477	6	5245013-3	Patent No. 5245013
903	24	60.0	478	4	US-09-252-991A-18005	Sequence 18005, A
904	24	60.0	478	4	US-09-738-946-6	Sequence 6, Appli
905	24	60.0	478	4	US-09-134-000C-6219	Sequence 6219, Ap
906	24	60.0	481	1	US-07-754-918A-13	Sequence 13, Appli
907	24	60.0	481	1	US-08-186-811-2	Sequence 2, Appli
908	24	60.0	481	1	US-08-311-611A-98	Sequence 98, Appli
909	24	60.0	481	1	US-08-372-783-98	Sequence 98, Appli
910	24	60.0	481	1	US-08-372-105-98	Sequence 98, Appli
911	24	60.0	481	1	US-08-306-473A-98	Sequence 98, Appli
912	24	60.0	481	1	US-08-261-660A-4	Sequence 4, Appli
913	24	60.0	481	1	US-08-209-762-98	Sequence 98, Appli
914	24	60.0	481	1	US-08-473-344-98	Sequence 98, Appli
915	24	60.0	481	1	US-08-274-303-6	Sequence 6, Appli
916	24	60.0	481	1	US-08-377-391A-2	Sequence 2, Appli
917	24	60.0	481	2	US-08-215-089-9	Sequence 9, Appli
918	24	60.0	481	2	US-08-485-445A-98	Sequence 98, Appli
919	24	60.0	481	2	US-08-779-400-2	Sequence 2, Appli
920	24	60.0	481	2	US-08-955-660-2	Sequence 2, Appli
921	24	60.0	481	3	US-09-119-263-98	Sequence 98, Appli
922	24	60.0	481	3	US-08-657-162-98	Sequence 98, Appli
923	24	60.0	481	3	US-09-224-480-98	Sequence 98, Appli

924	24	60.0	481	3	US-09-093-539-98	Sequence 98, Appl
925	24	60.0	481	3	US-08-431-517F-2	Sequence 2, Appli
926	24	60.0	481	3	US-08-431-517F-7	Sequence 7, Appli
927	24	60.0	481	3	US-08-431-517F-11	Sequence 11, Appl
928	24	60.0	481	3	US-09-146-620-2	Sequence 2, Appli
929	24	60.0	481	4	US-09-395-453-2	Sequence 2, Appli
930	24	60.0	481	4	US-09-280-909A-4	Sequence 4, Appli
931	24	60.0	481	4	US-09-790-230-98	Sequence 98, Appl
932	24	60.0	481	5	PCT-US94-02465-98	Sequence 98, Appl
933	24	60.0	481	5	PCT-US94-06931-4	Sequence 4, Appli
934	24	60.0	481	5	PCT-US94-07834-6	Sequence 6, Appli
935	24	60.0	481	5	PCT-US95-00498-98	Sequence 98, Appl
936	24	60.0	481	5	PCT-US95-00656-98	Sequence 98, Appl
937	24	60.0	481	5	PCT-US95-03384-9	Sequence 9, Appli
938	24	60.0	493	4	US-09-543-681A-7520	Sequence 7520, Ap
939	24	60.0	494	4	US-09-489-039A-12255	Sequence 12255, A
940	24	60.0	499	2	US-09-032-315-2	Sequence 2, Appli
941	24	60.0	499	2	US-08-993-318A-2	Sequence 2, Appli
942	24	60.0	499	3	US-09-399-886-2	Sequence 2, Appli
943	24	60.0	499	3	US-09-396-260-2	Sequence 2, Appli
944	24	60.0	499	3	US-09-576-281-2	Sequence 2, Appli
945	24	60.0	500	4	US-08-985-492-8	Sequence 8, Appli
946	24	60.0	501	4	US-09-328-352-6371	Sequence 6371, Ap
947	24	60.0	502	4	US-09-489-039A-11955	Sequence 11955, A
948	24	60.0	503	4	US-09-134-001C-3948	Sequence 3948, Ap
949	24	60.0	516	3	US-08-689-421-29	Sequence 29, Appl
950	24	60.0	516	3	US-09-389-528-29	Sequence 29, Appl
951	24	60.0	516	3	US-09-181-827A-29	Sequence 29, Appl
952	24	60.0	517	3	US-08-689-421-33	Sequence 33, Appl
953	24	60.0	517	3	US-09-389-528-33	Sequence 33, Appl
954	24	60.0	517	3	US-09-181-827A-33	Sequence 33, Appl
955	24	60.0	517	4	US-09-252-991A-25364	Sequence 25364, A
956	24	60.0	519	4	US-09-198-452A-971	Sequence 971, App
957	24	60.0	520	1	US-08-462-484-2	Sequence 2, Appli
958	24	60.0	520	1	US-08-441-147-2	Sequence 2, Appli
959	24	60.0	520	4	US-09-391-104-10	Sequence 10, Appl
960	24	60.0	520	5	PCT-US95-07536-2	Sequence 2, Appli
961	24	60.0	526	4	US-09-252-991A-32984	Sequence 32984, A
962	24	60.0	528	2	US-08-793-229-35	Sequence 35, Appl
963	24	60.0	528	3	US-09-285-957-35	Sequence 35, Appl
964	24	60.0	533	4	US-09-221-275-4	Sequence 4, Appli
965	24	60.0	534	4	US-09-134-000C-4924	Sequence 4924, Ap
966	24	60.0	545	4	US-09-252-991A-32219	Sequence 32219, A
967	24	60.0	557	4	US-09-540-236-2206	Sequence 2206, Ap
968	24	60.0	558	1	US-08-333-358-12	Sequence 12, Appl
969	24	60.0	558	1	US-08-463-694-12	Sequence 12, Appl
970	24	60.0	558	1	US-08-694-501-12	Sequence 12, Appl
971	24	60.0	558	3	US-08-836-567-6	Sequence 6, Appli
972	24	60.0	558	4	US-09-606-304-6	Sequence 6, Appli
973	24	60.0	569	4	US-09-543-681A-6977	Sequence 6977, Ap
974	24	60.0	575	4	US-09-489-039A-10911	Sequence 10911, A
975	24	60.0	576	2	US-08-676-279-58	Sequence 58, Appl
976	24	60.0	582	4	US-09-091-725-17	Sequence 17, Appl
977	24	60.0	589	4	US-08-976-063E-30	Sequence 30, Appl
978	24	60.0	591	4	US-09-252-991A-20700	Sequence 20700, A
979	24	60.0	628	4	US-09-252-991A-30904	Sequence 30904, A
980	24	60.0	631	3	US-08-448-489-17	Sequence 17, Appl

981	24	60.0	633	4	US-09-328-352-6519	Sequence 6519, Ap
982	24	60.0	635	4	US-09-341-833A-6	Sequence 6, Appli
983	24	60.0	635	4	US-09-341-833A-7	Sequence 7, Appli
984	24	60.0	635	4	US-09-341-833A-9	Sequence 9, Appli
985	24	60.0	637	4	US-09-543-681A-5869	Sequence 5869, Ap
986	24	60.0	642	4	US-08-911-393-4	Sequence 4, Appli
987	24	60.0	645	4	US-09-543-681A-7757	Sequence 7757, Ap
988	24	60.0	646	4	US-09-107-532A-6308	Sequence 6308, Ap
989	24	60.0	659	4	US-09-228-986-75	Sequence 75, Appl
990	24	60.0	660	3	US-08-704-711A-18	Sequence 18, Appl
991	24	60.0	660	4	US-09-521-220-18	Sequence 18, Appl
992	24	60.0	660	4	US-09-391-104-19	Sequence 19, Appl
993	24	60.0	663	4	US-09-194-468A-30	Sequence 30, Appl
994	24	60.0	666	4	US-09-228-986-68	Sequence 68, Appl
995	24	60.0	673	4	US-09-091-725-13	Sequence 13, Appl
996	24	60.0	673	4	US-09-091-725-19	Sequence 19, Appl
997	24	60.0	673	4	US-09-091-725-23	Sequence 23, Appl
998	24	60.0	677	4	US-09-341-833A-8	Sequence 8, Appli
999	24	60.0	690	2	US-08-619-554-8	Sequence 8, Appli
1000	24	60.0	690	4	US-09-388-743-6	Sequence 6, Appli

#### ALIGNMENTS

RESULT 1  
 US-08-630-645-1  
 ; Sequence 1, Application US/08630645  
 ; Patent No. 5948763  
 ; GENERAL INFORMATION:  
 ; APPLICANT: SOTO-JARA, Claudio  
 ; APPLICANT: BAUMANN, Marc  
 ; APPLICANT: FRANGIONE, Blas  
 ; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
 ; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
 ASSOCIATED  
 ; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
 DEPOSITS  
 ; NUMBER OF SEQUENCES: 26  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: BROWDY AND NEIMARK  
 ; STREET: 419 Seventh Street, N.W., Suite 400  
 ; CITY: Washington  
 ; STATE: D.C.  
 ; COUNTRY: USA  
 ; ZIP: 20004  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/630,645  
 ; FILING DATE:  
 ; CLASSIFICATION: 530  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/478,326

; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-630-645-1

Query Match 100.0%; Score 40; DB 2; Length 8;  
Best Local Similarity 100.0%; Pred. No. 3e+05;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 1 KLVFFAED 8

RESULT 2  
US-08-766-596A-1  
; Sequence 1, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-1

Query Match 100.0%; Score 40; DB 4; Length 8;  
Best Local Similarity 100.0%; Pred. No. 3e+05;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 1 KLVFFAED 8

RESULT 3  
PCT-US96-10220-1  
; Sequence 1, Application PC/TUS9610220  
; GENERAL INFORMATION:  
; APPLICANT:  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
ASSOCIATED  
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
DEPOSITS  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US96/10220  
; FILING DATE:

; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: BROWDY, Roger L.  
; REGISTRATION NUMBER: 25,618  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1 PCT  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
PCT-US96-10220-1

Query Match 100.0%; Score 40; DB 5; Length 8;  
Best Local Similarity 100.0%; Pred. No. 3e+05;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 1 KLVFFAED 8

RESULT 4  
US-08-766-596A-64  
; Sequence 64, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 64:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 9 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-64

Query Match 100.0%; Score 40; DB 4; Length 9;  
Best Local Similarity 100.0%; Pred. No. 3e+05;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
      |||||||  
Db 2 KLVFFAED 9

RESULT 5  
US-08-970-833-3  
; Sequence 3, Application US/08970833  
; Patent No. 6022859  
; GENERAL INFORMATION:  
; APPLICANT: Kiessling, Laura L.  
; APPLICANT: Murphy, Regina M.  
; TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Quarles & Brady  
; STREET: 411 East Wisconsin Avenue  
; CITY: Milwaukee  
; STATE: Wisconsin  
; COUNTRY: U.S.A.  
; ZIP: 53202-4497  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/970,833  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Baker, Jean C.  
; REGISTRATION NUMBER: 35,433  
; REFERENCE/DOCKET NUMBER: 960296.94291  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (414) 277-5709  
; TELEFAX: (414) 271-3552  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 10 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-970-833-3

Query Match 100.0%; Score 40; DB 3; Length 10;  
Best Local Similarity 100.0%; Pred. No. 0.015;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
|||  
Db 1 KLVFFAED 8

RESULT 6  
US-08-630-645-14  
; Sequence 14, Application US/08630645  
; Patent No. 5948763  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
ASSOCIATED  
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
DEPOSITS  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/630,645

; FILING DATE:  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-630-645-14

Query Match 100.0%; Score 40; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 0.017;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | |  
Db 2 KLVFFAED 9

RESULT 7  
US-08-766-596A-14  
; Sequence 14, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-14

Query Match 100.0%; Score 40; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 0.017;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 2 KLVFFAED 9

RESULT 8  
PCT-US96-10220-14  
; Sequence 14, Application PC/TUS9610220  
; GENERAL INFORMATION:  
; APPLICANT:  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
; TITLE OF INVENTION: THEREOF FOR TREATMENT OF DISORDERS OR DISEASES  
ASSOCIATED  
; TITLE OF INVENTION: WITH PROTEIN FOLDING INTO AMYLOID OR AMYLOID-LIKE  
DEPOSITS  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US96/10220  
; FILING DATE:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: BROWDY, Roger L.  
; REGISTRATION NUMBER: 25,618  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1 PCT  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
PCT-US96-10220-14

Query Match 100.0%; Score 40; DB 5; Length 11;  
Best Local Similarity 100.0%; Pred. No. 0.017;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | |  
Db 2 KLVFFAED 9

RESULT 9  
US-09-594-366-5  
; Sequence 5, Application US/09594366  
; Patent No. 6582945  
; GENERAL INFORMATION:  
; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2004  
; CURRENT APPLICATION NUMBER: US/09/594,366  
; CURRENT FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 5  
; LENGTH: 14  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-594-366-5

Query Match 100.0%; Score 40; DB 4; Length 14;  
Best Local Similarity 100.0%; Pred. No. 0.021;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 4 KLVFFAED 11

RESULT 10

US-08-612-785B-14

; Sequence 14, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal

US-08-612-785B-14

Query Match 100.0%; Score 40; DB 2; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.023;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 1 KLVFFAED 8

RESULT 11  
US-08-612-785B-37  
; Sequence 37, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 37:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal

US-08-612-785B-37

```
Query Match          100.0%;  Score 40;  DB 2;  Length 15;
Best Local Similarity 100.0%;  Pred. No. 0.023;
Matches     8;  Conservative    0;  Mismatches    0;  Indels      0;  Gaps      0;

Qy          1 KLVFFAED 8
           |||||||
Db          6 KLVFFAED 13
```

```
RESULT 12
US-08-617-267C-14
; Sequence 14, Application US/08617267C
; Patent No. 6319498
; GENERAL INFORMATION:
;   APPLICANT: Findeis, Mark A. et al.
;   TITLE OF INVENTION: Modulators of Amyloid Aggregation
;   NUMBER OF SEQUENCES: 45
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: LAHIVE & COCKFIELD, LLP
;     STREET: 28 State Street
;     CITY: Boston
;     STATE: Massachusetts
;     COUNTRY: USA
;     ZIP: 02109-1875
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/08/617,267C
;   FILING DATE: 14-MAR-1996
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: USSN 08/404,831
;   FILING DATE: 14-MAR-1995
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: USSN 08/475,579
;   FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: USSN 08/548,998
;   FILING DATE: 27-OCT-1995
; ATTORNEY/AGENT INFORMATION:
;   NAME: DeConti, Giulio A.
;   REGISTRATION NUMBER: 31,503
;   REFERENCE/DOCKET NUMBER: PPI-002CP2
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (617)227-7400
;   TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 14:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 15 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
;     MOLECULE TYPE: peptide
;     FRAGMENT TYPE: internal
```

US-08-617-267C-14

Query Match 100.0%; Score 40; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.023;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 1 KLVFFAED 8

RESULT 13

US-08-766-596A-56  
; Sequence 56, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 56:  
; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-56

Query Match 100.0%; Score 40; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.023;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
Db 5 KLVFFAED 12

RESULT 14

US-08-766-596A-57

; Sequence 57, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A

; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 57:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-766-596A-57

Query Match 100.0%; Score 40; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.023;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
Db 5 KLVFFAED 12

RESULT 15

US-08-766-596A-58

; Sequence 58, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326

; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 58:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-58

Query Match 100.0%; Score 40; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.023;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 5 KLVFFAED 12

RESULT 16  
US-08-766-596A-63  
; Sequence 63, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 63:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-63

Query Match 100.0%; Score 40; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.023;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
Db 5 KLVFFAED 12

RESULT 17  
US-08-766-596A-65  
; Sequence 65, Application US/08766596A  
; Patent No. 6462171  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; APPLICANT: BAUMANN, Marc  
; APPLICANT: FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; TITLE OF INVENTION: COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; TITLE OF INVENTION: DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596A  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 65:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-766-596A-65

Query Match 100.0%; Score 40; DB 4; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.023;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 5 KLVFFAED 12

RESULT 18  
US-09-264-709A-2  
; Sequence 2, Application US/09264709A  
; Patent No. 6320024  
; GENERAL INFORMATION:  
; APPLICANT: Roberts, Eugene  
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and  
; TITLE OF INVENTION: Improve the Quality of Life  
; FILE REFERENCE: 2124-310  
; CURRENT APPLICATION NUMBER: US/09/264,709A  
; CURRENT FILING DATE: 1999-03-09  
; PRIOR APPLICATION NUMBER: 08/797,782  
; PRIOR FILING DATE: 1997-02-07  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 17  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-264-709A-2

Query Match 100.0%; Score 40; DB 4; Length 17;  
Best Local Similarity 100.0%; Pred. No. 0.026;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 5 KLVFFAED 12

RESULT 19

US-09-594-366-3

; Sequence 3, Application US/09594366  
; Patent No. 6582945  
; GENERAL INFORMATION:  
; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2004  
; CURRENT APPLICATION NUMBER: US/09/594,366  
; CURRENT FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 3  
; LENGTH: 17  
; TYPE: PRT  
; ORGANISM: Homo sapiens

US-09-594-366-3

Query Match 100.0%; Score 40; DB 4; Length 17;  
Best Local Similarity 100.0%; Pred. No. 0.026;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 8 KLVFFAED 15

RESULT 20

US-08-970-833-11

; Sequence 11, Application US/08970833  
; Patent No. 6022859  
; GENERAL INFORMATION:  
; APPLICANT: Kiessling, Laura L.  
; APPLICANT: Murphy, Regina M.  
; TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Quarles & Brady  
; STREET: 411 East Wisconsin Avenue  
; CITY: Milwaukee  
; STATE: Wisconsin  
; COUNTRY: U.S.A.  
; ZIP: 53202-4497  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/970,833  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Baker, Jean C.  
; REGISTRATION NUMBER: 35,433  
; REFERENCE/DOCKET NUMBER: 960296.94291  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (414) 277-5709  
; TELEFAX: (414) 271-3552  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 19 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-970-833-11

Query Match 100.0%; Score 40; DB 3; Length 19;  
Best Local Similarity 100.0%; Pred. No. 0.029;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 10 KLVFFAED 17

RESULT 21  
US-08-970-833-10  
; Sequence 10, Application US/08970833  
; Patent No. 6022859  
; GENERAL INFORMATION:  
; APPLICANT: Kiessling, Laura L.  
; APPLICANT: Murphy, Regina M.  
; TITLE OF INVENTION: INHIBITORS OF BETA-AMYLOID TOXICITY  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Quarles & Brady  
; STREET: 411 East Wisconsin Avenue  
; CITY: Milwaukee  
; STATE: Wisconsin  
; COUNTRY: U.S.A.  
; ZIP: 53202-4497  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/970,833  
; FILING DATE:  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:

; NAME: Baker, Jean C.  
; REGISTRATION NUMBER: 35,433  
; REFERENCE/DOCKET NUMBER: 960296.94291  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (414) 277-5709  
; TELEFAX: (414) 271-3552  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 20 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FEATURE:  
; NAME/KEY: Peptide  
; LOCATION: 13..14  
; OTHER INFORMATION: /note= "amino caproate should  
; appear between residues 13 and 14."  
US-08-970-833-10

Query Match 100.0%; Score 40; DB 3; Length 20;  
Best Local Similarity 100.0%; Pred. No. 0.031;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
|||  
Db 3 KLVFFAED 10

RESULT 22  
US-08-304-585-7  
; Sequence 7, Application US/08304585  
; Patent No. 5721106  
; GENERAL INFORMATION:  
; APPLICANT: Maggio, John E.  
; APPLICANT: Mantyh, Patrick W.  
; TITLE OF INVENTION: LABELLED BETA-AMYLOID PEPTIDE AND  
; TITLE OF INVENTION: METHODS FOR USE IN DETECTING ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Muetting, Raasch, Gebhardt & Schwappach, P.A.  
; STREET: P.O. Box 581415  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55458-1415  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/304,585  
; FILING DATE: 12-SEP-1994  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Muetting, Ann M.

; REGISTRATION NUMBER: 33,977  
; REFERENCE/DOCKET NUMBER: 110.00010120  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612-305-1217  
; TELEFAX: 612-305-1228  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 26 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: peptide  
US-08-304-585-7

Query Match 100.0%; Score 40; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 0.04;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | |  
Db 7 KLVFFAED 14

RESULT 23  
US-08-346-849-4  
; Sequence 4, Application US/08346849  
; Patent No. 5670483  
; GENERAL INFORMATION:  
; APPLICANT: Zhang, Shuguang  
; APPLICANT: Lockshin, Curtis  
; APPLICANT: Rich, Alexander  
; APPLICANT: Holmes, Todd  
; TITLE OF INVENTION: STABLE MACROSCOPIC MEMBRANES FORMED BY  
; TITLE OF INVENTION: SELF-ASSEMBLY OF AMPHIPHILIC PEPTIDES AND USES  
; TITLE OF INVENTION: THEREFOR  
; NUMBER OF SEQUENCES: 64  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02173-4799  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/346,849  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/973,326  
; FILING DATE: 28 DECEMBER 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Brook, David E.

; REGISTRATION NUMBER: 22,592  
; REFERENCE/DOCKET NUMBER: MIT-6008  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 861-6240  
; TELEFAX: (617) 861-9540  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-346-849-4

Query Match 100.0%; Score 40; DB 1; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 24

US-08-302-808-7

; Sequence 7, Application US/08302808  
; Patent No. 5750349  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5750349uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/302,808  
; FILING DATE: 15-SEP-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993

; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
US-08-302-808-7

Query Match 100.0%; Score 40; DB 1; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 25  
US-08-609-090-2  
; Sequence 2, Application US/08609090  
; Patent No. 5840838  
; GENERAL INFORMATION:  
; APPLICANT: HENSLEY, Kenneth  
; APPLICANT: BUTTERFIELD, D. A.  
; APPLICANT: CARNEY, John M.  
; APPLICANT: AKSENOV, Michael  
; TITLE OF INVENTION: A PROCESS FOR ENHANCING THE ACTIVITY OF  
; TITLE OF INVENTION: AN OLIGOPEPTIDE OR POLYPEPTIDES  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LOWE PRICE LEBLANC & BECKER  
; STREET: 99 Canal Center Plaza, Suite 300  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/609,090  
; FILING DATE: 29-FEB-1996  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kraus, Eric J.  
; REGISTRATION NUMBER: 36,190  
; REFERENCE/DOCKET NUMBER: 434-059  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-684-1111  
; TELEFAX: 703-684-1124  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-609-090-2

Query Match 100.0%; Score 40; DB 2; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 26

US-08-986-948-7

; Sequence 7, Application US/08986948

; Patent No. 5955317

; GENERAL INFORMATION:

; APPLICANT: SUZUKI, No. 5955317uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02019

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/986,948  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/302,808  
; FILING DATE: 15-SEP-1994  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
US-08-986-948-7

Query Match 100.0%; Score 40; DB 2; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
Db 16 KLVFFAED 23

RESULT 27  
US-08-293-284A-4  
; Sequence 4, Application US/08293284A  
; Patent No. 5955343  
; GENERAL INFORMATION:  
; APPLICANT: Holmes, Todd  
; APPLICANT: Zhang, Shuguang  
; APPLICANT: Rich, Alexander  
; APPLICANT: DiPersio, C. Michael  
; APPLICANT: Lockshin, Curtis  
; TITLE OF INVENTION: STABLE MACROSCOPIC MEMBRANES FORMED BY  
; TITLE OF INVENTION: SELF-ASSEMBLY OF AMPHIPHILIC PEPTIDES AND USES  
; TITLE OF INVENTION: THEREFOR  
; NUMBER OF SEQUENCES: 64  
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02173-4799  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,284A  
; FILING DATE: 22-AUG-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/973,326  
; FILING DATE: 28-DEC-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Brook, David E.  
; REGISTRATION NUMBER: 22,592  
; REFERENCE/DOCKET NUMBER: MIT-6008A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 861-6240  
; TELEFAX: (617) 861-9540  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-293-284A-4

Query Match 100.0%; Score 40; DB 2; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 28  
US-08-461-216-2  
; Sequence 2, Application US/08461216  
; Patent No. 5958883  
; GENERAL INFORMATION:  
; APPLICANT: Snow, A.D.  
; TITLE OF INVENTION: ANIMAL MODELS OF HUMAN AMYLOIDOSES  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Christensen, O'Connor, Johnson and Kindness  
; STREET: 1420 Fifth Avenue, Suite 2800  
; CITY: Seattle  
; STATE: Washington  
; COUNTRY: USA  
; ZIP: 98101-2347

; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette-5.25 inch, 1.2Mb storage  
; COMPUTER: IBM PC/386 Compatible  
; OPERATING SYSTEM: MS-DOS 4.01  
; SOFTWARE: Word for Windows-t  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/461,216  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/969,734  
; FILING DATE: October 23, 1992  
; APPLICATION NUMBER: 07/950,417  
; FILING DATE: September 23, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Broderick, Thomas F.  
; REGISTRATION NUMBER: 31,332  
; REFERENCE/DOCKET NUMBER: UOEW-1-6707  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 1-206-682-8100; 1-206-224-0709 (direct)  
; TELEFAX: 1-206-224-0779  
; TELEX: 4938023  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; DESCRIPTION: {SYMBOL 98 \f "Symbol"}/A4(1-28);  
; DESCRIPTION: page 83, line 31

US-08-461-216-2

Query Match 100.0%; Score 40; DB 2; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 16 KLVFFAED 23

RESULT 29

US-09-388-890-2

; Sequence 2, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: B(1-28) peptide of amyloid B protein  
US-09-388-890-2

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 30  
US-09-388-890-3  
; Sequence 3, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: D1N B(1-28) peptide of amyloid B protein  
US-09-388-890-3

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 31  
US-09-388-890-4  
; Sequence 4, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: E3Q B(1-28) peptide of amyloid B protein

US-09-388-890-4

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 32  
US-09-388-890-5  
; Sequence 5, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: R5Q B(1-28) peptide of amyloid B protein

US-09-388-890-5

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 33

US-09-388-890-6

; Sequence 6, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: H6Q B(1-28) peptide of amyloid B protein  
US-09-388-890-6

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 34  
US-09-388-890-7  
; Sequence 7, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: D7Q B(1-28) peptide of amyloid B protein  
US-09-388-890-7

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 35  
US-09-388-890-8  
; Sequence 8, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: E11Q B(1-28) peptide of amyloid B protein  
US-09-388-890-8

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 36  
US-09-388-890-9  
; Sequence 9, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 9:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: H13Q B(1-28) peptide of amyloid B protein  
US-09-388-890-9

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 37  
US-09-388-890-10  
; Sequence 10, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: H14Q B(1-28) peptide of amyloid B protein  
US-09-388-890-10

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 38  
US-09-388-890-14  
; Sequence 14, Application US/09388890  
; Patent No. 6136548  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: K28Q B(1-28) peptide of amyloid B protein  
US-09-388-890-14

Query Match 100.0%; Score 40; DB 3; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 39  
US-09-264-709A-1  
; Sequence 1, Application US/09264709A  
; Patent No. 6320024  
; GENERAL INFORMATION:  
; APPLICANT: Roberts, Eugene  
; TITLE OF INVENTION: Method for Design of Substances that Enhance Memory and  
; TITLE OF INVENTION: Improve the Quality of Life  
; FILE REFERENCE: 2124-310  
; CURRENT APPLICATION NUMBER: US/09/264,709A  
; CURRENT FILING DATE: 1999-03-09  
; PRIOR APPLICATION NUMBER: 08/797,782  
; PRIOR FILING DATE: 1997-02-07  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 1  
; LENGTH: 28  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-264-709A-1

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 40  
US-08-723-661B-2  
; Sequence 2, Application US/08723661B  
; Patent No. 6340783  
; GENERAL INFORMATION:  
; APPLICANT: Alan D Snow  
; TITLE OF INVENTION: Animal Models of Human Amyloidoses  
; NUMBER OF SEQUENCES: 7  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrick M. Dwyer  
; STREET: 1818 Westlake Avenue N, Suite 114  
; CITY: Seattle  
; STATE: WA (Washington)  
; COUNTRY: United States of America  
; ZIP: 98109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette - 3.50 inch, 1.44 Mb storage  
; COMPUTER: IBM PC  
; OPERATING SYSTEM: PC-DOS (Windows 98)  
; SOFTWARE: WordPerfect 5.2  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/723,661B  
; FILING DATE: 31-Oct-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/461,216  
; FILING DATE: 05-Jun-1995  
; APPLICATION NUMBER: 07/969,734  
; FILING DATE: 23-Oct-1992  
; APPLICATION NUMBER: 07/950,417  
; FILING DATE: 23-Sep-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Dwyer, Patrick M.  
; REGISTRATION NUMBER: 32,411  
; REFERENCE/DOCKET NUMBER: PROTEO.P00C1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (206) 343-7074  
; TELEFAX: (206) 343-7085  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 AMINO ACIDS  
; TYPE: AMINO ACID  
; STRANDEDNESS: SINGLE

; TOPOLOGY: LINEAR  
; MOLECULE TYPE: PEPTIDE  
; DESCRIPTION: /A4 (1-28); page 83, line 31  
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
US-08-723-661B-2

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 41  
US-09-660-954-2  
; Sequence 2, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/660,954  
; FILING DATE: 13-Sep-2000  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

HYPOTHETICAL: NO  
FRAGMENT TYPE: N-terminal  
ORIGINAL SOURCE:  
ORGANISM: HOMO SAPIENS  
IMMEDIATE SOURCE:  
CLONE: B(1-28) peptide of amyloid B protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
US-09-660-954-2

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
           |||||||  
 Pb 16 KLVFFAED 23

RESULT 42  
US-09-660-954-3  
; Sequence 3, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/660,954  
; FILING DATE: 13-Sep-2000  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids

; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: D1N B(1-28) peptide of amyloid B protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 3:  
US-09-660-954-3

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 43  
US-09-660-954-4  
; Sequence 4, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/660,954  
; FILING DATE: 13-Sep-2000  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610

; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: E3Q B(1-28) peptide of amyloid B protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:  
US-09-660-954-4

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
||| | | | |  
Db 16 KLVFFAED 23

RESULT 44  
US-09-660-954-5  
; Sequence 5, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/660,954  
; FILING DATE: 13-Sep-2000  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680

; TELECOMMUNICATION INFORMATION:  
;     TELEPHONE: (202) 383-7451  
;     TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 5:  
;     SEQUENCE CHARACTERISTICS:  
;         LENGTH: 28 amino acids  
;         TYPE: amino acid  
;         TOPOLOGY: linear  
;     MOLECULE TYPE: peptide  
;     HYPOTHETICAL: YES  
;     FRAGMENT TYPE: N-terminal  
;     ORIGINAL SOURCE:  
;         ORGANISM: HOMO SAPIENS  
;     IMMEDIATE SOURCE:  
;         CLONE: R5Q B(1-28) peptide of amyloid B protein  
;     SEQUENCE DESCRIPTION: SEQ ID NO: 5:  
US-09-660-954-5

Query Match                   100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity   100.0%; Pred. No. 0.044;  
Matches   8; Conservative   0; Mismatches   0; Indels   0; Gaps   0;  
  
Qy            1 KLVFFAED 8  
                |||||||  
Db            16 KLVFFAED 23

RESULT 45  
US-09-660-954-6  
; Sequence 6, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
;     APPLICANT: ANDERSON, STEPHEN  
;     TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
;                           OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
;     NUMBER OF SEQUENCES: 14  
;     CORRESPONDENCE ADDRESS:  
;         ADDRESSEE: HOWREY & SIMON  
;         STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
;         CITY: WASHINGTON  
;         STATE: D.C.  
;         COUNTRY: US  
;         ZIP: 20004  
;     COMPUTER READABLE FORM:  
;         MEDIUM TYPE: Floppy disk  
;         COMPUTER: IBM PC compatible  
;         OPERATING SYSTEM: PC-DOS/MS-DOS  
;         SOFTWARE: PatentIn Release #1.0, Version #1.25  
;     CURRENT APPLICATION DATA:  
;         APPLICATION NUMBER: US/09/660,954  
;         FILING DATE: 13-Sep-2000  
;         CLASSIFICATION: <Unknown>  
;     PRIOR APPLICATION DATA:  
;         APPLICATION NUMBER: US/09/388,890  
;         FILING DATE: <Unknown>  
;         APPLICATION NUMBER: 08/686,959  
;         FILING DATE: <Unknown>

; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: H6Q B(1-28) peptide of amyloid B protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:  
US-09-660-954-6

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 46  
US-09-660-954-7  
; Sequence 7, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/660,954  
; FILING DATE: 13-Sep-2000  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890

; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: D7Q B(1-28) peptide of amyloid B protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 7:  
US-09-660-954-7

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 47  
US-09-660-954-8  
; Sequence 8, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/660,954  
; FILING DATE: 13-Sep-2000

; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: E11Q B(1-28) peptide of amyloid B protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:  
US-09-660-954-8

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 48  
US-09-660-954-9  
; Sequence 9, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/660,954  
; FILING DATE: 13-Sep-2000  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 9:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: H13Q B(1-28) peptide of amyloid B protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:  
US-09-660-954-9

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 49  
US-09-660-954-10  
; Sequence 10, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/660,954  
; FILING DATE: 13-Sep-2000  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: H14Q B(1-28) peptide of amyloid B protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:  
US-09-660-954-10

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
      |||||||  
Db 16 KLVFFAED 23

RESULT 50  
US-09-660-954-14  
; Sequence 14, Application US/09660954  
; Patent No. 6471960  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
                          OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/660,954  
; FILING DATE: 13-Sep-2000  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/388,890  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 08/686,959  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: YES  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: HOMO SAPIENS  
; IMMEDIATE SOURCE:  
; CLONE: K28Q B(1-28) peptide of amyloid B protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:  
US-09-660-954-14

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
|||  
Db 16 KLVFFAED 23

RESULT 51  
US-08-898-300-4  
; Sequence 4, Application US/08898300  
; Patent No. 6548630  
; GENERAL INFORMATION:  
; APPLICANT: Zhang, Shuguang  
; APPLICANT: Lockshin, Curtis  
; APPLICANT: Rich, Alexander  
; APPLICANT: Holmes, Todd  
; TITLE OF INVENTION: STABLE MACROSCOPIC MEMBRANES FORMED BY  
; TITLE OF INVENTION: SELF-ASSEMBLY OF AMPHIPHILIC PEPTIDES AND USES  
; TITLE OF INVENTION: THEREFOR

; NUMBER OF SEQUENCES: 64  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02173-4799  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/898,300  
; FILING DATE: 22 JULY 1997  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/346,849  
; FILING DATE: 30 NOVEMBER 1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/973,326  
; FILING DATE: 28 DECEMBER 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Brook, David E.  
; REGISTRATION NUMBER: 22,592  
; REFERENCE/DOCKET NUMBER: MIT-6008FB  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (781) 861-6240  
; TELEFAX: (781) 861-9540  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 28 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-898-300-4

Query Match 100.0%; Score 40; DB 4; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.044;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
Db 16 KLVFFAED 23

RESULT 52  
US-08-609-090-3  
; Sequence 3, Application US/08609090  
; Patent No. 5840838  
; GENERAL INFORMATION:  
; APPLICANT: HENSLEY, Kenneth  
; APPLICANT: BUTTERFIELD, D. A.  
; APPLICANT: CARNEY, John M.  
; APPLICANT: AKSENOV, Michael  
; TITLE OF INVENTION: A PROCESS FOR ENHANCING THE ACTIVITY OF

; TITLE OF INVENTION: AN OLIGOPEPTIDE OR POLYPEPTIDES  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LOWE PRICE LEBLANC & BECKER  
; STREET: 99 Canal Center Plaza, Suite 300  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/609,090  
; FILING DATE: 29-FEB-1996  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kraus, Eric J.  
; REGISTRATION NUMBER: 36,190  
; REFERENCE/DOCKET NUMBER: 434-059  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-684-1111  
; TELEFAX: 703-684-1124  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 30 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-609-090-3

Query Match 100.0%; Score 40; DB 2; Length 30;  
Best Local Similarity 100.0%; Pred. No. 0.047;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 53  
US-08-609-090-4  
; Sequence 4, Application US/08609090  
; Patent No. 5840838  
; GENERAL INFORMATION:  
; APPLICANT: HENSLEY, Kenneth  
; APPLICANT: BUTTERFIELD, D. A.  
; APPLICANT: CARNEY, John M.  
; APPLICANT: AKSENOV, Michael  
; TITLE OF INVENTION: A PROCESS FOR ENHANCING THE ACTIVITY OF  
; TITLE OF INVENTION: AN OLIGOPEPTIDE OR POLYPEPTIDES  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LOWE PRICE LEBLANC & BECKER

; STREET: 99 Canal Center Plaza, Suite 300  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/609,090  
; FILING DATE: 29-FEB-1996  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kraus, Eric J.  
; REGISTRATION NUMBER: 36,190  
; REFERENCE/DOCKET NUMBER: 434-059  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-684-1111  
; TELEFAX: 703-684-1124  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 33 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-609-090-4

Query Match 100.0%; Score 40; DB 2; Length 33;  
Best Local Similarity 100.0%; Pred. No. 0.052;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 54  
US-08-475-579A-4  
; Sequence 4, Application US/08475579A  
; Patent No. 5854215  
; GENERAL INFORMATION:  
; APPLICANT: Mark A. Findeis et al.  
; TITLE OF INVENTION: Modulators of {SYMBOL 98 \f "Symbol"}-Amyloid Peptide Aggrega  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/475,579A  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/404,831  
; FILING DATE: 14-MAR-1995  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kara, Catherine J.  
; REGISTRATION NUMBER: P41,106  
; REFERENCE/DOCKET NUMBER: PPI-002CP  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 34 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
US-08-475-579A-4

Query Match 100.0%; Score 40; DB 2; Length 34;  
Best Local Similarity 100.0%; Pred. No. 0.053;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 10 KLVFFAED 17

RESULT 55  
US-08-304-585-6  
; Sequence 6, Application US/08304585  
; Patent No. 5721106  
; GENERAL INFORMATION:  
; APPLICANT: Maggio, John E.  
; APPLICANT: Mantyh, Patrick W.  
; TITLE OF INVENTION: LABELLED BETA-AMYLOID PEPTIDE AND  
; TITLE OF INVENTION: METHODS FOR USE IN DETECTING ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Muetting, Raasch, Gebhardt & Schwappach, P.A.  
; STREET: P.O. Box 581415  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55458-1415  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/304,585  
; FILING DATE: 12-SEP-1994  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Mueting, Ann M.  
; REGISTRATION NUMBER: 33,977  
; REFERENCE/DOCKET NUMBER: 110.00010120  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612-305-1217  
; TELEFAX: 612-305-1228  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: peptide  
US-08-304-585-6

Query Match 100.0%; Score 40; DB 1; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.055;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 16 KLVFFAED 23

RESULT 56  
US-08-612-785B-16  
; Sequence 16, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831

; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal

US-08-612-785B-16

Query Match 100.0%; Score 40; DB 2; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.055;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 11 KLVFFAED 18

RESULT 57

US-08-612-785B-36

; Sequence 36, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 36:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
US-08-612-785B-36

Query Match 100.0%; Score 40; DB 2; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.055;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 11 KLVFFAED 18

RESULT 58  
US-08-612-785B-38  
; Sequence 38, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B

; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 38:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
US-08-612-785B-38

Query Match 100.0%; Score 40; DB 2; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.055;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 59  
US-08-612-785B-40  
; Sequence 40, Application US/08612785B  
; Patent No. 5854204  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Ab Peptides that Modulate b-Amyloid  
; TITLE OF INVENTION: Aggregation  
; NUMBER OF SEQUENCES: 40  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street, Suite 510  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/612,785B  
; FILING DATE: Herewith  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 40:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
US-08-612-785B-40

Query Match 100.0%; Score 40; DB 2; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.055;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 11 KLVFFAED 18

RESULT 60  
US-08-617-267C-16  
; Sequence 16, Application US/08617267C  
; Patent No. 6319498  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/617,267C  
; FILING DATE: 14-MAR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
US-08-617-267C-16

Query Match 100.0%; Score 40; DB 4; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.055;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 11 KLVFFAED 18

RESULT 61  
US-08-609-090-6  
; Sequence 6, Application US/08609090  
; Patent No. 5840838  
; GENERAL INFORMATION:  
; APPLICANT: HENSLEY, Kenneth  
; APPLICANT: BUTTERFIELD, D. A.  
; APPLICANT: CARNEY, John M.  
; APPLICANT: AKSENOV, Michael  
; TITLE OF INVENTION: A PROCESS FOR ENHANCING THE ACTIVITY OF  
; TITLE OF INVENTION: AN OLIGOPEPTIDE OR POLYPEPTIDES  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LOWE PRICE LEBLANC & BECKER  
; STREET: 99 Canal Center Plaza, Suite 300  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314

; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/609,090  
; FILING DATE: 29-FEB-1996  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kraus, Eric J.  
; REGISTRATION NUMBER: 36,190  
; REFERENCE/DOCKET NUMBER: 434-059  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-684-1111  
; TELEFAX: 703-684-1124  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 36 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-609-090-6

Query Match 100.0%; Score 40; DB 2; Length 36;  
Best Local Similarity 100.0%; Pred. No. 0.057;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 62  
US-08-302-808-1  
; Sequence 1, Application US/08302808  
; Patent No. 5750349  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5750349uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5

; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/302,808  
; FILING DATE: 15-SEP-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 38 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
US-08-302-808-1

Query Match 100.0%; Score 40; DB 1; Length 38;  
Best Local Similarity 100.0%; Pred. No. 0.06;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 63  
US-07-737-371E-68  
; Sequence 68, Application US/07737371E  
; Patent No. 5876948  
; GENERAL INFORMATION:  
; APPLICANT: Yankner, Bruce A.  
; TITLE OF INVENTION: SCREENING METHODS TO IDENTIFY  
; TITLE OF INVENTION: NEUROTOXIN INHIBITORS (AS AMENDED)  
; NUMBER OF SEQUENCES: 77  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street

; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/737,371E  
; FILING DATE: 29-JUL-1991  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/559,172  
; FILING DATE: 27-JUL-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Freeman, John W.  
; REGISTRATION NUMBER: 29,066  
; REFERENCE/DOCKET NUMBER: 00108/028002  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-542-5070  
; TELEFAX: 617-542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 68:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 38 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein

US-07-737-371E-68

Query Match 100.0%; Score 40; DB 2; Length 38;  
Best Local Similarity 100.0%; Pred. No. 0.06;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 64  
US-08-986-948-1  
; Sequence 1, Application US/08986948  
; Patent No. 5955317  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5955317uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA

; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/986,948  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/302,808  
; FILING DATE: 15-SEP-1994  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 38 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
US-08-986-948-1

Query Match 100.0%; Score 40; DB 2; Length 38;  
Best Local Similarity 100.0%; Pred. No. 0.06;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 65  
US-08-304-585-5  
; Sequence 5, Application US/08304585

; Patent No. 5721106  
; GENERAL INFORMATION:  
; APPLICANT: Maggio, John E.  
; APPLICANT: Mantyh, Patrick W.  
; TITLE OF INVENTION: LABELLED BETA-AMYLOID PEPTIDE AND  
; TITLE OF INVENTION: METHODS FOR USE IN DETECTING ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Muetting, Raasch, Gebhardt & Schwappach, P.A.  
; STREET: P.O. Box 581415  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55458-1415  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/304,585  
; FILING DATE: 12-SEP-1994  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Muetting, Ann M.  
; REGISTRATION NUMBER: 33,977  
; REFERENCE/DOCKET NUMBER: 110.00010120  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612-305-1217  
; TELEFAX: 612-305-1228  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: peptide  
US-08-304-585-5

Query Match 100.0%; Score 40; DB 1; Length 39;  
Best Local Similarity 100.0%; Pred. No. 0.062;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 15 KLVFFAED 22

RESULT 66  
US-08-302-808-2  
; Sequence 2, Application US/08302808  
; Patent No. 5750349  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5750349uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR

; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/302,808  
; FILING DATE: 15-SEP-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
US-08-302-808-2

Query Match 100.0%; Score 40; DB 1; Length 39;  
Best Local Similarity 100.0%; Pred. No. 0.062;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 67  
US-08-609-090-7  
; Sequence 7, Application US/08609090  
; Patent No. 5840838  
; GENERAL INFORMATION:  
; APPLICANT: HENSLEY, Kenneth  
; APPLICANT: BUTTERFIELD, D. A.  
; APPLICANT: CARNEY, John M.  
; APPLICANT: AKSENOV, Michael  
; TITLE OF INVENTION: A PROCESS FOR ENHANCING THE ACTIVITY OF  
; TITLE OF INVENTION: AN OLIGOPEPTIDE OR POLYPEPTIDES  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LOWE PRICE LEBLANC & BECKER  
; STREET: 99 Canal Center Plaza, Suite 300  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/609,090  
; FILING DATE: 29-FEB-1996  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kraus, Eric J.  
; REGISTRATION NUMBER: 36,190  
; REFERENCE/DOCKET NUMBER: 434-059  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-684-1111  
; TELEFAX: 703-684-1124  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-609-090-7

Query Match 100.0%; Score 40; DB 2; Length 39;  
Best Local Similarity 100.0%; Pred. No. 0.062;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
Db 16 KLVFFAED 23

RESULT 68  
US-08-682-245A-1

; Sequence 1, Application US/08682245A  
; Patent No. 5919631  
; GENERAL INFORMATION:  
; APPLICANT: GOYAL, SHEFALI  
; APPLICANT: PAUL, JOSEPH W  
; APPLICANT: RIEDEL, NORBERT G  
; APPLICANT: SAHASRABUDHE, SUDHIR  
; TITLE OF INVENTION: A METHOD OF DETERMINING THE DEGREE OF  
; TITLE OF INVENTION: AGGREGATION OF THE BA4 PEPTIDE  
; NUMBER OF SEQUENCES: 5  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOECHST MARION ROUSSEL, INC.  
; STREET: 2110 E. GALBRAITH RD., P.O. BOX 156300  
; CITY: CINCINNATI  
; STATE: OHIO  
; COUNTRY: U.S.A.  
; ZIP: 45215-6300  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/682,245A  
; FILING DATE: 17-JUL-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/039,414  
; FILING DATE: 16-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: LENTZ, NELSEN L  
; REGISTRATION NUMBER: 38,537  
; REFERENCE/DOCKET NUMBER: HR-1257A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 513-948-7369  
; TELEFAX: 513-948-7961 OR 4681  
; TELEX: 214320  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-682-245A-1

Query Match 100.0%; Score 40; DB 2; Length 39;  
Best Local Similarity 100.0%; Pred. No. 0.062;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 69  
US-08-986-948-2

; Sequence 2, Application US/08986948  
; Patent No. 5955317  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5955317uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/986,948  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/302,808  
; FILING DATE: 15-SEP-1994  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:

US-08-986-948-2

Query Match 100.0%; Score 40; DB 2; Length 39;  
Best Local Similarity 100.0%; Pred. No. 0.062;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 70

US-07-744-767A-1

; Sequence 1, Application US/07744767A  
; Patent No. 5434050

; GENERAL INFORMATION:

; APPLICANT: Maggio, John E.  
; APPLICANT: Mantyh, Patrick W.  
; TITLE OF INVENTION: Labelled -Amyloid Peptide and Methods  
; TITLE OF INVENTION: for Use in Detecting Alzheimer's Disease  
; NUMBER OF SEQUENCES: 3

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Schwegman, Lundberg & Woessner, P.A.  
; STREET: 3500 IDS Center  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55402

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/07/744,767A  
; FILING DATE: 13-AUG-1991  
; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Muetting, Ann M.  
; REGISTRATION NUMBER: 33,977  
; REFERENCE/DOCKET NUMBER: 600.226-US-01

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 612-339-0331  
; TELEFAX: 612-339-3061

; INFORMATION FOR SEQ ID NO: 1:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 40 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-07-744-767A-1

Query Match 100.0%; Score 40; DB 1; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8

Db 16 KLVFFAED 23

|||||||  
RESULT 71  
US-08-235-400-2  
; Sequence 2, Application US/08235400  
; Patent No. 5552426  
; GENERAL INFORMATION:  
; APPLICANT: Lunn, William H.  
; APPLICANT: Monn, James A.  
; APPLICANT: Zimmerman, Dennis M.  
; TITLE OF INVENTION: METHODS FOR TREATING A PHYSIOLOGICAL  
; TITLE OF INVENTION: DISORDER ASSOCIATED WITH BETA AMYLOID PEPTIDE  
; NUMBER OF SEQUENCES: 2  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Eli Lilly and Company  
; STREET: Lilly Corporate Center/1104  
; CITY: Indianapolis  
; STATE: Indiana  
; COUNTRY: United States of America  
; ZIP: 46285  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/235,400  
; FILING DATE:  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Gaylo, Paul J.  
; REGISTRATION NUMBER: 36,808  
; REFERENCE/DOCKET NUMBER: X-9507  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (317) 276-0756  
; TELEFAX: (317) 276-3861  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-235-400-2

Query Match 100.0%; Score 40; DB 1; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
Db 16 KLVFFAED 23

|||||||  
RESULT 72

US-08-476-464A-2  
; Sequence 2, Application US/08476464A  
; Patent No. 5707821  
; GENERAL INFORMATION:  
; APPLICANT: RYDEL, RUSSELL E.  
; APPLICANT: DAPPEN, MICHAEL S.  
; TITLE OF INVENTION: THERAPEUTIC INHIBITION OF PHOSPHOLIPASE  
; TITLE OF INVENTION: A2 IN A-BETA PEPTIDE-MEDIATED NEURODEGENERATIVE  
DISEASE  
; NUMBER OF SEQUENCES: 2  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: TOWNSEND & TOWNSEND & CREW LLP  
; STREET: TWO EMBARCADERO CENTER, 8TH FLOOR  
; CITY: SAN FRANCISCO  
; STATE: CALIFORNIA  
; COUNTRY: U.S.A.  
; ZIP: 94111-3834  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/476,464A  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: STORELLA, JOHN R.  
; REGISTRATION NUMBER: 32,944  
; REFERENCE/DOCKET NUMBER: 15270-002300  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 326-2400  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-476-464A-2

Query Match 100.0%; Score 40; DB 1; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 73  
US-08-304-585-1  
; Sequence 1, Application US/08304585  
; Patent No. 5721106  
; GENERAL INFORMATION:  
; APPLICANT: Maggio, John E.

; APPLICANT: Mantyh, Patrick W.  
; TITLE OF INVENTION: LABELLED BETA-AMYLOID PEPTIDE AND  
; TITLE OF INVENTION: METHODS FOR USE IN DETECTING ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Mueting, Raasch, Gebhardt & Schwappach, P.A.  
; STREET: P.O. Box 581415  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55458-1415  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/304,585  
; FILING DATE: 12-SEP-1994  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Mueting, Ann M.  
; REGISTRATION NUMBER: 33,977  
; REFERENCE/DOCKET NUMBER: 110.00010120  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612-305-1217  
; TELEFAX: 612-305-1228  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: peptide  
US-08-304-585-1

Query Match 100.0%; Score 40; DB 1; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 74  
US-08-302-808-3  
; Sequence 3, Application US/08302808  
; Patent No. 5750349  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5750349uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/302,808  
; FILING DATE: 15-SEP-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
US-08-302-808-3

Query Match 100.0%; Score 40; DB 1; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
Db 16 KLVFFAED 23

RESULT 75

US-08-433-734-1  
; Sequence 1, Application US/08433734  
; Patent No. 5837473  
; GENERAL INFORMATION:  
; APPLICANT: Maggio, John E.  
; APPLICANT: Mantyh, Patrick W.  
; TITLE OF INVENTION: Labelled -Amyloid Peptide and Methods  
; TITLE OF INVENTION: for Use in Detecting Alzheimer's Disease  
; NUMBER OF SEQUENCES: 3  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Mueting, Raasch, Gebhardt & Schwappach, P.A.  
; STREET: P.O. Box 581415  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55458-1415  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/433,734  
; FILING DATE: 03-MAY-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Mueting, Ann M.  
; REGISTRATION NUMBER: 33,977  
; REFERENCE/DOCKET NUMBER: 110.00010102  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612-305-1220  
; TELEFAX: 612-305-1228  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-433-734-1

Query Match 100.0%; Score 40; DB 2; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 76  
US-08-609-090-8  
; Sequence 8, Application US/08609090  
; Patent No. 5840838  
; GENERAL INFORMATION:  
; APPLICANT: HENSLEY, Kenneth  
; APPLICANT: BUTTERFIELD, D. A.  
; APPLICANT: CARNEY, John M.

; APPLICANT: AKSENOV, Michael  
; TITLE OF INVENTION: A PROCESS FOR ENHANCING THE ACTIVITY OF  
; TITLE OF INVENTION: AN OLIGOPEPTIDE OR POLYPEPTIDES  
; NUMBER OF SEQUENCES: 11  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LOWE PRICE LEBLANC & BECKER  
; STREET: 99 Canal Center Plaza, Suite 300  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/609,090  
; FILING DATE: 29-FEB-1996  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kraus, Eric J.  
; REGISTRATION NUMBER: 36,190  
; REFERENCE/DOCKET NUMBER: 434-059  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 703-684-1111  
; TELEFAX: 703-684-1124  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-609-090-8

Query Match 100.0%; Score 40; DB 2; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 77  
US-07-737-371E-69  
; Sequence 69, Application US/07737371E  
; Patent No. 5876948  
; GENERAL INFORMATION:  
; APPLICANT: Yankner, Bruce A.  
; TITLE OF INVENTION: SCREENING METHODS TO IDENTIFY  
; TITLE OF INVENTION: NEUROTOXIN INHIBITORS (AS AMENDED)  
; NUMBER OF SEQUENCES: 77  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street

; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/737,371E  
; FILING DATE: 29-JUL-1991  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/559,172  
; FILING DATE: 27-JUL-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Freeman, John W.  
; REGISTRATION NUMBER: 29,066  
; REFERENCE/DOCKET NUMBER: 00108/028002  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-542-5070  
; TELEFAX: 617-542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 69:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein

US-07-737-371E-69

Query Match 100.0%; Score 40; DB 2; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 78  
US-08-682-245A-2  
; Sequence 2, Application US/08682245A  
; Patent No. 5919631  
; GENERAL INFORMATION:  
; APPLICANT: GOYAL, SHEFALI  
; APPLICANT: PAUL, JOSEPH W  
; APPLICANT: RIEDEL, NORBERT G  
; APPLICANT: SAHASRABUDHE, SUDHIR  
; TITLE OF INVENTION: A METHOD OF DETERMINING THE DEGREE OF  
; TITLE OF INVENTION: AGGREGATION OF THE BA4 PEPTIDE  
; NUMBER OF SEQUENCES: 5  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOECHST MARION ROUSSEL, INC.  
; STREET: 2110 E. GALBRAITH RD., P.O. BOX 156300  
; CITY: CINCINNATI

; STATE: OHIO  
; COUNTRY: U.S.A.  
; ZIP: 45215-6300  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/682,245A  
; FILING DATE: 17-JUL-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/039,414  
; FILING DATE: 16-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: LENTZ, NELSEN L  
; REGISTRATION NUMBER: 38,537  
; REFERENCE/DOCKET NUMBER: HR-1257A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 513-948-7369  
; TELEFAX: 513-948-7961 OR 4681  
; TELEX: 214320  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein

US-08-682-245A-2

Query Match 100.0%; Score 40; DB 2; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 16 KLVFFAED 23

RESULT 79  
US-08-986-948-3  
; Sequence 3, Application US/08986948  
; Patent No. 5955317  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5955317uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA

; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/986,948  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/302,808  
; FILING DATE: 15-SEP-1994  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
US-08-986-948-3

Query Match 100.0%; Score 40; DB 2; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 80  
US-08-461-216-1  
; Sequence 1, Application US/08461216

; Patent No. 5958883  
; GENERAL INFORMATION:  
; APPLICANT: Snow, A.D.  
; TITLE OF INVENTION: ANIMAL MODELS OF HUMAN AMYLOIDOSSES  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Christensen, O'Connor, Johnson and Kindness  
; STREET: 1420 Fifth Avenue, Suite 2800  
; CITY: Seattle  
; STATE: Washington  
; COUNTRY: USA  
; ZIP: 98101-2347  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette-5.25 inch, 1.2Mb storage  
; COMPUTER: IBM PC/386 Compatible  
; OPERATING SYSTEM: MS-DOS 4.01  
; SOFTWARE: Word for Windows-t  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/461,216  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/969,734  
; FILING DATE: October 23, 1992  
; APPLICATION NUMBER: 07/950,417  
; FILING DATE: September 23, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Broderick, Thomas F.  
; REGISTRATION NUMBER: 31,332  
; REFERENCE/DOCKET NUMBER: UOFW-1-6707  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 1-206-682-8100; 1-206-224-0709 (direct)  
; TELEFAX: 1-206-224-0779  
; TELEX: 4938023  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; DESCRIPTION: {SYMBOL 98 \f "Symbol"}/A4(1-40);  
; DESCRIPTION: FIGURES 23-29  
US-08-461-216-1  
  
Query Match 100.0%; Score 40; DB 2; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
Db 16 KLVFFAED 23

RESULT 81  
US-08-959-148-1  
; Sequence 1, Application US/08959148

; Patent No. 6172277  
; GENERAL INFORMATION:  
; APPLICANT: Tate, Barbara A.  
; APPLICANT: Majocha, Ronald  
; APPLICANT: Newton, Julie L.  
; TITLE OF INVENTION: NON-TRANSGENIC ANIMAL MODEL OF ALZHEIMER'S DISEASE  
; FILE REFERENCE: 04930/022001  
; CURRENT APPLICATION NUMBER: US/08/959,148  
; CURRENT FILING DATE: 1997-10-28  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 1  
; LENGTH: 40  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-08-959-148-1

Query Match 100.0%; Score 40; DB 3; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 82

US-09-242-724-22

; Sequence 22, Application US/09242724  
; Patent No. 6316405  
; GENERAL INFORMATION:  
; APPLICANT: Solomon, Michael E.  
; APPLICANT: Rich, Daniel H.  
; TITLE OF INVENTION: Cyclosporin A Conjugates and Uses Therefor  
; FILE REFERENCE: Cyclosporin Analogs  
; CURRENT APPLICATION NUMBER: US/09/242,724  
; CURRENT FILING DATE: 1999-02-22  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 22  
; LENGTH: 40  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-242-724-22

Query Match 100.0%; Score 40; DB 4; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 83

US-08-723-661B-1

; Sequence 1, Application US/08723661B

; Patent No. 6340783  
; GENERAL INFORMATION:  
; APPLICANT: Alan D Snow  
; TITLE OF INVENTION: Animal Models of Human Amyloidoses  
; NUMBER OF SEQUENCES: 7  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrick M. Dwyer  
; STREET: 1818 Westlake Avenue N, Suite 114  
; CITY: Seattle  
; STATE: WA (Washington)  
; COUNTRY: United States of America  
; ZIP: 98109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette - 3.50 inch, 1.44 Mb storage  
; COMPUTER: IBM PC  
; OPERATING SYSTEM: PC-DOS (Windows 98)  
; SOFTWARE: WordPerfect 5.2  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/723,661B  
; FILING DATE: 31-Oct-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/461,216  
; FILING DATE: 05-Jun-1995  
; APPLICATION NUMBER: 07/969,734  
; FILING DATE: 23-Oct-1992  
; APPLICATION NUMBER: 07/950,417  
; FILING DATE: 23-Sep-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Dwyer, Patrick M.  
; REGISTRATION NUMBER: 32,411  
; REFERENCE/DOCKET NUMBER: PROTEO.P00C1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (206) 343-7074  
; TELEFAX: (206) 343-7085  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 AMINO ACIDS  
; TYPE: AMINO ACID  
; STRANDEDNESS: SINGLE  
; TOPOLOGY: LINEAR  
; MOLECULE TYPE: PEPTIDE  
; DESCRIPTION: /A4 (1-40); FIGURES 23-29  
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:  
US-08-723-661B-1

Query Match 100.0%; Score 40; DB 4; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 84  
US-09-062-365-3  
; Sequence 3, Application US/09062365

; Patent No. 6465422  
; GENERAL INFORMATION:  
; APPLICANT: Schmidt, Ann Marie  
; APPLICANT: Stern, David  
; TITLE OF INVENTION: METHOD FOR INHIBITING TUMOR INVASION OR SPREADING IN A  
; TITLE OF INVENTION: SUBJECT  
; FILE REFERENCE: 55424  
; CURRENT APPLICATION NUMBER: US/09/062,365  
; CURRENT FILING DATE: 1998-04-17  
; NUMBER OF SEQ ID NOS: 6  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 3  
; LENGTH: 40  
; TYPE: PRT  
; ORGANISM: Human  
US-09-062-365-3

Query Match 100.0%; Score 40; DB 4; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 85

US-09-133-866-1

; Sequence 1, Application US/09133866  
; Patent No. 6600017  
; GENERAL INFORMATION:  
; APPLICANT: Glabe, Charles  
; APPLICANT: Garzon-Rodriguez, William  
; TITLE OF INVENTION: FLUORESCENT AMYLOID ABETA PEPTIDES AND  
; TITLE OF INVENTION: USES THEREOF  
; FILE REFERENCE: 50016/002002  
; CURRENT APPLICATION NUMBER: US/09/133,866  
; CURRENT FILING DATE: 1998-08-13  
; EARLIER APPLICATION NUMBER: 60/055,660  
; EARLIER FILING DATE: 1997-08-14  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 1  
; LENGTH: 40  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-133-866-1

Query Match 100.0%; Score 40; DB 4; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 86  
PCT-US92-06700-1  
; Sequence 1, Application PC/TUS9206700  
; GENERAL INFORMATION:  
; APPLICANT: Mantyh, Patrick W.  
; APPLICANT: Maggio, John E.  
; TITLE OF INVENTION: Labelled -Amyloid Peptide  
; TITLE OF INVENTION: and Alzheimer's Disease Detection  
; NUMBER OF SEQUENCES: 2  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Merchant & Gould  
; STREET: 3100 Norwest Center  
; CITY: Minneapolis  
; STATE: Minnesota  
; COUNTRY: USA  
; ZIP: 55402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.5 inch, 720 Kb  
; COMPUTER: Northgate 386  
; OPERATING SYSTEM: DOS 4.0  
; SOFTWARE: WordPerfect 5.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US92/06700  
; FILING DATE: 19920810  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kowalchyk, Alan W.  
; REGISTRATION NUMBER: 31,535  
; REFERENCE/DOCKET NUMBER: 600.226-WO-01  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (612) 332-5300  
; TELEFAX: (612) 332-9081  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 40 amino acid residues  
; TYPE: AMINO ACID  
; TOPOLOGY: Linear  
; MOLECULE TYPE: Peptide  
; FRAGMENT TYPE: Internal Fragment  
; ORIGINAL SOURCE: Synthetically Derived  
; FEATURE:  
; NAME/KEY: Internal fragment of the -  
; NAME/KEY: amyloid peptide precursor  
; LOCATION: Represents isolated internal  
; LOCATION: sequence of 40 amino acid residues from  
; LOCATION: the -amyloid peptide precursor  
PCT-US92-06700-1  
  
Query Match 100.0%; Score 40; DB 5; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.063;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
Db 16 KLVFFAED 23

RESULT 87  
US-08-302-808-4  
; Sequence 4, Application US/08302808  
; Patent No. 5750349  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5750349uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/302,808  
; FILING DATE: 15-SEP-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 41 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:

US-08-302-808-4

Query Match 100.0%; Score 40; DB 1; Length 41;  
Best Local Similarity 100.0%; Pred. No. 0.065;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 88

US-08-682-245A-3

; Sequence 3, Application US/08682245A  
; Patent No. 5919631  
; GENERAL INFORMATION:  
; APPLICANT: GOYAL, SHEFALI  
; APPLICANT: PAUL, JOSEPH W  
; APPLICANT: RIEDEL, NORBERT G  
; APPLICANT: SAHASRABUDHE, SUDHIR  
; TITLE OF INVENTION: A METHOD OF DETERMINING THE DEGREE OF  
; TITLE OF INVENTION: AGGREGATION OF THE BA4 PEPTIDE  
; NUMBER OF SEQUENCES: 5  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOECHST MARION ROUSSEL, INC.  
; STREET: 2110 E. GALBRAITH RD., P.O. BOX 156300  
; CITY: CINCINNATI  
; STATE: OHIO  
; COUNTRY: U.S.A.  
; ZIP: 45215-6300  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/682,245A  
; FILING DATE: 17-JUL-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/039,414  
; FILING DATE: 16-AUG-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: LENTZ, NELSEN L  
; REGISTRATION NUMBER: 38,537  
; REFERENCE/DOCKET NUMBER: HR-1257A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 513-948-7369  
; TELEFAX: 513-948-7961 OR 4681  
; TELEX: 214320  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 41 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein

US-08-682-245A-3

Query Match 100.0%; Score 40; DB 2; Length 41;  
Best Local Similarity 100.0%; Pred. No. 0.065;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 89

US-08-986-948-4

; Sequence 4, Application US/08986948  
; Patent No. 5955317  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5955317uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/986,948  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/302,808  
; FILING DATE: 15-SEP-1994  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993  
; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400

; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 41 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
US-08-986-948-4

Query Match 100.0%; Score 40; DB 2; Length 41;  
Best Local Similarity 100.0%; Pred. No. 0.065;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 90

US-07-744-767A-2

; Sequence 2, Application US/07744767A  
; Patent No. 5434050  
; GENERAL INFORMATION:  
; APPLICANT: Maggio, John E.  
; APPLICANT: Mantyh, Patrick W.  
; TITLE OF INVENTION: Labelled -Amyloid Peptide and Methods  
; TITLE OF INVENTION: for Use in Detecting Alzheimer's Disease  
; NUMBER OF SEQUENCES: 3  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Schwegman, Lundberg & Woessner, P.A.  
; STREET: 3500 IDS Center  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/744,767A  
; FILING DATE: 13-AUG-1991  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Mueting, Ann M.  
; REGISTRATION NUMBER: 33,977  
; REFERENCE/DOCKET NUMBER: 600.226-US-01  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612-339-0331  
; TELEFAX: 612-339-3061

; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-07-744-767A-2

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 91  
US-08-179-574-1  
; Sequence 1, Application US/08179574  
; Patent No. 5506097  
; GENERAL INFORMATION:  
; APPLICANT: Huntington Potter  
; APPLICANT: Usamah Kayyali  
; TITLE OF INVENTION: Compounds and Methods for Inhibiting  
; NUMBER OF SEQUENCES: 6  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02173  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/179,574  
; FILING DATE:  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/819,361  
; FILING DATE: 13-JAN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Granahan, Patricia  
; REGISTRATION NUMBER: 32,227  
; REFERENCE/DOCKET NUMBER: HU90-03A3  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-861-6240  
; TELEFAX: 617-861-9540  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear

US-08-179-574-1

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 92

US-08-271-162-5

; Sequence 5, Application US/08271162  
; Patent No. 5523295  
; GENERAL INFORMATION:  
; APPLICANT: Fasman, Gerald D.  
; TITLE OF INVENTION: METHOD FOR TREATING AND PREVENTING  
; TITLE OF INVENTION: ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 5  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Wolf, Greenfield & Sacks P.C.  
; STREET: 600 Atlantic Avenue  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02210  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/271,162  
; FILING DATE: July , 1994  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Greer, Helen A.  
; REGISTRATION NUMBER: 36,816  
; REFERENCE/DOCKET NUMBER: F0437/7000  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-720-3500  
; TELEFAX: 617-720-2441  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear

US-08-271-162-5

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 93  
US-08-347-144-1  
; Sequence 1, Application US/08347144  
; Patent No. 5589154  
; GENERAL INFORMATION:  
; APPLICANT: ANDERSON, STEPHEN  
; TITLE OF INVENTION: METHODS FOR THE PREVENTION AND TREATMENT  
; TITLE OF INVENTION: OF VASCULAR HEMORRHAGING AND ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 1  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: HOWREY & SIMON  
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.  
; CITY: WASHINGTON  
; STATE: D.C.  
; COUNTRY: US  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/347,144  
; FILING DATE:  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: AUERBACH, JEFFREY I.  
; REGISTRATION NUMBER: 32,680  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 383-7451  
; TELEFAX: (202) 383-6610  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
; ORGANISM: AMYLOID PEPTIDE  
US-08-347-144-1

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 94  
US-08-462-859A-19  
; Sequence 19, Application US/08462859A

; Patent No. 5652092  
; GENERAL INFORMATION:  
; APPLICANT: Jacobsen, J. S.  
; APPLICANT: Vitek, M. P.  
; TITLE OF INVENTION: No. 5652092el Amyloid Precursor and Method of  
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate  
Formation  
; TITLE OF INVENTION: of B-Amyloid Peptide  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: American Cyanamid Company  
; STREET: One Cyanamid Plaza  
; CITY: Wayne  
; STATE: New Jersey  
; COUNTRY: United States  
; ZIP: 07470-8426  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/462,859A  
; FILING DATE: 05-JUN-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Barnhard, Elizabeth M.  
; REGISTRATION NUMBER: 31,088  
; REFERENCE/DOCKET NUMBER: 31,844-04  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (201)831-3246  
; TELEFAX: (201)831-3305  
; INFORMATION FOR SEQ ID NO: 19:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-462-859A-19

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 95  
US-08-123-659A-19  
; Sequence 19, Application US/08123659A  
; Patent No. 5656477  
; GENERAL INFORMATION:  
; APPLICANT: Jacobsen, J. S.  
; APPLICANT: Vitek, M. P.

; TITLE OF INVENTION: No. 5656477el Amyloid Precursor and Method of  
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate  
Formation  
; TITLE OF INVENTION: of B-Amyloid Peptide  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Anne Rosenblum  
; STREET: 163 Delaware Avenue, Suite 212  
; CITY: Delmar  
; STATE: New York  
; COUNTRY: U.S.A.  
; ZIP: 12054  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/123,659A  
; FILING DATE: 20-SEP-1993  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Rosenblum, Anne M.  
; REGISTRATION NUMBER: 30,419  
; REFERENCE/DOCKET NUMBER: 31,844-01  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (518)475-0611  
; TELEFAX: (518)475-0619  
; INFORMATION FOR SEQ ID NO: 19:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-123-659A-19

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 96  
US-08-464-247A-19  
; Sequence 19, Application US/08464247A  
; Patent No. 5693478  
; GENERAL INFORMATION:  
; APPLICANT: Jacobsen, J. S.  
; APPLICANT: Vitek, M. P.  
; TITLE OF INVENTION: No. 5693478el Amyloid Precursor and Method of  
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate  
Formation  
; TITLE OF INVENTION: of B-Amyloid Peptide  
; NUMBER OF SEQUENCES: 19

; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: American Cyanamid Company  
; STREET: One Campus Drive  
; CITY: Parsippany  
; STATE: New Jersey  
; COUNTRY: United States  
; ZIP: 07054  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/464,247A  
; FILING DATE: 05-JUN-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Barnhard, Elizabeth M.  
; REGISTRATION NUMBER: 31,088  
; REFERENCE/DOCKET NUMBER: 31,844-03  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 201-683-2158  
; TELEFAX: 201-683-4117  
; INFORMATION FOR SEQ ID NO: 19:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-464-247A-19

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 16 KLVFFAED 23

RESULT 97  
US-08-464-248A-19  
; Sequence 19, Application US/08464248A  
; Patent No. 5703209  
; GENERAL INFORMATION:  
; APPLICANT: Jacobsen, J. S.  
; APPLICANT: Vitek, M. P.  
; TITLE OF INVENTION: No. 5703209el Amyloid Precursor and Method of  
; TITLE OF INVENTION: Using Same to Access Agents Which Down-Regulate  
Formation  
; TITLE OF INVENTION: of B-Amyloid Peptide  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: American Cyanamid Company  
; STREET: One Cyanamid Plaza  
; CITY: Wayne

; STATE: New Jersey  
; COUNTRY: United States  
; ZIP: 07470-8426  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/464,248A  
; FILING DATE: 05-JUN-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Barnhard, Elizabeth M.  
; REGISTRATION NUMBER: 31,088  
; REFERENCE/DOCKET NUMBER: 31,844-02  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (201)831-3246  
; TELEFAX: (201)831-3305  
; INFORMATION FOR SEQ ID NO: 19:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-464-248A-19

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 16 KLVFFAED 23

RESULT 98  
US-08-476-464A-1  
; Sequence 1, Application US/08476464A  
; Patent No. 5707821  
; GENERAL INFORMATION:  
; APPLICANT: RYDEL, RUSSELL E.  
; APPLICANT: DAPPEN, MICHAEL S.  
; TITLE OF INVENTION: THERAPEUTIC INHIBITION OF PHOSPHOLIPASE  
; TITLE OF INVENTION: A2 IN A-BETA PEPTIDE-MEDIATED NEURODEGENERATIVE  
DISEASE  
; NUMBER OF SEQUENCES: 2  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: TOWNSEND & TOWNSEND & CREW LLP  
; STREET: TWO EMBARCADERO CENTER, 8TH FLOOR  
; CITY: SAN FRANCISCO  
; STATE: CALIFORNIA  
; COUNTRY: U.S.A.  
; ZIP: 94111-3834  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/476,464A  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: STORELLA, JOHN R.  
; REGISTRATION NUMBER: 32,944  
; REFERENCE/DOCKET NUMBER: 15270-002300  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415)326-2400  
; TELEFAX: (415)576-0300  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-476-464A-1

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 99  
US-08-304-585-2  
; Sequence 2, Application US/08304585  
; Patent No. 5721106  
; GENERAL INFORMATION:  
; APPLICANT: Maggio, John E.  
; APPLICANT: Mantyh, Patrick W.  
; TITLE OF INVENTION: LABELLED BETA-AMYLOID PEPTIDE AND  
; TITLE OF INVENTION: METHODS FOR USE IN DETECTING ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Muetting, Raasch, Gebhardt & Schwappach, P.A.  
; STREET: P.O. Box 581415  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: USA  
; ZIP: 55458-1415  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/304,585  
; FILING DATE: 12-SEP-1994

; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Muetting, Ann M.  
; REGISTRATION NUMBER: 33,977  
; REFERENCE/DOCKET NUMBER: 110.00010120  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612-305-1217  
; TELEFAX: 612-305-1228  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: not relevant  
; TOPOLOGY: not relevant  
; MOLECULE TYPE: peptide

US-08-304-585-2

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 100

US-08-302-808-5

; Sequence 5, Application US/08302808  
; Patent No. 5750349  
; GENERAL INFORMATION:  
; APPLICANT: SUZUKI, No. 5750349uhiro  
; APPLICANT: ODAKA, Asano  
; APPLICANT: KITADA, Chieko  
; TITLE OF INVENTION: ANTIBODIES TO B-AMYLOIDS OR THEIR  
; TITLE OF INVENTION: DERIVATIVES AND USE THEREOF  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
; STREET: 130 WATER STREET  
; CITY: BOSTON  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02019  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/302,808  
; FILING DATE: 15-SEP-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/JP94/00089  
; FILING DATE: 24-JAN-1994  
; APPLICATION NUMBER: 010132/1993

; FILING DATE: 25-JAN-1993  
; APPLICATION NUMBER: 019035/1993  
; FILING DATE: 05-FEB-1993  
; APPLICATION NUMBER: 286985/1993  
; FILING DATE: 16-NOV-1993  
; APPLICATION NUMBER: 334773/1993  
; FILING DATE: 28-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DAVID, RESNICK S  
; REGISTRATION NUMBER: 34,235  
; REFERENCE/DOCKET NUMBER: 44631  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-523-3400  
; TELEFAX: 617-523-6440  
; TELEX: 200291 STRE  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 42 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE: N-terminal  
; ORIGINAL SOURCE:  
US-08-302-808-5

Query Match 100.0%; Score 40; DB 1; Length 42;  
Best Local Similarity 100.0%; Pred. No. 0.067;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

Search completed: February 28, 2004, 08:57:01  
Job time : 50.5 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 28, 2004, 08:56:50 ; Search time 44.5 Seconds  
(without alignments)  
37.960 Million cell updates/sec

Title: US-09-668-314C-73

Perfect score: 40

Sequence: 1 KLVFFAED 8

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 809742 seqs, 211153259 residues

Total number of hits satisfying chosen parameters: 809742

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 1000 summaries

Database : Published\_Applications\_AA:\*

1: /cgn2\_6/ptodata/2/pubpaa/US07\_PUBCOMB.pep:\*

2: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB.pep:\*

3: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB.pep:\*

4: /cgn2\_6/ptodata/2/pubpaa/US06\_PUBCOMB.pep:\*

5: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB.pep:\*

6: /cgn2\_6/ptodata/2/pubpaa/PCTUS\_PUBCOMB.pep:\*

7: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB.pep:\*

8: /cgn2\_6/ptodata/2/pubpaa/US08\_PUBCOMB.pep:\*

9: /cgn2\_6/ptodata/2/pubpaa/US09A\_PUBCOMB.pep:\*

10: /cgn2\_6/ptodata/2/pubpaa/US09B\_PUBCOMB.pep:\*

11: /cgn2\_6/ptodata/2/pubpaa/US09C\_PUBCOMB.pep:\*

12: /cgn2\_6/ptodata/2/pubpaa/US09\_NEW\_PUB.pep:\*

13: /cgn2\_6/ptodata/2/pubpaa/US10A\_PUBCOMB.pep:\*

14: /cgn2\_6/ptodata/2/pubpaa/US10B\_PUBCOMB.pep:\*

15: /cgn2\_6/ptodata/2/pubpaa/US10C\_PUBCOMB.pep:\*

16: /cgn2\_6/ptodata/2/pubpaa/US10\_NEW\_PUB.pep:\*

17: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB.pep:\*

18: /cgn2\_6/ptodata/2/pubpaa/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

%

Result	Query					Description
No.	Score	Match	Length	DB	ID	

1	40	100.0	8	14	US-10-235-483-1	Sequence 1, Appli
2	40	100.0	9	9	US-09-899-815-2	Sequence 2, Appli
3	40	100.0	9	14	US-10-235-483-64	Sequence 64, Appli
4	40	100.0	11	9	US-09-988-842-9	Sequence 9, Appli
5	40	100.0	11	9	US-09-988-842-25	Sequence 25, Appli
6	40	100.0	11	14	US-10-235-483-14	Sequence 14, Appli
7	40	100.0	13	14	US-10-281-458-1	Sequence 1, Appli
8	40	100.0	14	9	US-09-992-800-5	Sequence 5, Appli
9	40	100.0	14	9	US-09-992-994-5	Sequence 5, Appli
10	40	100.0	14	15	US-10-385-065-5	Sequence 5, Appli
11	40	100.0	15	9	US-09-972-475-14	Sequence 14, Appli
12	40	100.0	15	9	US-09-996-357-9	Sequence 9, Appli
13	40	100.0	15	14	US-10-235-483-56	Sequence 56, Appli
14	40	100.0	15	14	US-10-235-483-57	Sequence 57, Appli
15	40	100.0	15	14	US-10-235-483-58	Sequence 58, Appli
16	40	100.0	15	14	US-10-235-483-63	Sequence 63, Appli
17	40	100.0	15	14	US-10-235-483-65	Sequence 65, Appli
18	40	100.0	15	15	US-10-463-729-14	Sequence 14, Appli
19	40	100.0	17	9	US-09-992-800-3	Sequence 3, Appli
20	40	100.0	17	9	US-09-992-994-3	Sequence 3, Appli
21	40	100.0	17	10	US-09-998-491-8	Sequence 8, Appli
22	40	100.0	17	15	US-10-385-065-3	Sequence 3, Appli
23	40	100.0	19	10	US-09-825-242-5	Sequence 5, Appli
24	40	100.0	26	10	US-09-792-079-11	Sequence 11, Appli
25	40	100.0	26	14	US-10-159-279-11	Sequence 11, Appli
26	40	100.0	28	9	US-09-867-847-4	Sequence 4, Appli
27	40	100.0	28	10	US-09-865-294-66	Sequence 66, Appli
28	40	100.0	28	10	US-09-792-079-5	Sequence 5, Appli
29	40	100.0	28	14	US-10-159-279-5	Sequence 5, Appli
30	40	100.0	30	9	US-09-861-847-1	Sequence 1, Appli
31	40	100.0	30	14	US-10-301-488A-1	Sequence 1, Appli
32	40	100.0	33	10	US-09-930-915A-295	Sequence 295, App
33	40	100.0	33	14	US-10-082-014-84	Sequence 84, Appli
34	40	100.0	33	14	US-10-372-076-85	Sequence 85, Appli
35	40	100.0	35	9	US-09-867-847-3	Sequence 3, Appli
36	40	100.0	35	9	US-09-972-475-16	Sequence 16, Appli
37	40	100.0	35	15	US-10-463-729-16	Sequence 16, Appli
38	40	100.0	36	9	US-09-861-847-6	Sequence 6, Appli
39	40	100.0	36	9	US-09-861-847-11	Sequence 11, Appli
40	40	100.0	36	14	US-10-301-488A-6	Sequence 6, Appli
41	40	100.0	36	14	US-10-301-488A-11	Sequence 11, Appli
42	40	100.0	39	13	US-10-051-496-5	Sequence 5, Appli
43	40	100.0	39	14	US-10-190-548A-5	Sequence 5, Appli
44	40	100.0	40	9	US-09-861-847-7	Sequence 7, Appli
45	40	100.0	40	9	US-09-861-847-8	Sequence 8, Appli
46	40	100.0	40	9	US-09-867-847-2	Sequence 2, Appli
47	40	100.0	40	9	US-09-988-842-3	Sequence 3, Appli
48	40	100.0	40	9	US-09-851-071-3	Sequence 3, Appli
49	40	100.0	40	10	US-09-962-955C-36	Sequence 36, Appli
50	40	100.0	40	10	US-09-792-079-12	Sequence 12, Appli
51	40	100.0	40	13	US-10-007-779A-1	Sequence 1, Appli
52	40	100.0	40	13	US-10-051-496-4	Sequence 4, Appli
53	40	100.0	40	14	US-10-217-584-3	Sequence 3, Appli
54	40	100.0	40	14	US-10-169-580-1	Sequence 1, Appli
55	40	100.0	40	14	US-10-143-534-3	Sequence 3, Appli
56	40	100.0	40	14	US-10-190-548A-4	Sequence 4, Appli

57	40	100.0	40	14	US-10-051-663-3	Sequence 3, Appli
58	40	100.0	40	14	US-10-151-614-1	Sequence 1, Appli
59	40	100.0	40	14	US-10-159-279-12	Sequence 12, Appli
60	40	100.0	40	14	US-10-301-488A-7	Sequence 7, Appli
61	40	100.0	40	14	US-10-301-488A-8	Sequence 8, Appli
62	40	100.0	40	15	US-10-366-125-27	Sequence 27, Appli
63	40	100.0	41	13	US-10-051-496-3	Sequence 3, Appli
64	40	100.0	41	14	US-10-190-548A-3	Sequence 3, Appli
65	40	100.0	42	8	US-08-923-055-2	Sequence 2, Appli
66	40	100.0	42	9	US-09-867-847-1	Sequence 1, Appli
67	40	100.0	42	9	US-09-956-625-26	Sequence 26, Appli
68	40	100.0	42	9	US-09-731-460-1	Sequence 1, Appli
69	40	100.0	42	10	US-09-962-955C-37	Sequence 37, Appli
70	40	100.0	42	10	US-09-848-616-174	Sequence 174, App
71	40	100.0	42	10	US-09-865-294-65	Sequence 65, Appli
72	40	100.0	42	10	US-09-792-079-13	Sequence 13, Appli
73	40	100.0	42	10	US-09-825-242-1	Sequence 1, Appli
74	40	100.0	42	10	US-09-930-915A-293	Sequence 293, App
75	40	100.0	42	13	US-10-051-496-2	Sequence 2, Appli
76	40	100.0	42	13	US-10-082-804-7	Sequence 7, Appli
77	40	100.0	42	14	US-10-217-584-2	Sequence 2, Appli
78	40	100.0	42	14	US-10-169-580-2	Sequence 2, Appli
79	40	100.0	42	14	US-10-278-181-1	Sequence 1, Appli
80	40	100.0	42	14	US-10-143-534-2	Sequence 2, Appli
81	40	100.0	42	14	US-10-190-548A-1	Sequence 1, Appli
82	40	100.0	42	14	US-10-051-663-2	Sequence 2, Appli
83	40	100.0	42	14	US-10-159-279-13	Sequence 13, Appli
84	40	100.0	42	14	US-10-318-302-4	Sequence 4, Appli
85	40	100.0	42	14	US-10-050-902-220	Sequence 220, App
86	40	100.0	42	14	US-10-050-898-220	Sequence 220, App
87	40	100.0	42	14	US-10-082-014-81	Sequence 81, Appli
88	40	100.0	42	14	US-10-372-076-82	Sequence 82, Appli
89	40	100.0	42	15	US-10-231-298B-15	Sequence 15, Appli
90	40	100.0	42	15	US-10-231-470C-15	Sequence 15, Appli
91	40	100.0	42	15	US-10-366-125-28	Sequence 28, Appli
92	40	100.0	42	15	US-10-411-544-2	Sequence 2, Appli
93	40	100.0	42	15	US-10-231-213D-15	Sequence 15, Appli
94	40	100.0	42	15	US-10-231-114C-15	Sequence 15, Appli
95	40	100.0	43	9	US-09-280-966-1	Sequence 1, Appli
96	40	100.0	43	9	US-09-904-987-1	Sequence 1, Appli
97	40	100.0	43	9	US-09-808-037-3	Sequence 3, Appli
98	40	100.0	43	9	US-09-866-712-3	Sequence 3, Appli
99	40	100.0	43	9	US-09-972-475-1	Sequence 1, Appli
100	40	100.0	43	9	US-09-992-800-1	Sequence 1, Appli
101	40	100.0	43	9	US-09-895-443-1	Sequence 1, Appli
102	40	100.0	43	9	US-09-996-357-1	Sequence 1, Appli
103	40	100.0	43	9	US-09-992-994-1	Sequence 1, Appli
104	40	100.0	43	9	US-09-984-834-1	Sequence 1, Appli
105	40	100.0	43	10	US-09-425-956-1	Sequence 1, Appli
106	40	100.0	43	10	US-09-942-253-1	Sequence 1, Appli
107	40	100.0	43	13	US-10-041-605-1	Sequence 1, Appli
108	40	100.0	43	13	US-10-076-708-7	Sequence 7, Appli
109	40	100.0	43	13	US-10-051-496-1	Sequence 1, Appli
110	40	100.0	43	14	US-10-217-459-1	Sequence 1, Appli
111	40	100.0	43	14	US-10-162-889-3	Sequence 3, Appli
112	40	100.0	43	14	US-10-217-584-1	Sequence 1, Appli
113	40	100.0	43	14	US-10-326-049-1	Sequence 1, Appli

114	40	100.0	43	14	US-10-190-548A-2	Sequence 2, Appli
115	40	100.0	43	14	US-10-197-954-22	Sequence 22, Appli
116	40	100.0	43	14	US-10-335-035-1	Sequence 1, Appli
117	40	100.0	43	14	US-10-267-017-1	Sequence 1, Appli
118	40	100.0	43	14	US-10-314-221-1	Sequence 1, Appli
119	40	100.0	43	14	US-10-437-706-2	Sequence 2, Appli
120	40	100.0	43	15	US-10-385-065-1	Sequence 1, Appli
121	40	100.0	43	15	US-10-395-290-1	Sequence 1, Appli
122	40	100.0	43	15	US-10-463-729-1	Sequence 1, Appli
123	40	100.0	43	15	US-10-355-700-1	Sequence 1, Appli
124	40	100.0	43	15	US-10-384-788-3	Sequence 3, Appli
125	40	100.0	45	10	US-09-865-294-70	Sequence 70, Appli
126	40	100.0	48	10	US-09-865-294-74	Sequence 74, Appli
127	40	100.0	53	9	US-09-797-543-5	Sequence 5, Appli
128	40	100.0	53	13	US-10-016-717-1	Sequence 1, Appli
129	40	100.0	55	9	US-09-823-153-10	Sequence 10, Appli
130	40	100.0	59	14	US-10-084-380A-1	Sequence 1, Appli
131	40	100.0	67	14	US-10-437-706-1	Sequence 1, Appli
132	40	100.0	70	9	US-09-155-076-14	Sequence 14, Appli
133	40	100.0	82	10	US-09-848-616-173	Sequence 173, App
134	40	100.0	82	14	US-10-050-902-219	Sequence 219, App
135	40	100.0	82	14	US-10-050-898-219	Sequence 219, App
136	40	100.0	99	14	US-10-183-119-2	Sequence 2, Appli
137	40	100.0	100	9	US-09-794-975-4	Sequence 4, Appli
138	40	100.0	100	15	US-10-275-025-1	Sequence 1, Appli
139	40	100.0	100	15	US-10-275-025-2	Sequence 2, Appli
140	40	100.0	100	15	US-10-275-025-3	Sequence 3, Appli
141	40	100.0	100	15	US-10-275-025-4	Sequence 4, Appli
142	40	100.0	100	15	US-10-275-025-5	Sequence 5, Appli
143	40	100.0	103	9	US-09-972-475-2	Sequence 2, Appli
144	40	100.0	103	9	US-09-895-443-2	Sequence 2, Appli
145	40	100.0	103	15	US-10-395-290-2	Sequence 2, Appli
146	40	100.0	103	15	US-10-463-729-2	Sequence 2, Appli
147	40	100.0	108	15	US-10-275-025-9	Sequence 9, Appli
148	40	100.0	108	15	US-10-275-025-10	Sequence 10, Appli
149	40	100.0	108	15	US-10-275-025-11	Sequence 11, Appli
150	40	100.0	108	15	US-10-275-025-12	Sequence 12, Appli
151	40	100.0	108	15	US-10-275-025-13	Sequence 13, Appli
152	40	100.0	117	9	US-09-794-975-6	Sequence 6, Appli
153	40	100.0	117	9	US-09-823-153-2	Sequence 2, Appli
154	40	100.0	117	10	US-09-422-569-10	Sequence 10, Appli
155	40	100.0	247	9	US-09-996-357-13	Sequence 13, Appli
156	40	100.0	267	9	US-09-996-357-12	Sequence 12, Appli
157	40	100.0	283	15	US-10-185-297-2	Sequence 2, Appli
158	40	100.0	285	15	US-10-185-297-4	Sequence 4, Appli
159	40	100.0	355	9	US-09-794-975-13	Sequence 13, Appli
160	40	100.0	534	10	US-09-998-491-2	Sequence 2, Appli
161	40	100.0	695	9	US-09-794-927-10	Sequence 10, Appli
162	40	100.0	695	9	US-09-794-927-12	Sequence 12, Appli
163	40	100.0	695	9	US-09-794-927-14	Sequence 14, Appli
164	40	100.0	695	9	US-09-795-847-10	Sequence 10, Appli
165	40	100.0	695	9	US-09-795-847-12	Sequence 12, Appli
166	40	100.0	695	9	US-09-795-847-14	Sequence 14, Appli
167	40	100.0	695	9	US-09-794-743-10	Sequence 10, Appli
168	40	100.0	695	9	US-09-794-743-12	Sequence 12, Appli
169	40	100.0	695	9	US-09-794-743-14	Sequence 14, Appli
170	40	100.0	695	9	US-09-794-748-10	Sequence 10, Appli

171	40	100.0	695	9	US-09-794-748-12	Sequence 12, Appl
172	40	100.0	695	9	US-09-794-748-14	Sequence 14, Appl
173	40	100.0	695	9	US-09-794-925-10	Sequence 10, Appl
174	40	100.0	695	9	US-09-794-925-12	Sequence 12, Appl
175	40	100.0	695	9	US-09-794-925-14	Sequence 14, Appl
176	40	100.0	695	9	US-09-681-442-10	Sequence 10, Appl
177	40	100.0	695	9	US-09-681-442-12	Sequence 12, Appl
178	40	100.0	695	9	US-09-681-442-14	Sequence 14, Appl
179	40	100.0	695	9	US-09-149-718-2	Sequence 2, Appl
180	40	100.0	695	10	US-09-869-414-10	Sequence 10, Appl
181	40	100.0	695	10	US-09-869-414-12	Sequence 12, Appl
182	40	100.0	695	10	US-09-869-414-14	Sequence 14, Appl
183	40	100.0	695	10	US-09-548-366-10	Sequence 10, Appl
184	40	100.0	695	10	US-09-548-366-12	Sequence 12, Appl
185	40	100.0	695	10	US-09-548-366-14	Sequence 14, Appl
186	40	100.0	695	10	US-09-998-491-1	Sequence 1, Appl
187	40	100.0	695	14	US-10-169-580-3	Sequence 3, Appl
188	40	100.0	695	14	US-10-357-935-1	Sequence 1, Appl
189	40	100.0	695	15	US-10-427-208-24	Sequence 24, Appl
190	40	100.0	695	15	US-10-427-208-25	Sequence 25, Appl
191	40	100.0	695	15	US-10-427-208-26	Sequence 26, Appl
192	40	100.0	695	15	US-10-427-208-27	Sequence 27, Appl
193	40	100.0	695	15	US-10-427-208-28	Sequence 28, Appl
194	40	100.0	695	15	US-10-427-208-29	Sequence 29, Appl
195	40	100.0	695	15	US-10-427-208-30	Sequence 30, Appl
196	40	100.0	695	15	US-10-427-208-31	Sequence 31, Appl
197	40	100.0	695	15	US-10-427-208-32	Sequence 32, Appl
198	40	100.0	695	15	US-10-427-208-33	Sequence 33, Appl
199	40	100.0	695	15	US-10-427-208-34	Sequence 34, Appl
200	40	100.0	695	15	US-10-427-208-35	Sequence 35, Appl
201	40	100.0	695	15	US-10-427-208-36	Sequence 36, Appl
202	40	100.0	695	15	US-10-427-208-37	Sequence 37, Appl
203	40	100.0	695	15	US-10-427-208-38	Sequence 38, Appl
204	40	100.0	695	15	US-10-427-208-39	Sequence 39, Appl
205	40	100.0	695	15	US-10-427-208-40	Sequence 40, Appl
206	40	100.0	695	15	US-10-427-208-41	Sequence 41, Appl
207	40	100.0	695	15	US-10-427-208-42	Sequence 42, Appl
208	40	100.0	695	15	US-10-427-208-43	Sequence 43, Appl
209	40	100.0	695	15	US-10-427-208-44	Sequence 44, Appl
210	40	100.0	695	15	US-10-427-208-45	Sequence 45, Appl
211	40	100.0	695	15	US-10-427-208-46	Sequence 46, Appl
212	40	100.0	697	9	US-09-794-927-16	Sequence 16, Appl
213	40	100.0	697	9	US-09-794-927-18	Sequence 18, Appl
214	40	100.0	697	9	US-09-794-927-20	Sequence 20, Appl
215	40	100.0	697	9	US-09-795-847-16	Sequence 16, Appl
216	40	100.0	697	9	US-09-795-847-18	Sequence 18, Appl
217	40	100.0	697	9	US-09-795-847-20	Sequence 20, Appl
218	40	100.0	697	9	US-09-794-743-16	Sequence 16, Appl
219	40	100.0	697	9	US-09-794-743-18	Sequence 18, Appl
220	40	100.0	697	9	US-09-794-743-20	Sequence 20, Appl
221	40	100.0	697	9	US-09-794-748-16	Sequence 16, Appl
222	40	100.0	697	9	US-09-794-748-18	Sequence 18, Appl
223	40	100.0	697	9	US-09-794-748-20	Sequence 20, Appl
224	40	100.0	697	9	US-09-794-925-16	Sequence 16, Appl
225	40	100.0	697	9	US-09-794-925-18	Sequence 18, Appl
226	40	100.0	697	9	US-09-794-925-20	Sequence 20, Appl
227	40	100.0	697	9	US-09-681-442-16	Sequence 16, Appl

228	40	100.0	697	9	US-09-681-442-18	Sequence 18, Appl
229	40	100.0	697	9	US-09-681-442-20	Sequence 20, Appl
230	40	100.0	697	10	US-09-869-414-16	Sequence 16, Appl
231	40	100.0	697	10	US-09-869-414-18	Sequence 18, Appl
232	40	100.0	697	10	US-09-869-414-20	Sequence 20, Appl
233	40	100.0	697	10	US-09-548-366-16	Sequence 16, Appl
234	40	100.0	697	10	US-09-548-366-18	Sequence 18, Appl
235	40	100.0	697	10	US-09-548-366-20	Sequence 20, Appl
236	40	100.0	751	9	US-09-794-927-57	Sequence 57, Appl
237	40	100.0	751	9	US-09-795-847-57	Sequence 57, Appl
238	40	100.0	751	9	US-09-794-743-57	Sequence 57, Appl
239	40	100.0	751	9	US-09-794-748-57	Sequence 57, Appl
240	40	100.0	751	9	US-09-794-925-57	Sequence 57, Appl
241	40	100.0	751	9	US-09-681-442-57	Sequence 57, Appl
242	40	100.0	751	9	US-09-149-718-4	Sequence 4, Appli
243	40	100.0	751	10	US-09-869-414-57	Sequence 57, Appl
244	40	100.0	751	10	US-09-548-366-57	Sequence 57, Appl
245	40	100.0	751	14	US-10-169-580-4	Sequence 4, Appli
246	40	100.0	751	14	US-10-357-935-2	Sequence 2, Appli
247	40	100.0	751	15	US-10-427-208-74	Sequence 74, Appl
248	40	100.0	753	9	US-09-794-927-61	Sequence 61, Appl
249	40	100.0	753	9	US-09-795-847-61	Sequence 61, Appl
250	40	100.0	753	9	US-09-794-743-61	Sequence 61, Appl
251	40	100.0	753	9	US-09-794-748-61	Sequence 61, Appl
252	40	100.0	753	9	US-09-794-925-61	Sequence 61, Appl
253	40	100.0	753	9	US-09-681-442-61	Sequence 61, Appl
254	40	100.0	753	10	US-09-869-414-61	Sequence 61, Appl
255	40	100.0	753	10	US-09-548-366-61	Sequence 61, Appl
256	40	100.0	770	9	US-09-794-927-55	Sequence 55, Appl
257	40	100.0	770	9	US-09-795-847-55	Sequence 55, Appl
258	40	100.0	770	9	US-09-794-743-55	Sequence 55, Appl
259	40	100.0	770	9	US-09-794-748-55	Sequence 55, Appl
260	40	100.0	770	9	US-09-904-987-2	Sequence 2, Appli
261	40	100.0	770	9	US-09-794-925-55	Sequence 55, Appl
262	40	100.0	770	9	US-09-681-442-55	Sequence 55, Appl
263	40	100.0	770	9	US-09-149-718-6	Sequence 6, Appli
264	40	100.0	770	9	US-09-785-215-2	Sequence 2, Appli
265	40	100.0	770	10	US-09-848-616-172	Sequence 172, App
266	40	100.0	770	10	US-09-869-414-55	Sequence 55, Appl
267	40	100.0	770	10	US-09-548-366-55	Sequence 55, Appl
268	40	100.0	770	14	US-10-217-584-5	Sequence 5, Appli
269	40	100.0	770	14	US-10-204-362-2	Sequence 2, Appli
270	40	100.0	770	14	US-10-169-580-5	Sequence 5, Appli
271	40	100.0	770	14	US-10-335-035-3	Sequence 3, Appli
272	40	100.0	770	14	US-10-223-809A-2	Sequence 2, Appli
273	40	100.0	770	14	US-10-010-942B-38	Sequence 38, Appl
274	40	100.0	770	14	US-10-357-935-3	Sequence 3, Appli
275	40	100.0	770	14	US-10-050-902-218	Sequence 218, App
276	40	100.0	770	14	US-10-050-898-218	Sequence 218, App
277	40	100.0	770	15	US-10-427-208-75	Sequence 75, Appl
278	40	100.0	770	15	US-10-428-487-12	Sequence 12, Appl
279	40	100.0	772	9	US-09-794-927-59	Sequence 59, Appl
280	40	100.0	772	9	US-09-795-847-59	Sequence 59, Appl
281	40	100.0	772	9	US-09-794-743-59	Sequence 59, Appl
282	40	100.0	772	9	US-09-794-748-59	Sequence 59, Appl
283	40	100.0	772	9	US-09-794-925-59	Sequence 59, Appl
284	40	100.0	772	9	US-09-681-442-59	Sequence 59, Appl

285	40	100.0	772	10	US-09-869-414-59	Sequence 59, Appl
286	40	100.0	772	10	US-09-548-366-59	Sequence 59, Appl
287	37	92.5	42	14	US-10-217-584-8	Sequence 8, Appli
288	37	92.5	100	15	US-10-275-025-7	Sequence 7, Appli
289	37	92.5	108	15	US-10-275-025-15	Sequence 15, Appl
290	36	90.0	42	14	US-10-217-584-7	Sequence 7, Appli
291	36	90.0	42	14	US-10-217-584-9	Sequence 9, Appli
292	36	90.0	100	15	US-10-275-025-6	Sequence 6, Appli
293	36	90.0	108	15	US-10-275-025-14	Sequence 14, Appl
294	35	87.5	9	14	US-10-235-483-54	Sequence 54, Appl
295	35	87.5	15	14	US-10-235-483-59	Sequence 59, Appl
296	35	87.5	42	14	US-10-217-584-11	Sequence 11, Appl
297	35	87.5	1149	15	US-10-427-208-63	Sequence 63, Appl
298	34	85.0	9	14	US-10-235-483-51	Sequence 51, Appl
299	34	85.0	15	14	US-10-235-483-60	Sequence 60, Appl
300	34	85.0	15	14	US-10-235-483-61	Sequence 61, Appl
301	34	85.0	15	14	US-10-235-483-62	Sequence 62, Appl
302	34	85.0	321	11	US-09-906-179A-75	Sequence 75, Appl
303	33	82.5	9	14	US-10-235-483-50	Sequence 50, Appl
304	33	82.5	42	9	US-09-899-815-1	Sequence 1, Appli
305	33	82.5	42	14	US-10-217-584-10	Sequence 10, Appl
306	32	80.0	104	9	US-09-823-153-4	Sequence 4, Appli
307	31	77.5	7	9	US-09-867-847-27	Sequence 27, Appl
308	31	77.5	7	9	US-09-867-847-28	Sequence 28, Appl
309	31	77.5	7	10	US-09-747-408-18	Sequence 18, Appl
310	31	77.5	7	10	US-09-747-408-19	Sequence 19, Appl
311	31	77.5	10	9	US-09-867-847-29	Sequence 29, Appl
312	31	77.5	49	9	US-09-864-761-33582	Sequence 33582, A
313	31	77.5	49	9	US-09-864-761-34163	Sequence 34163, A
314	31	77.5	179	14	US-10-156-761-10288	Sequence 10288, A
315	31	77.5	259	9	US-09-738-626-6113	Sequence 6113, Ap
316	31	77.5	391	15	US-10-108-260A-3661	Sequence 3661, Ap
317	30	75.0	9	14	US-10-235-483-52	Sequence 52, Appl
318	30	75.0	9	14	US-10-235-483-53	Sequence 53, Appl
319	30	75.0	15	14	US-10-235-483-55	Sequence 55, Appl
320	30	75.0	89	9	US-09-864-761-44113	Sequence 44113, A
321	30	75.0	369	14	US-10-017-161-1044	Sequence 1044, Ap
322	30	75.0	370	13	US-10-043-945-2	Sequence 2, Appli
323	30	75.0	370	14	US-10-318-142-4	Sequence 4, Appli
324	30	75.0	370	14	US-10-318-142-24	Sequence 24, Appl
325	30	75.0	370	14	US-10-225-567A-611	Sequence 611, App
326	30	75.0	370	14	US-10-272-983-26	Sequence 26, Appl
327	30	75.0	370	14	US-10-393-807-26	Sequence 26, Appl
328	30	75.0	370	15	US-10-417-820A-28	Sequence 28, Appl
329	30	75.0	370	15	US-10-292-798-886	Sequence 886, App
330	30	75.0	379	14	US-10-073-885-79	Sequence 79, Appl
331	30	75.0	1294	13	US-10-071-223-2	Sequence 2, Appli
332	30	75.0	1353	9	US-09-751-100B-2	Sequence 2, Appli
333	30	75.0	1353	9	US-09-751-100B-99	Sequence 99, Appl
334	30	75.0	1353	13	US-10-071-223-3	Sequence 3, Appli
335	29	72.5	6	9	US-09-867-847-7	Sequence 7, Appli
336	29	72.5	6	9	US-09-867-847-20	Sequence 20, Appl
337	29	72.5	6	9	US-09-972-475-9	Sequence 9, Appli
338	29	72.5	6	9	US-09-972-475-27	Sequence 27, Appl
339	29	72.5	6	9	US-09-956-625-25	Sequence 25, Appl
340	29	72.5	6	10	US-09-747-408-3	Sequence 3, Appli
341	29	72.5	6	10	US-09-747-408-11	Sequence 11, Appl

342	29	72.5	6	15	US-10-463-729-9	Sequence 9, Appli
343	29	72.5	6	15	US-10-463-729-27	Sequence 27, Appl
344	29	72.5	7	9	US-09-867-847-12	Sequence 12, Appl
345	29	72.5	7	9	US-09-972-475-7	Sequence 7, Appli
346	29	72.5	7	10	US-09-747-408-2	Sequence 2, Appli
347	29	72.5	7	15	US-10-463-729-7	Sequence 7, Appli
348	29	72.5	8	9	US-09-850-061A-44	Sequence 44, Appl
349	29	72.5	8	9	US-09-972-475-5	Sequence 5, Appli
350	29	72.5	8	15	US-10-463-729-5	Sequence 5, Appli
351	29	72.5	9	9	US-09-867-847-9	Sequence 9, Appli
352	29	72.5	9	10	US-09-747-408-20	Sequence 20, Appl
353	29	72.5	11	14	US-10-050-200-33	Sequence 33, Appl
354	29	72.5	12	9	US-09-867-847-8	Sequence 8, Appli
355	29	72.5	81	10	US-09-764-891-4983	Sequence 4983, Ap
356	29	72.5	143	9	US-09-864-761-34585	Sequence 34585, A
357	29	72.5	143	9	US-09-864-761-34587	Sequence 34587, A
358	29	72.5	143	10	US-09-974-879-567	Sequence 567, App
359	29	72.5	143	10	US-09-305-736-519	Sequence 519, App
360	29	72.5	143	11	US-09-818-683-519	Sequence 32687, A
361	29	72.5	143	14	US-10-029-386-32687	Sequence 35104, A
362	29	72.5	189	9	US-09-864-761-35104	Sequence 11617, A
363	29	72.5	335	14	US-10-156-761-11617	Sequence 2, Appli
364	29	72.5	352	15	US-10-418-146-2	Sequence 37011, A
365	29	72.5	446	9	US-09-864-761-37011	Sequence 13, Appli
366	29	72.5	539	14	US-10-325-891-13	Sequence 33857, A
367	29	72.5	551	14	US-10-029-386-33857	Sequence 6, Appli
368	29	72.5	806	14	US-10-199-869-6	Sequence 4086, Ap
369	29	72.5	807	15	US-10-108-260A-4086	Sequence 5, Appli
370	29	72.5	854	14	US-10-199-869-5	Sequence 6, Appli
371	28	70.0	149	14	US-10-410-681-6	Sequence 7, Appli
372	28	70.0	193	13	US-10-126-099-7	Sequence 8, Appli
373	28	70.0	383	14	US-10-410-681-8	Sequence 9053, Ap
374	28	70.0	402	15	US-10-369-493-9053	Sequence 1841, Ap
375	28	70.0	417	16	US-10-389-566-1841	Sequence 7895, Ap
376	28	70.0	495	15	US-10-369-493-7895	Sequence 12, Appli
377	28	70.0	750	14	US-10-410-681-12	Sequence 51, Appli
378	28	70.0	754	14	US-10-410-681-51	Sequence 4, Appli
379	28	70.0	755	14	US-10-410-681-4	Sequence 2, Appli
380	28	70.0	1458	13	US-10-054-691-2	Sequence 5010, Ap
381	28	70.0	2643	15	US-10-369-493-5010	Sequence 11, Appli
382	27	67.5	6	9	US-09-867-847-11	Sequence 19, Appli
383	27	67.5	6	9	US-09-867-847-19	Sequence 1, Appli
384	27	67.5	6	10	US-09-747-408-1	Sequence 10, Appli
385	27	67.5	6	10	US-09-747-408-10	Sequence 10, Appli
386	27	67.5	22	10	US-09-792-079-10	Sequence 10, Appli
387	27	67.5	22	14	US-10-159-279-10	Sequence 289, App
388	27	67.5	42	9	US-09-984-245-289	Sequence 289, App
389	27	67.5	42	10	US-09-966-262-289	Sequence 289, App
390	27	67.5	42	10	US-09-983-966-289	Sequence 289, App
391	27	67.5	42	14	US-10-143-090-289	Sequence 722, App
392	27	67.5	64	14	US-10-083-357-722	Sequence 765, App
393	27	67.5	71	15	US-10-291-265-765	Sequence 196, App
394	27	67.5	116	14	US-10-078-770-196	Sequence 1867, Ap
395	27	67.5	120	9	US-09-764-877-1867	Sequence 1867, Ap
396	27	67.5	120	15	US-10-242-515-1867	Sequence 283, App
397	27	67.5	141	9	US-09-764-870-283	Sequence 283, App
398	27	67.5	141	14	US-10-125-540-283	

399	27	67.5	176	15	US-10-004-378A-81	Sequence 81, Appl
400	27	67.5	193	9	US-09-984-245-294	Sequence 294, App
401	27	67.5	193	10	US-09-966-262-294	Sequence 294, App
402	27	67.5	193	10	US-09-983-966-294	Sequence 294, App
403	27	67.5	193	14	US-10-143-090-294	Sequence 294, App
404	27	67.5	203	9	US-09-738-626-6068	Sequence 6068, Ap
405	27	67.5	258	9	US-09-954-737-7	Sequence 7, Appli
406	27	67.5	264	15	US-10-240-145-163	Sequence 163, App
407	27	67.5	273	10	US-09-813-153-125	Sequence 125, App
408	27	67.5	279	10	US-09-882-227-30	Sequence 30, Appl
409	27	67.5	281	15	US-10-369-493-21339	Sequence 21339, A
410	27	67.5	289	15	US-10-312-273-183	Sequence 183, App
411	27	67.5	293	9	US-09-738-626-5171	Sequence 5171, Ap
412	27	67.5	298	10	US-09-813-153-212	Sequence 212, App
413	27	67.5	304	15	US-10-289-762-9	Sequence 9, Appli
414	27	67.5	309	9	US-09-862-027-37	Sequence 37, Appl
415	27	67.5	316	15	US-10-369-493-2431	Sequence 2431, Ap
416	27	67.5	328	9	US-09-815-242-10692	Sequence 10692, A
417	27	67.5	331	15	US-10-104-047-3873	Sequence 3873, Ap
418	27	67.5	332	15	US-10-369-493-11167	Sequence 11167, A
419	27	67.5	345	11	US-09-906-179A-117	Sequence 117, App
420	27	67.5	350	15	US-10-369-493-3274	Sequence 3274, Ap
421	27	67.5	350	15	US-10-369-493-12737	Sequence 12737, A
422	27	67.5	387	15	US-10-369-493-21935	Sequence 21935, A
423	27	67.5	445	15	US-10-369-493-2341	Sequence 2341, Ap
424	27	67.5	445	15	US-10-264-237-1847	Sequence 1847, Ap
425	27	67.5	451	14	US-10-128-714-3220	Sequence 3220, Ap
426	27	67.5	453	14	US-10-128-714-8220	Sequence 8220, Ap
427	27	67.5	455	15	US-10-369-493-21518	Sequence 21518, A
428	27	67.5	462	10	US-09-815-207-3	Sequence 3, Appli
429	27	67.5	462	15	US-10-369-493-17853	Sequence 17853, A
430	27	67.5	468	14	US-10-032-585-7730	Sequence 7730, Ap
431	27	67.5	500	9	US-09-925-300-1382	Sequence 1382, Ap
432	27	67.5	524	14	US-10-156-761-11709	Sequence 11709, A
433	27	67.5	576	15	US-10-369-493-22712	Sequence 22712, A
434	27	67.5	685	15	US-10-158-034-96	Sequence 96, Appl
435	27	67.5	779	14	US-10-353-929-49	Sequence 49, Appl
436	27	67.5	896	15	US-10-004-378A-16	Sequence 16, Appl
437	27	67.5	909	13	US-10-078-929-168	Sequence 168, App
438	27	67.5	909	14	US-10-078-770-190	Sequence 190, App
439	27	67.5	915	9	US-09-909-320-34	Sequence 34, Appl
440	27	67.5	915	9	US-09-909-088B-34	Sequence 34, Appl
441	27	67.5	915	9	US-09-905-291A-34	Sequence 34, Appl
442	27	67.5	915	9	US-09-902-853-34	Sequence 34, Appl
443	27	67.5	915	9	US-09-907-824-34	Sequence 34, Appl
444	27	67.5	915	9	US-09-907-841-34	Sequence 34, Appl
445	27	67.5	915	10	US-09-904-011-34	Sequence 34, Appl
446	27	67.5	915	10	US-09-906-742-34	Sequence 34, Appl
447	27	67.5	915	10	US-09-906-838-34	Sequence 34, Appl
448	27	67.5	915	10	US-09-907-613-34	Sequence 34, Appl
449	27	67.5	915	10	US-09-907-942-34	Sequence 34, Appl
450	27	67.5	915	10	US-09-904-859-34	Sequence 34, Appl
451	27	67.5	915	10	US-09-909-204-34	Sequence 34, Appl
452	27	67.5	915	10	US-09-904-820-34	Sequence 34, Appl
453	27	67.5	915	10	US-09-904-786-34	Sequence 34, Appl
454	27	67.5	915	10	US-09-906-646-34	Sequence 34, Appl
455	27	67.5	915	10	US-09-906-700-34	Sequence 34, Appl

456	27	67.5	915	10	US-09-903-786-34	Sequence 34, Appl
457	27	67.5	915	10	US-09-902-903-34	Sequence 34, Appl
458	27	67.5	915	10	US-09-903-749A-34	Sequence 34, Appl
459	27	67.5	915	10	US-09-904-119-34	Sequence 34, Appl
460	27	67.5	915	10	US-09-904-956-34	Sequence 34, Appl
461	27	67.5	915	10	US-09-902-736-34	Sequence 34, Appl
462	27	67.5	915	10	US-09-907-794-34	Sequence 34, Appl
463	27	67.5	915	10	US-09-903-943-34	Sequence 34, Appl
464	27	67.5	915	10	US-09-904-462-34	Sequence 34, Appl
465	27	67.5	915	10	US-09-907-925-34	Sequence 34, Appl
466	27	67.5	915	10	US-09-902-692-34	Sequence 34, Appl
467	27	67.5	915	10	US-09-903-520-34	Sequence 34, Appl
468	27	67.5	915	10	US-09-905-056-34	Sequence 34, Appl
469	27	67.5	915	10	US-09-909-064-34	Sequence 34, Appl
470	27	67.5	915	10	US-09-904-553-34	Sequence 34, Appl
471	27	67.5	915	10	US-09-905-381-34	Sequence 34, Appl
472	27	67.5	915	10	US-09-905-088-34	Sequence 34, Appl
473	27	67.5	915	10	US-09-907-575-34	Sequence 34, Appl
474	27	67.5	915	10	US-09-905-075-34	Sequence 34, Appl
475	27	67.5	915	10	US-09-902-759-34	Sequence 34, Appl
476	27	67.5	915	10	US-09-902-634-34	Sequence 34, Appl
477	27	67.5	915	10	US-09-902-713-34	Sequence 34, Appl
478	27	67.5	915	10	US-09-907-979-34	Sequence 34, Appl
479	27	67.5	915	10	US-09-902-615-34	Sequence 34, Appl
480	27	67.5	915	10	US-09-903-925-34	Sequence 34, Appl
481	27	67.5	915	10	US-09-906-760A-34	Sequence 34, Appl
482	27	67.5	915	10	US-09-903-823-34	Sequence 34, Appl
483	27	67.5	915	10	US-09-907-652-34	Sequence 34, Appl
484	27	67.5	915	10	US-09-902-572A-34	Sequence 34, Appl
485	27	67.5	915	10	US-09-902-979-34	Sequence 34, Appl
486	27	67.5	915	10	US-09-905-125-34	Sequence 34, Appl
487	27	67.5	915	10	US-09-906-815A-34	Sequence 34, Appl
488	27	67.5	915	10	US-09-905-449-34	Sequence 34, Appl
489	27	67.5	915	10	US-09-903-806-34	Sequence 34, Appl
490	27	67.5	915	10	US-09-904-992-34	Sequence 34, Appl
491	27	67.5	915	10	US-09-904-838-34	Sequence 34, Appl
492	27	67.5	915	10	US-09-906-777-34	Sequence 34, Appl
493	27	67.5	915	10	US-09-903-603A-34	Sequence 34, Appl
494	27	67.5	915	10	US-09-904-532-34	Sequence 34, Appl
495	27	67.5	915	10	US-09-904-766-34	Sequence 34, Appl
496	27	67.5	915	10	US-09-904-920A-34	Sequence 34, Appl
497	27	67.5	915	10	US-09-904-877A-34	Sequence 34, Appl
498	27	67.5	915	10	US-09-903-562-34	Sequence 34, Appl
499	27	67.5	915	10	US-09-906-618-34	Sequence 34, Appl
500	27	67.5	915	10	US-09-907-728-34	Sequence 34, Appl
501	27	67.5	915	11	US-09-904-805-34	Sequence 34, Appl
502	27	67.5	915	11	US-09-904-938A-34	Sequence 34, Appl
503	27	67.5	915	11	US-09-906-722A-34	Sequence 34, Appl
504	27	67.5	915	11	US-09-908-576-34	Sequence 34, Appl
505	27	67.5	915	14	US-10-028-072-294	Sequence 294, App
506	27	67.5	915	14	US-10-121-049-294	Sequence 294, App
507	27	67.5	915	14	US-10-123-904-294	Sequence 294, App
508	27	67.5	915	14	US-10-140-470-294	Sequence 294, App
509	27	67.5	915	14	US-10-175-746-294	Sequence 294, App
510	27	67.5	915	14	US-10-176-918-294	Sequence 294, App
511	27	67.5	915	14	US-10-176-921-294	Sequence 294, App
512	27	67.5	915	14	US-10-137-865-294	Sequence 294, App

513	27	67.5	915	14	US-10-140-474-294	Sequence 294, App
514	27	67.5	915	14	US-10-142-431-294	Sequence 294, App
515	27	67.5	915	14	US-10-143-114-294	Sequence 294, App
516	27	67.5	915	14	US-10-140-002-294	Sequence 294, App
517	27	67.5	915	14	US-10-142-419-294	Sequence 294, App
518	27	67.5	915	14	US-10-123-262-294	Sequence 294, App
519	27	67.5	915	14	US-10-142-423-294	Sequence 294, App
520	27	67.5	915	14	US-10-121-050-294	Sequence 294, App
521	27	67.5	915	14	US-10-141-755-294	Sequence 294, App
522	27	67.5	915	14	US-10-143-032-294	Sequence 294, App
523	27	67.5	915	14	US-10-123-108-294	Sequence 294, App
524	27	67.5	915	14	US-10-123-236-294	Sequence 294, App
525	27	67.5	915	14	US-10-123-261-294	Sequence 294, App
526	27	67.5	915	14	US-10-140-921-294	Sequence 294, App
527	27	67.5	915	14	US-10-140-928-294	Sequence 294, App
528	27	67.5	915	14	US-10-121-045-294	Sequence 294, App
529	27	67.5	915	14	US-10-123-292-294	Sequence 294, App
530	27	67.5	915	14	US-10-123-903-294	Sequence 294, App
531	27	67.5	915	14	US-10-124-819-294	Sequence 294, App
532	27	67.5	915	14	US-10-124-822-294	Sequence 294, App
533	27	67.5	915	14	US-10-140-925-294	Sequence 294, App
534	27	67.5	915	14	US-10-160-498-294	Sequence 294, App
535	27	67.5	915	14	US-10-124-824-294	Sequence 294, App
536	27	67.5	915	14	US-10-127-825A-294	Sequence 294, App
537	27	67.5	915	14	US-10-127-829A-294	Sequence 294, App
538	27	67.5	915	14	US-10-127-835A-294	Sequence 294, App
539	27	67.5	915	14	US-10-127-839A-294	Sequence 294, App
540	27	67.5	915	14	US-10-127-901A-294	Sequence 294, App
541	27	67.5	915	14	US-10-128-693A-294	Sequence 294, App
542	27	67.5	915	14	US-10-131-813A-294	Sequence 294, App
543	27	67.5	915	14	US-10-131-818A-294	Sequence 294, App
544	27	67.5	915	14	US-10-131-823A-294	Sequence 294, App
545	27	67.5	915	14	US-10-131-824A-294	Sequence 294, App
546	27	67.5	915	14	US-10-131-830A-294	Sequence 294, App
547	27	67.5	915	14	US-10-131-837A-294	Sequence 294, App
548	27	67.5	915	14	US-10-137-872A-294	Sequence 294, App
549	27	67.5	915	14	US-10-147-500-294	Sequence 294, App
550	27	67.5	915	14	US-10-147-502-294	Sequence 294, App
551	27	67.5	915	14	US-10-147-515-294	Sequence 294, App
552	27	67.5	915	14	US-10-147-517-294	Sequence 294, App
553	27	67.5	915	14	US-10-147-526-294	Sequence 294, App
554	27	67.5	915	14	US-10-147-527-294	Sequence 294, App
555	27	67.5	915	14	US-10-121-041-294	Sequence 294, App
556	27	67.5	915	14	US-10-121-043-294	Sequence 294, App
557	27	67.5	915	14	US-10-121-047-294	Sequence 294, App
558	27	67.5	915	14	US-10-123-215-294	Sequence 294, App
559	27	67.5	915	14	US-10-123-902-294	Sequence 294, App
560	27	67.5	915	14	US-10-123-908-294	Sequence 294, App
561	27	67.5	915	14	US-10-123-909-294	Sequence 294, App
562	27	67.5	915	14	US-10-123-910-294	Sequence 294, App
563	27	67.5	915	14	US-10-124-813-294	Sequence 294, App
564	27	67.5	915	14	US-10-124-817-294	Sequence 294, App
565	27	67.5	915	14	US-10-125-922-294	Sequence 294, App
566	27	67.5	915	14	US-10-125-924-294	Sequence 294, App
567	27	67.5	915	14	US-10-140-860-294	Sequence 294, App
568	27	67.5	915	14	US-10-142-417-294	Sequence 294, App
569	27	67.5	915	14	US-10-147-519-294	Sequence 294, App

570	27	67.5	915	14	US-10-157-782-294	Sequence 294, App
571	27	67.5	915	14	US-10-152-395-294	Sequence 294, App
572	27	67.5	915	14	US-10-125-926A-294	Sequence 294, App
573	27	67.5	915	14	US-10-125-930A-294	Sequence 294, App
574	27	67.5	915	14	US-10-127-831A-294	Sequence 294, App
575	27	67.5	915	14	US-10-127-837A-294	Sequence 294, App
576	27	67.5	915	14	US-10-127-838B-294	Sequence 294, App
577	27	67.5	915	14	US-10-127-842A-294	Sequence 294, App
578	27	67.5	915	14	US-10-127-843A-294	Sequence 294, App
579	27	67.5	915	14	US-10-127-845A-294	Sequence 294, App
580	27	67.5	915	14	US-10-127-846A-294	Sequence 294, App
581	27	67.5	915	14	US-10-127-848A-294	Sequence 294, App
582	27	67.5	915	14	US-10-127-849A-294	Sequence 294, App
583	27	67.5	915	14	US-10-127-850A-294	Sequence 294, App
584	27	67.5	915	14	US-10-127-851A-294	Sequence 294, App
585	27	67.5	915	14	US-10-128-684A-294	Sequence 294, App
586	27	67.5	915	14	US-10-128-686A-294	Sequence 294, App
587	27	67.5	915	14	US-10-128-690A-294	Sequence 294, App
588	27	67.5	915	14	US-10-128-691A-294	Sequence 294, App
589	27	67.5	915	14	US-10-131-819A-294	Sequence 294, App
590	27	67.5	915	14	US-10-131-829A-294	Sequence 294, App
591	27	67.5	915	14	US-10-131-836A-294	Sequence 294, App
592	27	67.5	915	14	US-10-146-729-294	Sequence 294, App
593	27	67.5	915	14	US-10-146-791-294	Sequence 294, App
594	27	67.5	915	14	US-10-147-484-294	Sequence 294, App
595	27	67.5	915	14	US-10-147-508-294	Sequence 294, App
596	27	67.5	915	14	US-10-147-512-294	Sequence 294, App
597	27	67.5	915	14	US-10-175-735-294	Sequence 294, App
598	27	67.5	915	14	US-10-121-040-294	Sequence 294, App
599	27	67.5	915	14	US-10-121-056-294	Sequence 294, App
600	27	67.5	915	14	US-10-121-061-294	Sequence 294, App
601	27	67.5	915	14	US-10-123-235-294	Sequence 294, App
602	27	67.5	915	14	US-10-124-818-294	Sequence 294, App
603	27	67.5	915	14	US-10-137-868-294	Sequence 294, App
604	27	67.5	915	14	US-10-147-492-294	Sequence 294, App
605	27	67.5	915	14	US-10-158-782-294	Sequence 294, App
606	27	67.5	915	14	US-10-123-905-294	Sequence 294, App
607	27	67.5	915	14	US-10-123-907-294	Sequence 294, App
608	27	67.5	915	14	US-10-124-815-294	Sequence 294, App
609	27	67.5	915	14	US-10-125-921A-294	Sequence 294, App
610	27	67.5	915	14	US-10-125-928A-294	Sequence 294, App
611	27	67.5	915	14	US-10-127-821A-294	Sequence 294, App
612	27	67.5	915	14	US-10-127-822A-294	Sequence 294, App
613	27	67.5	915	14	US-10-127-824A-294	Sequence 294, App
614	27	67.5	915	14	US-10-127-826A-294	Sequence 294, App
615	27	67.5	915	14	US-10-127-827A-294	Sequence 294, App
616	27	67.5	915	14	US-10-127-828A-294	Sequence 294, App
617	27	67.5	915	14	US-10-127-830A-294	Sequence 294, App
618	27	67.5	915	14	US-10-127-832A-294	Sequence 294, App
619	27	67.5	915	14	US-10-127-833A-294	Sequence 294, App
620	27	67.5	915	14	US-10-127-834A-294	Sequence 294, App
621	27	67.5	915	14	US-10-127-836A-294	Sequence 294, App
622	27	67.5	915	14	US-10-127-841A-294	Sequence 294, App
623	27	67.5	915	14	US-10-127-844A-294	Sequence 294, App
624	27	67.5	915	14	US-10-128-687A-294	Sequence 294, App
625	27	67.5	915	14	US-10-128-688A-294	Sequence 294, App
626	27	67.5	915	14	US-10-128-689A-294	Sequence 294, App

627	27	67.5	915	14	US-10-128-694A-294	Sequence 294, App
628	27	67.5	915	14	US-10-131-825A-294	Sequence 294, App
629	27	67.5	915	14	US-10-230-417-294	Sequence 294, App
630	27	67.5	915	14	US-10-131-815A-294	Sequence 294, App
631	27	67.5	915	14	US-10-131-817A-294	Sequence 294, App
632	27	67.5	915	14	US-10-131-821A-294	Sequence 294, App
633	27	67.5	915	14	US-10-131-822A-294	Sequence 294, App
634	27	67.5	915	14	US-10-131-828A-294	Sequence 294, App
635	27	67.5	915	14	US-10-131-835A-294	Sequence 294, App
636	27	67.5	915	14	US-10-137-864A-294	Sequence 294, App
637	27	67.5	915	14	US-10-137-869A-294	Sequence 294, App
638	27	67.5	915	14	US-10-147-523-294	Sequence 294, App
639	27	67.5	915	14	US-10-158-785-294	Sequence 294, App
640	27	67.5	915	14	US-10-121-051-294	Sequence 294, App
641	27	67.5	915	14	US-10-121-042-294	Sequence 294, App
642	27	67.5	915	14	US-10-123-912-294	Sequence 294, App
643	27	67.5	915	14	US-10-192-007-294	Sequence 294, App
644	27	67.5	915	14	US-10-194-359-294	Sequence 294, App
645	27	67.5	915	14	US-10-127-847A-294	Sequence 294, App
646	27	67.5	915	14	US-10-175-590-294	Sequence 294, App
647	27	67.5	915	14	US-10-137-866-294	Sequence 294, App
648	27	67.5	915	14	US-10-146-726-294	Sequence 294, App
649	27	67.5	915	14	US-10-146-727-294	Sequence 294, App
650	27	67.5	915	14	US-10-146-788-294	Sequence 294, App
651	27	67.5	915	14	US-10-152-380-294	Sequence 294, App
652	27	67.5	915	14	US-10-153-934-294	Sequence 294, App
653	27	67.5	915	14	US-10-140-807-294	Sequence 294, App
654	27	67.5	915	14	US-10-140-924-294	Sequence 294, App
655	27	67.5	915	14	US-10-140-926-294	Sequence 294, App
656	27	67.5	915	14	US-10-141-698-294	Sequence 294, App
657	27	67.5	915	14	US-10-141-702-294	Sequence 294, App
658	27	67.5	915	14	US-10-141-704-294	Sequence 294, App
659	27	67.5	915	14	US-10-142-421-294	Sequence 294, App
660	27	67.5	915	14	US-10-142-432-294	Sequence 294, App
661	27	67.5	915	14	US-10-142-767-294	Sequence 294, App
662	27	67.5	915	14	US-10-143-033-294	Sequence 294, App
663	27	67.5	915	14	US-10-144-994-294	Sequence 294, App
664	27	67.5	915	14	US-10-145-628-294	Sequence 294, App
665	27	67.5	915	14	US-10-145-746-294	Sequence 294, App
666	27	67.5	915	14	US-10-145-748-294	Sequence 294, App
667	27	67.5	915	14	US-10-145-823-294	Sequence 294, App
668	27	67.5	915	14	US-10-145-826-294	Sequence 294, App
669	27	67.5	915	14	US-10-145-870-294	Sequence 294, App
670	27	67.5	915	14	US-10-145-876-294	Sequence 294, App
671	27	67.5	915	14	US-10-145-959-294	Sequence 294, App
672	27	67.5	915	14	US-10-146-724-294	Sequence 294, App
673	27	67.5	915	14	US-10-146-725-294	Sequence 294, App
674	27	67.5	915	14	US-10-146-795-294	Sequence 294, App
675	27	67.5	915	14	US-10-147-495-294	Sequence 294, App
676	27	67.5	915	14	US-10-147-501-294	Sequence 294, App
677	27	67.5	915	14	US-10-147-504-294	Sequence 294, App
678	27	67.5	915	14	US-10-147-506-294	Sequence 294, App
679	27	67.5	915	14	US-10-147-509-294	Sequence 294, App
680	27	67.5	915	14	US-10-147-510-294	Sequence 294, App
681	27	67.5	915	14	US-10-147-511-294	Sequence 294, App
682	27	67.5	915	14	US-10-147-529-294	Sequence 294, App
683	27	67.5	915	14	US-10-152-397-294	Sequence 294, App

684	27	67.5	915	14	US-10-153-586-294	Sequence 294, App
685	27	67.5	915	14	US-10-158-786-294	Sequence 294, App
686	27	67.5	915	14	US-10-137-870-294	Sequence 294, App
687	27	67.5	915	14	US-10-140-018-294	Sequence 294, App
688	27	67.5	915	14	US-10-140-021-294	Sequence 294, App
689	27	67.5	915	14	US-10-140-471-294	Sequence 294, App
690	27	67.5	915	14	US-10-140-922-294	Sequence 294, App
691	27	67.5	915	14	US-10-145-631-294	Sequence 294, App
692	27	67.5	915	14	US-10-145-633-294	Sequence 294, App
693	27	67.5	915	14	US-10-158-783-294	Sequence 294, App
694	27	67.5	915	14	US-10-140-274-294	Sequence 294, App
695	27	67.5	915	14	US-10-140-019-294	Sequence 294, App
696	27	67.5	915	14	US-10-140-022-294	Sequence 294, App
697	27	67.5	915	14	US-10-140-861-294	Sequence 294, App
698	27	67.5	915	14	US-10-140-862-294	Sequence 294, App
699	27	67.5	915	14	US-10-141-697-294	Sequence 294, App
700	27	67.5	915	14	US-10-141-700-294	Sequence 294, App
701	27	67.5	915	14	US-10-141-705-294	Sequence 294, App
702	27	67.5	915	14	US-10-141-753-294	Sequence 294, App
703	27	67.5	915	14	US-10-141-758-294	Sequence 294, App
704	27	67.5	915	14	US-10-142-418-294	Sequence 294, App
705	27	67.5	915	14	US-10-142-420-294	Sequence 294, App
706	27	67.5	915	14	US-10-142-422-294	Sequence 294, App
707	27	67.5	915	14	US-10-142-427-294	Sequence 294, App
708	27	67.5	915	14	US-10-142-760-294	Sequence 294, App
709	27	67.5	915	14	US-10-145-821-294	Sequence 294, App
710	27	67.5	915	14	US-10-152-531-294	Sequence 294, App
711	27	67.5	915	14	US-10-127-840A-294	Sequence 294, App
712	27	67.5	915	14	US-10-142-424-294	Sequence 294, App
713	27	67.5	915	14	US-10-142-761-294	Sequence 294, App
714	27	67.5	915	14	US-10-142-763-294	Sequence 294, App
715	27	67.5	915	14	US-10-142-765-294	Sequence 294, App
716	27	67.5	915	14	US-10-142-887-294	Sequence 294, App
717	27	67.5	915	14	US-10-142-888-294	Sequence 294, App
718	27	67.5	915	14	US-10-143-034-294	Sequence 294, App
719	27	67.5	915	14	US-10-143-116-294	Sequence 294, App
720	27	67.5	915	14	US-10-144-957-294	Sequence 294, App
721	27	67.5	915	14	US-10-144-992-294	Sequence 294, App
722	27	67.5	915	14	US-10-145-015-294	Sequence 294, App
723	27	67.5	915	14	US-10-145-090-294	Sequence 294, App
724	27	67.5	915	14	US-10-145-091-294	Sequence 294, App
725	27	67.5	915	14	US-10-145-629-294	Sequence 294, App
726	27	67.5	915	14	US-10-145-630-294	Sequence 294, App
727	27	67.5	915	14	US-10-145-747-294	Sequence 294, App
728	27	67.5	915	14	US-10-145-752-294	Sequence 294, App
729	27	67.5	915	14	US-10-145-754-294	Sequence 294, App
730	27	67.5	915	14	US-10-145-755-294	Sequence 294, App
731	27	67.5	915	14	US-10-145-818-294	Sequence 294, App
732	27	67.5	915	14	US-10-145-820-294	Sequence 294, App
733	27	67.5	915	14	US-10-145-872-294	Sequence 294, App
734	27	67.5	915	14	US-10-145-873-294	Sequence 294, App
735	27	67.5	915	14	US-10-147-481-294	Sequence 294, App
736	27	67.5	915	14	US-10-147-482-294	Sequence 294, App
737	27	67.5	915	14	US-10-147-503-294	Sequence 294, App
738	27	67.5	915	14	US-10-147-522-294	Sequence 294, App
739	27	67.5	915	14	US-10-152-401-294	Sequence 294, App
740	27	67.5	915	14	US-10-157-783-294	Sequence 294, App

741	27	67.5	915	14	US-10-158-792-294	Sequence 294, App
742	27	67.5	915	14	US-10-158-462-294	Sequence 294, App
743	27	67.5	915	14	US-10-143-035-294	Sequence 294, App
744	27	67.5	915	14	US-10-145-751-294	Sequence 294, App
745	27	67.5	915	14	US-10-145-822-294	Sequence 294, App
746	27	67.5	915	14	US-10-145-824-294	Sequence 294, App
747	27	67.5	915	14	US-10-145-827-294	Sequence 294, App
748	27	67.5	915	14	US-10-145-869-294	Sequence 294, App
749	27	67.5	915	14	US-10-145-875-294	Sequence 294, App
750	27	67.5	915	14	US-10-145-877-294	Sequence 294, App
751	27	67.5	915	14	US-10-145-958-294	Sequence 294, App
752	27	67.5	915	14	US-10-146-787-294	Sequence 294, App
753	27	67.5	915	14	US-10-146-790-294	Sequence 294, App
754	27	67.5	915	14	US-10-146-793-294	Sequence 294, App
755	27	67.5	915	14	US-10-147-480-294	Sequence 294, App
756	27	67.5	915	14	US-10-147-485-294	Sequence 294, App
757	27	67.5	915	14	US-10-147-486-294	Sequence 294, App
758	27	67.5	915	14	US-10-147-487-294	Séquence 294, App
759	27	67.5	915	14	US-10-147-490-294	Sequence 294, App
760	27	67.5	915	14	US-10-147-494-294	Sequence 294, App
761	27	67.5	915	14	US-10-147-498-294	Sequence 294, App
762	27	67.5	915	14	US-10-147-514-294	Sequence 294, App
763	27	67.5	915	14	US-10-147-524-294	Sequence 294, App
764	27	67.5	915	14	US-10-152-379-294	Sequence 294, App
765	27	67.5	915	14	US-10-152-394-294	Sequence 294, App
766	27	67.5	915	14	US-10-152-406-294	Sequence 294, App
767	27	67.5	915	14	US-10-156-847-294	Sequence 294, App
768	27	67.5	915	14	US-10-157-778-294	Sequence 294, App
769	27	67.5	915	14	US-10-157-799-294	Sequence 294, App
770	27	67.5	915	14	US-10-160-504-294	Sequence 294, App
771	27	67.5	915	14	US-10-145-634-294	Sequence 294, App
772	27	67.5	915	14	US-10-147-520-294	Sequence 294, App
773	27	67.5	915	14	US-10-157-781-294	Sequence 294, App
774	27	67.5	915	14	US-10-176-989-294	Sequence 294, App
775	27	67.5	915	14	US-10-147-491-294	Sequence 294, App
776	27	67.5	915	14	US-10-152-378-294	Sequence 294, App
777	27	67.5	915	14	US-10-152-382-294	Sequence 294, App
778	27	67.5	915	14	US-10-152-383-294	Sequence 294, App
779	27	67.5	915	14	US-10-152-384-294	Sequence 294, App
780	27	67.5	915	14	US-10-152-387-294	Sequence 294, App
781	27	67.5	915	14	US-10-152-389-294	Sequence 294, App
782	27	67.5	915	14	US-10-152-390-294	Sequence 294, App
783	27	67.5	915	14	US-10-152-392-294	Sequence 294, App
784	27	67.5	915	14	US-10-153-756-294	Sequence 294, App
785	27	67.5	915	14	US-10-157-784-294	Sequence 294, App
786	27	67.5	915	14	US-10-157-797-294	Sequence 294, App
787	27	67.5	915	14	US-10-158-491-294	Sequence 294, App
788	27	67.5	915	14	US-10-299-976-34	Sequence 34, Appl
789	27	67.5	915	14	US-10-142-762-294	Sequence 294, App
790	27	67.5	915	14	US-10-142-764-294	Sequence 294, App
791	27	67.5	915	14	US-10-142-766-294	Sequence 294, App
792	27	67.5	915	14	US-10-145-625-294	Sequence 294, App
793	27	67.5	915	14	US-10-145-627-294	Sequence 294, App
794	27	67.5	915	14	US-10-145-960-294	Sequence 294, App
795	27	67.5	915	14	US-10-145-962-294	Sequence 294, App
796	27	67.5	915	14	US-10-146-789-294	Sequence 294, App
797	27	67.5	915	14	US-10-147-483-294	Sequence 294, App

798	27	67.5	915	14	US-10-147-496-294	Sequence 294, App
799	27	67.5	915	14	US-10-147-505-294	Sequence 294, App
800	27	67.5	915	14	US-10-147-516-294	Sequence 294, App
801	27	67.5	915	14	US-10-152-398-294	Sequence 294, App
802	27	67.5	915	14	US-10-139-980-294	Sequence 294, App
803	27	67.5	915	14	US-10-299-937-34	Sequence 34, Appl
804	27	67.5	915	14	US-10-145-750-294	Sequence 294, App
805	27	67.5	915	14	US-10-152-373-294	Sequence 294, App
806	27	67.5	915	14	US-10-121-044-294	Sequence 294, App
807	27	67.5	915	14	US-10-121-055-294	Sequence 294, App
808	27	67.5	915	14	US-10-121-057-294	Sequence 294, App
809	27	67.5	915	14	US-10-121-058-294	Sequence 294, App
810	27	67.5	915	14	US-10-121-059-294	Sequence 294, App
811	27	67.5	915	14	US-10-121-060-294	Sequence 294, App
812	27	67.5	915	14	US-10-123-109-294	Sequence 294, App
813	27	67.5	915	14	US-10-123-154-294	Sequence 294, App
814	27	67.5	915	14	US-10-123-157-294	Sequence 294, App
815	27	67.5	915	14	US-10-123-906-294	Sequence 294, App
816	27	67.5	915	14	US-10-124-814-294	Sequence 294, App
817	27	67.5	915	14	US-10-124-816-294	Sequence 294, App
818	27	67.5	915	14	US-10-124-820-294	Sequence 294, App
819	27	67.5	915	14	US-10-125-704-294	Sequence 294, App
820	27	67.5	915	14	US-10-125-927-294	Sequence 294, App
821	27	67.5	915	14	US-10-142-889-294	Sequence 294, App
822	27	67.5	915	14	US-10-145-874-294	Sequence 294, App
823	27	67.5	915	14	US-10-147-497-294	Sequence 294, App
824	27	67.5	915	14	US-10-152-371-294	Sequence 294, App
825	27	67.5	915	14	US-10-152-374-294	Sequence 294, App
826	27	67.5	915	14	US-10-152-375-294	Sequence 294, App
827	27	67.5	915	14	US-10-152-377-294	Sequence 294, App
828	27	67.5	915	14	US-10-152-386-294	Sequence 294, App
829	27	67.5	915	14	US-10-152-391-294	Sequence 294, App
830	27	67.5	915	14	US-10-152-399-294	Sequence 294, App
831	27	67.5	915	14	US-10-156-848-294	Sequence 294, App
832	27	67.5	915	14	US-10-157-785-294	Sequence 294, App
833	27	67.5	915	14	US-10-157-794-294	Sequence 294, App
834	27	67.5	915	14	US-10-157-796-294	Sequence 294, App
835	27	67.5	915	14	US-10-160-500-294	Sequence 294, App
836	27	67.5	915	14	US-10-121-046-294	Sequence 294, App
837	27	67.5	915	14	US-10-123-156-294	Sequence 294, App
838	27	67.5	915	14	US-10-123-214-294	Sequence 294, App
839	27	67.5	915	14	US-10-125-805-294	Sequence 294, App
840	27	67.5	915	14	US-10-124-821-294	Sequence 294, App
841	27	67.5	915	14	US-10-152-385-294	Sequence 294, App
842	27	67.5	915	14	US-10-152-393-294	Sequence 294, App
843	27	67.5	915	14	US-10-152-396-294	Sequence 294, App
844	27	67.5	915	14	US-10-153-552-294	Sequence 294, App
845	27	67.5	915	14	US-10-153-840-294	Sequence 294, App
846	27	67.5	915	14	US-10-156-841-294	Sequence 294, App
847	27	67.5	915	14	US-10-156-842-294	Sequence 294, App
848	27	67.5	915	14	US-10-156-844-294	Sequence 294, App
849	27	67.5	915	14	US-10-156-845-294	Sequence 294, App
850	27	67.5	915	14	US-10-156-846-294	Sequence 294, App
851	27	67.5	915	14	US-10-121-048-294	Sequence 294, App
852	27	67.5	915	14	US-10-121-052-294	Sequence 294, App
853	27	67.5	915	14	US-10-121-053-294	Sequence 294, App
854	27	67.5	915	14	US-10-121-054-294	Sequence 294, App

855	27	67.5	915	14	US-10-121-063-294	Sequence 294, App
856	27	67.5	915	14	US-10-123-212-294	Sequence 294, App
857	27	67.5	915	14	US-10-123-213-294	Sequence 294, App
858	27	67.5	915	14	US-10-123-291-294	Sequence 294, App
859	27	67.5	915	14	US-10-123-322-294	Sequence 294, App
860	27	67.5	915	14	US-10-123-771-294	Sequence 294, App
861	27	67.5	915	14	US-10-123-911-294	Sequence 294, App
862	27	67.5	915	14	US-10-124-823-294	Sequence 294, App
863	27	67.5	915	14	US-10-125-931-294	Sequence 294, App
864	27	67.5	915	14	US-10-125-932-294	Sequence 294, App
865	27	67.5	915	15	US-10-123-913-294	Sequence 294, App
866	27	67.5	915	15	US-10-140-473-294	Sequence 294, App
867	27	67.5	915	15	US-10-140-806-294	Sequence 294, App
868	27	67.5	915	15	US-10-140-810-294	Sequence 294, App
869	27	67.5	915	15	US-10-140-863-294	Sequence 294, App
870	27	67.5	915	15	US-10-141-699-294	Sequence 294, App
871	27	67.5	915	15	US-10-141-703-294	Sequence 294, App
872	27	67.5	915	15	US-10-141-706-294	Sequence 294, App
873	27	67.5	915	15	US-10-141-757-294	Sequence 294, App
874	27	67.5	915	15	US-10-141-762-294	Sequence 294, App
875	27	67.5	915	15	US-10-142-428-294	Sequence 294, App
876	27	67.5	915	15	US-10-142-429-294	Sequence 294, App
877	27	67.5	915	15	US-10-142-884-294	Sequence 294, App
878	27	67.5	915	15	US-10-143-027-294	Sequence 294, App
879	27	67.5	915	15	US-10-143-115-294	Sequence 294, App
880	27	67.5	915	15	US-10-144-956-294	Sequence 294, App
881	27	67.5	915	15	US-10-144-958-294	Sequence 294, App
882	27	67.5	915	15	US-10-145-632-294	Sequence 294, App
883	27	67.5	915	15	US-10-145-749-294	Sequence 294, App
884	27	67.5	915	15	US-10-145-753-294	Sequence 294, App
885	27	67.5	915	15	US-10-145-871-294	Sequence 294, App
886	27	67.5	915	15	US-10-145-878-294	Sequence 294, App
887	27	67.5	915	15	US-10-146-794-294	Sequence 294, App
888	27	67.5	915	15	US-10-147-489-294	Sequence 294, App
889	27	67.5	915	15	US-10-147-507-294	Sequence 294, App
890	27	67.5	915	15	US-10-147-535-294	Sequence 294, App
891	27	67.5	915	15	US-10-147-537-294	Sequence 294, App
892	27	67.5	915	15	US-10-152-376-294	Sequence 294, App
893	27	67.5	915	15	US-10-152-381-294	Sequence 294, App
894	27	67.5	915	15	US-10-152-400-294	Sequence 294, App
895	27	67.5	915	15	US-10-153-585-294	Sequence 294, App
896	27	67.5	915	15	US-10-157-780-294	Sequence 294, App
897	27	67.5	915	15	US-10-157-800-294	Sequence 294, App
898	27	67.5	915	15	US-10-157-801-294	Sequence 294, App
899	27	67.5	915	15	US-10-157-802-294	Sequence 294, App
900	27	67.5	915	15	US-10-158-784-294	Sequence 294, App
901	27	67.5	915	15	US-10-158-789-294	Sequence 294, App
902	27	67.5	915	15	US-10-192-011-294	Sequence 294, App
903	27	67.5	915	15	US-10-139-963-294	Sequence 294, App
904	27	67.5	915	15	US-10-140-020-294	Sequence 294, App
905	27	67.5	915	15	US-10-140-023-294	Sequence 294, App
906	27	67.5	915	15	US-10-140-809-294	Sequence 294, App
907	27	67.5	915	15	US-10-140-865-294	Sequence 294, App
908	27	67.5	915	15	US-10-141-701-294	Sequence 294, App
909	27	67.5	915	15	US-10-141-754-294	Sequence 294, App
910	27	67.5	915	15	US-10-141-760-294	Sequence 294, App
911	27	67.5	915	15	US-10-142-425-294	Sequence 294, App

912	27	67.5	915	15	US-10-142-430-294	Sequence 294, App
913	27	67.5	915	15	US-10-143-113-294	Sequence 294, App
914	27	67.5	915	15	US-10-146-730-294	Sequence 294, App
915	27	67.5	915	15	US-10-146-792-294	Sequence 294, App
916	27	67.5	915	15	US-10-158-791-294	Sequence 294, App
917	27	67.5	915	15	US-10-156-843-294	Sequence 294, App
918	27	67.5	915	15	US-10-157-786-294	Sequence 294, App
919	27	67.5	915	15	US-10-147-528-294	Sequence 294, App
920	27	67.5	915	15	US-10-449-656-34	Sequence 34, Appl
921	27	67.5	915	15	US-10-448-713-34	Sequence 34, Appl
922	27	67.5	915	15	US-10-128-692A-294	Sequence 294, App
923	27	67.5	915	15	US-10-140-927-294	Sequence 294, App
924	27	67.5	915	16	US-10-425-447-34	Sequence 34, Appl
925	27	67.5	930	9	US-09-815-242-13481	Sequence 13481, A
926	27	67.5	934	11	US-09-833-245-1291	Sequence 1291, Ap
927	27	67.5	937	15	US-10-004-378A-75	Sequence 75, Appl
928	27	67.5	956	15	US-10-004-378A-74	Sequence 74, Appl
929	27	67.5	956	15	US-10-004-378A-76	Sequence 76, Appl
930	27	67.5	956	15	US-10-004-378A-77	Sequence 77, Appl
931	27	67.5	956	15	US-10-231-913-92	Sequence 92, Appl
932	27	67.5	959	13	US-10-000-512-10	Sequence 10, Appl
933	27	67.5	959	15	US-10-074-566-10	Sequence 10, Appl
934	27	67.5	959	15	US-10-004-378A-73	Sequence 73, Appl
935	27	67.5	977	15	US-10-004-378A-14	Sequence 14, Appl
936	27	67.5	1225	15	US-10-158-034-76	Sequence 76, Appl
937	27	67.5	1381	14	US-10-233-131-25	Sequence 25, Appl
938	27	67.5	1381	15	US-10-240-145-77	Sequence 77, Appl
939	27	67.5	1693	15	US-10-603-725-4	Sequence 4, Appli
940	27	67.5	1693	15	US-10-603-725-8	Sequence 8, Appli
941	27	67.5	1694	15	US-10-603-725-12	Sequence 12, Appl
942	27	67.5	1713	14	US-10-171-311-113	Sequence 113, App
943	27	67.5	1713	15	US-10-372-683-10	Sequence 10, Appl
944	27	67.5	1713	15	US-10-603-725-6	Sequence 6, Appli
945	27	67.5	1724	15	US-10-603-725-2	Sequence 2, Appli
946	27	67.5	1725	15	US-10-603-725-10	Sequence 10, Appl
947	27	67.5	1743	15	US-10-460-545-2	Sequence 2, Appli
948	26	65.0	6	9	US-09-867-847-18	Sequence 18, Appl
949	26	65.0	6	9	US-09-867-847-26	Sequence 26, Appl
950	26	65.0	6	9	US-09-867-847-54	Sequence 54, Appl
951	26	65.0	6	9	US-09-867-847-55	Sequence 55, Appl
952	26	65.0	6	10	US-09-747-408-9	Sequence 9, Appli
953	26	65.0	6	10	US-09-747-408-17	Sequence 17, Appl
954	26	65.0	19	10	US-09-916-849A-7	Sequence 7, Appli
955	26	65.0	33	10	US-09-764-891-4206	Sequence 4206, Ap
956	26	65.0	35	9	US-09-972-475-15	Sequence 15, Appl
957	26	65.0	35	15	US-10-463-729-15	Sequence 15, Appl
958	26	65.0	40	14	US-10-029-386-33145	Sequence 33145, A
959	26	65.0	43	9	US-09-972-475-3	Sequence 3, Appli
960	26	65.0	43	15	US-10-463-729-3	Sequence 3, Appli
961	26	65.0	76	9	US-09-864-761-39363	Sequence 39363, A
962	26	65.0	77	14	US-10-029-386-31405	Sequence 31405, A
963	26	65.0	79	9	US-09-864-761-40407	Sequence 40407, A
964	26	65.0	104	15	US-10-264-237-2007	Sequence 2007, Ap
965	26	65.0	120	15	US-10-289-762-1016	Sequence 1016, Ap
966	26	65.0	124	11	US-09-833-245-1200	Sequence 1200, Ap
967	26	65.0	133	9	US-09-738-769A-4	Sequence 4, Appli
968	26	65.0	140	9	US-09-815-242-13616	Sequence 13616, A

969	26	65.0	140	9	US-09-932-702-2	Sequence 2, Appli
970	26	65.0	144	15	US-10-369-493-18373	Sequence 18373, A
971	26	65.0	145	9	US-09-738-626-6364	Sequence 6364, Ap
972	26	65.0	151	11	US-09-764-875-1107	Sequence 1107, Ap
973	26	65.0	155	9	US-09-738-626-6233	Sequence 6233, Ap
974	26	65.0	162	15	US-10-312-273-351	Sequence 351, App
975	26	65.0	166	15	US-10-264-049-3066	Sequence 3066, Ap
976	26	65.0	193	15	US-10-264-237-1673	Sequence 1673, Ap
977	26	65.0	194	16	US-10-389-566-611	Sequence 611, App
978	26	65.0	196	14	US-10-156-761-10750	Sequence 10750, A
979	26	65.0	197	9	US-09-944-277A-11	Sequence 11, Appl
980	26	65.0	197	9	US-09-816-095-5	Sequence 5, Appli
981	26	65.0	218	14	US-10-319-799-21	Sequence 21, Appl
982	26	65.0	219	14	US-10-319-799-18	Sequence 18, Appl
983	26	65.0	219	14	US-10-319-799-20	Sequence 20, Appl
984	26	65.0	223	11	US-09-801-944B-138	Sequence 138, App
985	26	65.0	242	10	US-09-805-354-16	Sequence 16, Appl
986	26	65.0	242	14	US-10-144-259-16	Sequence 16, Appl
987	26	65.0	250	15	US-10-369-493-10777	Sequence 10777, A
988	26	65.0	257	9	US-09-944-277A-2	Sequence 2, Appli
989	26	65.0	257	14	US-10-384-850-45	Sequence 45, Appl
990	26	65.0	264	9	US-09-848-696-4	Sequence 4, Appli
991	26	65.0	276	15	US-10-369-493-10943	Sequence 10943, A
992	26	65.0	276	15	US-10-369-493-12539	Sequence 12539, A
993	26	65.0	291	14	US-10-083-624-2	Sequence 2, Appli
994	26	65.0	299	10	US-09-764-891-4177	Sequence 4177, Ap
995	26	65.0	306	14	US-10-156-761-8651	Sequence 8651, Ap
996	26	65.0	315	15	US-10-369-493-10945	Sequence 10945, A
997	26	65.0	321	15	US-10-407-866-128	Sequence 128, App
998	26	65.0	323	9	US-09-816-095-2	Sequence 2, Appli
999	26	65.0	324	9	US-09-816-095-4	Sequence 4, Appli
1000	26	65.0	326	15	US-10-369-493-18694	Sequence 18694, A

#### ALIGNMENTS

RESULT 1  
 US-10-235-483-1  
; Sequence 1, Application US/10235483  
; Publication No. US20030087407A1  
; GENERAL INFORMATION:  
;     APPLICANT: SOTO-JARA, Claudio  
;                BAUMANN, Marc  
;                FRANGIONE, Blas  
;     TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
;                           COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
; DISEASES  
;                           ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
; AMYLOID-LIKE  
;     DEPOSITS  
;     NUMBER OF SEQUENCES: 69  
;     CORRESPONDENCE ADDRESS:  
;        ADDRESSEE: BROWDY AND NEIMARK  
;        STREET: 419 Seventh Street, N.W., Suite 400  
;        CITY: Washington  
;        STATE: D.C.

; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/235,483  
; FILING DATE: 06-Sep-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 8 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:  
US-10-235-483-1

Query Match 100.0%; Score 40; DB 14; Length 8;  
Best Local Similarity 100.0%; Pred. No. 7.1e+05;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 1 KLVFFAED 8

RESULT 2  
US-09-899-815-2  
; Sequence 2, Application US/09899815  
; Patent No. US20020162129A1  
; GENERAL INFORMATION:  
; APPLICANT: LANNFELT, Lars  
; TITLE OF INVENTION: PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE  
; FILE REFERENCE: LANNFELT=1A  
; CURRENT APPLICATION NUMBER: US/09/899,815  
; CURRENT FILING DATE: 2001-07-09  
; PRIOR APPLICATION NUMBER: US 60/217,098  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: EP 00202387.7

; PRIOR FILING DATE: 2000-07-07  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 2  
; LENGTH: 9  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic peptide (16-24 of SEQ ID NO:1)  
US-09-899-815-2

Query Match 100.0%; Score 40; DB 9; Length 9;  
Best Local Similarity 100.0%; Pred. No. 7.1e+05;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 1 KLVFFAED 8

RESULT 3  
US-10-235-483-64  
; Sequence 64, Application US/10235483  
; Publication No. US20030087407A1  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; BAUMANN, Marc  
; FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/235,483  
; FILING DATE: 06-Sep-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; APPLICATION NUMBER: US 08/478,326

; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 64:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 9 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 64:  
US-10-235-483-64

Query Match 100.0%; Score 40; DB 14; Length 9;  
Best Local Similarity 100.0%; Pred. No. 7.1e+05;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 2 KLVFFAED 9

RESULT 4

US-09-988-842-9

; Sequence 9, Application US/09988842  
; Patent No. US20020143105A1  
; GENERAL INFORMATION:  
; APPLICANT: Johansson, Jan  
; TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION  
; TITLE OF INVENTION: OF AMYLOID FORMATION  
; FILE REFERENCE: 12125-002001  
; CURRENT APPLICATION NUMBER: US/09/988,842  
; CURRENT FILING DATE: 2001-11-19  
; PRIOR APPLICATION NUMBER: US 60/251,662  
; PRIOR FILING DATE: 2000-12-06  
; PRIOR APPLICATION NUMBER: US 60/253,695  
; PRIOR FILING DATE: 2000-11-20  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 9  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetically generated peptide  
US-09-988-842-9

Query Match 100.0%; Score 40; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 0.059;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8

Db           |||||||  
2 KLVFFAED 9

RESULT 5  
US-09-988-842-25  
; Sequence 25, Application US/09988842  
; Patent No. US20020143105A1  
; GENERAL INFORMATION:  
; APPLICANT: Johansson, Jan  
; TITLE OF INVENTION: DISCORDANT HELIX STABILIZATION FOR PREVENTION  
; TITLE OF INVENTION: OF AMYLOID FORMATION  
; FILE REFERENCE: 12125-002001  
; CURRENT APPLICATION NUMBER: US/09/988,842  
; CURRENT FILING DATE: 2001-11-19  
; PRIOR APPLICATION NUMBER: US 60/251,662  
; PRIOR FILING DATE: 2000-12-06  
; PRIOR APPLICATION NUMBER: US 60/253,695  
; PRIOR FILING DATE: 2000-11-20  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 25  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetically generated peptide  
US-09-988-842-25

Query Match                 100.0%; Score 40; DB 9; Length 11;  
Best Local Similarity    100.0%; Pred. No. 0.059;  
Matches    8; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

QY           1 KLVFFAED 8  
            |||||||  
Db           2 KLVFFAED 9

RESULT 6  
US-10-235-483-14  
; Sequence 14, Application US/10235483  
; Publication No. US20030087407A1  
; GENERAL INFORMATION:  
;           APPLICANT: SOTO-JARA, Claudio  
;           BAUMANN, Marc  
;           FRANGIONE, Blas  
;           TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
;           COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
;           ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
;           DEPOSITS  
;           NUMBER OF SEQUENCES: 69  
;           CORRESPONDENCE ADDRESS:  
;           ADDRESSEE: BROWDY AND NEIMARK  
;           STREET: 419 Seventh Street, N.W., Suite 400  
;           CITY: Washington

; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/235,483  
; FILING DATE: 06-Sep-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:  
US-10-235-483-14

Query Match 100.0%; Score 40; DB 14; Length 11;  
Best Local Similarity 100.0%; Pred. No. 0.059;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | | |  
Db 2 KLVFFAED 9

RESULT 7  
US-10-281-458-1  
; Sequence 1, Application US/10281458  
; Publication No. US20030108978A1  
; GENERAL INFORMATION:  
; APPLICANT: Ciambrone, Gary J.  
; APPLICANT: Gibbons, Ian  
; TITLE OF INVENTION: Whole Cell Assay Systems for Cell  
; TITLE OF INVENTION: Surface Proteases  
; FILE REFERENCE: 50225-8093.US03  
; CURRENT APPLICATION NUMBER: US/10/281,458  
; CURRENT FILING DATE: 2002-10-25

; PRIOR APPLICATION NUMBER: US 60/337,641  
; PRIOR FILING DATE: 2001-10-25  
; PRIOR APPLICATION NUMBER: US 09/924,692  
; PRIOR FILING DATE: 2001-08-08  
; NUMBER OF SEQ ID NOS: 3  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 1  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-281-458-1

Query Match 100.0%; Score 40; DB 14; Length 13;  
Best Local Similarity 100.0%; Pred. No. 0.071;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 6 KLVFFAED 13

RESULT 8  
US-09-992-800-5  
; Sequence 5, Application US/09992800  
; Patent No. US20020102261A1  
; GENERAL INFORMATION:  
; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2006  
; CURRENT APPLICATION NUMBER: US/09/992,800  
; CURRENT FILING DATE: 2001-11-06  
; PRIOR APPLICATION NUMBER: 09/594,366  
; PRIOR FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 5  
; LENGTH: 14  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-992-800-5

Query Match 100.0%; Score 40; DB 9; Length 14;  
Best Local Similarity 100.0%; Pred. No. 0.077;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 4 KLVFFAED 11

RESULT 9  
US-09-992-994-5  
; Sequence 5, Application US/09992994  
; Patent No. US20020136718A1  
; GENERAL INFORMATION:

; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2005  
; CURRENT APPLICATION NUMBER: US/09/992,994  
; CURRENT FILING DATE: 2001-11-06  
; PRIOR APPLICATION NUMBER: 09/594,366  
; PRIOR FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 5  
; LENGTH: 14  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-992-994-5

Query Match 100.0%; Score 40; DB 9; Length 14;  
Best Local Similarity 100.0%; Pred. No. 0.077;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 4 KLVFFAED 11

RESULT 10

US-10-385-065-5

; Sequence 5, Application US/10385065  
; Publication No. US20030235897A1  
; GENERAL INFORMATION:  
; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2004  
; CURRENT APPLICATION NUMBER: US/10/385,065  
; CURRENT FILING DATE: 2003-03-10  
; PRIOR APPLICATION NUMBER: US/09/594,366  
; PRIOR FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 5  
; LENGTH: 14  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-385-065-5

Query Match 100.0%; Score 40; DB 15; Length 14;  
Best Local Similarity 100.0%; Pred. No. 0.077;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 4 KLVFFAED 11

RESULT 11  
US-09-972-475-14  
; Sequence 14, Application US/09972475  
; Patent No. US20020098173A1  
; GENERAL INFORMATION:  
;     APPLICANT: Findeis, Mark A. et al.  
;     TITLE OF INVENTION: Modulators of Amyloid Aggregation  
;     NUMBER OF SEQUENCES: 45  
;     CORRESPONDENCE ADDRESS:  
;         ADDRESSEE: LAHIVE & COCKFIELD, LLP  
;         STREET: 28 State Street  
;         CITY: Boston  
;         STATE: Massachusetts  
;         COUNTRY: USA  
;         ZIP: 02109-1875  
;     COMPUTER READABLE FORM:  
;         MEDIUM TYPE: Floppy disk  
;         COMPUTER: IBM PC compatible  
;         OPERATING SYSTEM: PC-DOS/MS-DOS  
;         SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
;     APPLICATION NUMBER: US/09/972,475  
;     FILING DATE: 04-Oct-2001  
; PRIOR APPLICATION DATA:  
;     APPLICATION NUMBER: 08/617,267  
;     FILING DATE: <Unknown>  
;     APPLICATION NUMBER: USSN 08/475,579  
;     FILING DATE: 07-JUN-1995  
;     APPLICATION NUMBER: USSN 08/548,998  
;     FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
;     NAME: DeConti, Giulio A.  
;     REGISTRATION NUMBER: 31,503  
;     REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
;     TELEPHONE: (617)227-7400  
;     TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
;     LENGTH: 15 amino acids  
;     TYPE: amino acid  
;     TOPOLOGY: linear  
;     MOLECULE TYPE: peptide  
;     FRAGMENT TYPE: internal  
;     SEQUENCE DESCRIPTION: SEQ ID NO: 14:  
US-09-972-475-14  
  
Query Match               100.0%; Score 40; DB 9; Length 15;  
Best Local Similarity   100.0%; Pred. No. 0.082;  
Matches   8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY           1 KLVFFAED 8  
            |||||||  
Db           1 KLVFFAED 8

RESULT 12

US-09-996-357-9  
; Sequence 9, Application US/09996357  
; Patent No. US20020133001A1  
; GENERAL INFORMATION:  
; APPLICANT: Gefter, Malcolm L  
; APPLICANT: Isreal, David I  
; APPLICANT: Joyal, John L  
; APPLICANT: Gosselin, Michael  
; TITLE OF INVENTION: THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR  
; TITLE OF INVENTION: TREATING AN AMYLOIDOGENIC DISEASE  
; FILE REFERENCE: PPI-105  
; CURRENT APPLICATION NUMBER: US/09/996,357  
; CURRENT FILING DATE: 2001-11-27  
; PRIOR APPLICATION NUMBER: 60/253,302  
; PRIOR FILING DATE: 2000-11-27  
; PRIOR APPLICATION NUMBER: 60/250,198  
; PRIOR FILING DATE: 2000-11-29  
; PRIOR APPLICATION NUMBER: 60/257,186  
; PRIOR FILING DATE: 2000-12-20  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 9  
; LENGTH: 15  
; TYPE: PRT  
; ORGANISM: Homo sapiens

US-09-996-357-9

Query Match 100.0%; Score 40; DB 9; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.082;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 1 KLVFFAED 8

RESULT 13  
US-10-235-483-56  
; Sequence 56, Application US/10235483  
; Publication No. US20030087407A1  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; BAUMANN, Marc  
; FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA

; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/235,483  
; FILING DATE: 06-Sep-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 56:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 56:  
US-10-235-483-56

Query Match 100.0%; Score 40; DB 14; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.082;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 5 KLVFFAED 12

RESULT 14  
US-10-235-483-57  
; Sequence 57, Application US/10235483  
; Publication No. US20030087407A1  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; BAUMANN, Marc  
; FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; DEPOSITS

; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/235,483  
; FILING DATE: 06-Sep-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 57:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 57:  
US-10-235-483-57

Query Match 100.0%; Score 40; DB 14; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.082;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
|||  
Db 5 KLVFFAED 12

RESULT 15  
US-10-235-483-58  
; Sequence 58, Application US/10235483  
; Publication No. US20030087407A1  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; BAUMANN, Marc

; FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/235,483  
; FILING DATE: 06-Sep-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 58:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 58:  
US-10-235-483-58

Query Match 100.0%; Score 40; DB 14; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.082;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
Db 5 KLVFFAED 12

RESULT 16  
US-10-235-483-63  
; Sequence 63, Application US/10235483  
; Publication No. US20030087407A1  
; GENERAL INFORMATION:  
; APPLICANT: SOTO-JARA, Claudio  
; BAUMANN, Marc  
; FRANGIONE, Blas  
; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR  
DISEASES  
; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE  
; DEPOSITS  
; NUMBER OF SEQUENCES: 69  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BROWDY AND NEIMARK  
; STREET: 419 Seventh Street, N.W., Suite 400  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/235,483  
; FILING DATE: 06-Sep-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/766,596  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: US 08/630,645  
; FILING DATE: 10-APR-1996  
; APPLICATION NUMBER: US 08/478,326  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: YUN, Allen C.  
; REGISTRATION NUMBER: 37,971  
; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-628-5197  
; TELEFAX: 202-737-3528  
; INFORMATION FOR SEQ ID NO: 63:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 63:  
US-10-235-483-63

Query Match 100.0%; Score 40; DB 14; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.082;

Matches	8;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1	KLVFFAED	8						
Db	5	KLVFFAED	12						

RESULT 17

US-10-235-483-65

; Sequence 65, Application US/10235483

; Publication No. US20030087407A1

; GENERAL INFORMATION:

; APPLICANT: SOTO-JARA, Claudio

; BAUMANN, Marc

; FRANGIONE, Blas

; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL  
; COMPOSITIONS THEREOF FOR TREATMENT OF DISORDERS OR

DISEASES

; ASSOCIATED WITH PROTEIN FOLDING INTO AMYLOID OR  
AMYLOID-LIKE

; DEPOSITS

; NUMBER OF SEQUENCES: 69

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: BROWDY AND NEIMARK

; STREET: 419 Seventh Street, N.W., Suite 400

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20004

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/10/235,483

; FILING DATE: 06-Sep-2002

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/766,596

; FILING DATE: <Unknown>

; APPLICATION NUMBER: US 08/630,645

; FILING DATE: 10-APR-1996

; APPLICATION NUMBER: US 08/478,326

; FILING DATE: 06-JUN-1995

; ATTORNEY/AGENT INFORMATION:

; NAME: YUN, Allen C.

; REGISTRATION NUMBER: 37,971

; REFERENCE/DOCKET NUMBER: SOTO-JARA=1A

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 202-628-5197

; TELEFAX: 202-737-3528

; INFORMATION FOR SEQ ID NO: 65:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; SEQUENCE DESCRIPTION: SEQ ID NO: 65:  
US-10-235-483-65

Query Match 100.0%; Score 40; DB 14; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.082;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 5 KLVFFAED 12

RESULT 18  
US-10-463-729-14  
; Sequence 14, Application US/10463729  
; Publication No. US20040005307A1  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/463,729  
; FILING DATE: 17-JUNE-2003  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/617,267C  
; FILING DATE: 14-MAR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 14:

; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal

US-10-463-729-14

Query Match 100.0%; Score 40; DB 15; Length 15;  
Best Local Similarity 100.0%; Pred. No. 0.082;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 1 KLVFFAED 8

RESULT 19

US-09-992-800-3

; Sequence 3, Application US/09992800  
; Patent No. US20020102261A1  
; GENERAL INFORMATION:  
; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2006  
; CURRENT APPLICATION NUMBER: US/09/992,800  
; CURRENT FILING DATE: 2001-11-06  
; PRIOR APPLICATION NUMBER: 09/594,366  
; PRIOR FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 3  
; LENGTH: 17  
; TYPE: PRT  
; ORGANISM: Homo sapiens

US-09-992-800-3

Query Match 100.0%; Score 40; DB 9; Length 17;  
Best Local Similarity 100.0%; Pred. No. 0.094;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 8 KLVFFAED 15

RESULT 20

US-09-992-994-3

; Sequence 3, Application US/09992994  
; Patent No. US20020136718A1  
; GENERAL INFORMATION:  
; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2005  
; CURRENT APPLICATION NUMBER: US/09/992,994

; CURRENT FILING DATE: 2001-11-06  
; PRIOR APPLICATION NUMBER: 09/594,366  
; PRIOR FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 3  
; LENGTH: 17  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-992-994-3

Query Match 100.0%; Score 40; DB 9; Length 17;  
Best Local Similarity 100.0%; Pred. No. 0.094;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 8 KLVFFAED 15

RESULT 21

US-09-998-491-8

; Sequence 8, Application US/09998491  
; Publication No. US20030166529A1  
; GENERAL INFORMATION:  
; APPLICANT: Mileusnic, Radmilla  
; APPLICANT: Rose, Stephen Peter Russell  
; TITLE OF INVENTION: Polypeptides and their Uses  
; FILE REFERENCE: 3578-120  
; CURRENT APPLICATION NUMBER: US/09/998,491  
; CURRENT FILING DATE: 2001-11-30  
; PRIOR APPLICATION NUMBER: GB 0109558.7  
; PRIOR FILING DATE: 2001-04-18  
; PRIOR APPLICATION NUMBER: GB 0120084  
; PRIOR FILING DATE: 2001-08-07  
; NUMBER OF SEQ ID NOS: 11  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 8  
; LENGTH: 17  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: 17-mer polypeptide  
US-09-998-491-8

Query Match 100.0%; Score 40; DB 10; Length 17;  
Best Local Similarity 100.0%; Pred. No. 0.094;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 5 KLVFFAED 12

RESULT 22

US-10-385-065-3  
; Sequence 3, Application US/10385065  
; Publication No. US20030235897A1  
; GENERAL INFORMATION:  
; APPLICANT: Raso, Victor  
; TITLE OF INVENTION: IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
; FILE REFERENCE: BBRI-2004  
; CURRENT APPLICATION NUMBER: US/10/385,065  
; CURRENT FILING DATE: 2003-03-10  
; PRIOR APPLICATION NUMBER: US/09/594,366  
; PRIOR FILING DATE: 2000-06-15  
; PRIOR APPLICATION NUMBER: 60/139,408  
; PRIOR FILING DATE: 1999-06-16  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 3  
; LENGTH: 17  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-385-065-3

Query Match 100.0%; Score 40; DB 15; Length 17;  
Best Local Similarity 100.0%; Pred. No. 0.094;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 KLVFFAED 8  
| | | | | | |  
Db 8 KLVFFAED 15

RESULT 23  
US-09-825-242-5  
; Sequence 5, Application US/09825242  
; Publication No. US20030092000A1  
; GENERAL INFORMATION:  
; APPLICANT: Schenk, Dale B.  
; APPLICANT: Neuralab Limited  
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease  
; FILE REFERENCE: 15270J-004720US  
; CURRENT APPLICATION NUMBER: US/09/825,242  
; CURRENT FILING DATE: 2001-04-02  
; PRIOR APPLICATION NUMBER: 09/201,430  
; PRIOR FILING DATE: 1998-11-30  
; PRIOR APPLICATION NUMBER: US 60/080,970  
; PRIOR FILING DATE: 1998-04-07  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 19  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28  
; OTHER INFORMATION: peptide with carboxyl terminal Cys residue  
; OTHER INFORMATION: inserted and two added Gly residues  
; NAME/KEY: MOD\_RES  
; LOCATION: (1)

; OTHER INFORMATION: Xaa = acetyl histidine  
US-09-825-242-5

Query Match 100.0%; Score 40; DB 10; Length 19;  
Best Local Similarity 100.0%; Pred. No. 0.11;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 4 KLVFFAED 11

RESULT 24

US-09-792-079-11

; Sequence 11, Application US/09792079  
; Publication No. US20030083277A1  
; GENERAL INFORMATION:  
; APPLICANT: University of Kentucky Research Foundation  
; APPLICANT: Hersh, Louis B.  
; APPLICANT: Mukherjee, Atish  
; TITLE OF INVENTION: Use Of Insulin Degrading Enzyme (IDE) For The Treatment  
Of Alzheimer's  
; TITLE OF INVENTION: Disease Patients  
; FILE REFERENCE: 050229-0261  
; CURRENT APPLICATION NUMBER: US/09/792,079  
; CURRENT FILING DATE: 2001-02-26  
; PRIOR APPLICATION NUMBER: 60/184,826  
; PRIOR FILING DATE: 2000-02-24  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 11  
; LENGTH: 26  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-792-079-11

Query Match 100.0%; Score 40; DB 10; Length 26;  
Best Local Similarity 100.0%; Pred. No. 0.15;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | | |  
Db 2 KLVFFAED 9

RESULT 25

US-10-159-279-11

; Sequence 11, Application US/10159279  
; Publication No. US20030165481A1  
; GENERAL INFORMATION:  
; APPLICANT: University of Kentucky Research Foundation  
; APPLICANT: Hersh, Louis B.  
; APPLICANT: Mukherjee, Atish  
; TITLE OF INVENTION: Use Of Insulin Degrading Enzyme (IDE) For The Treatment  
Of Alzheimer's  
; TITLE OF INVENTION: Disease Patients  
; FILE REFERENCE: 050229-0298

; CURRENT APPLICATION NUMBER: US/10/159,279  
; CURRENT FILING DATE: 2002-06-03  
; PRIOR APPLICATION NUMBER: 60/184,826  
; PRIOR FILING DATE: 2000-02-24  
; PRIOR APPLICATION NUMBER: 09/792,079  
; PRIOR FILING DATE: 2001-02-26  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 11  
; LENGTH: 26  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-159-279-11

Query Match 100.0%; Score 40; DB 14; Length 26;  
Best Local Similarity 100.0%; Pred. No. 0.15;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 2 KLVFFAED 9

#### RESULT 26

US-09-867-847-4

; Sequence 4, Application US/09867847  
; Patent No. US20020094335A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xianqi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; TITLE OF INVENTION: AND AMYLOID RELATED DISEASES  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847  
; CURRENT FILING DATE: 2001-09-20  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: 09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; NUMBER OF SEQ ID NOS: 65  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 28  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
; OTHER INFORMATION: or peptidomimetics  
US-09-867-847-4

Query Match 100.0%; Score 40; DB 9; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.16;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8

Db 16 KLVFFAED 23  
|||||||

RESULT 27  
US-09-865-294-66  
; Sequence 66, Application US/09865294  
; Publication No. US20030068325A1  
; GENERAL INFORMATION:  
; APPLICANT: Wang, Chang Yi  
; TITLE OF INVENTION: Immunogenic peptide composition as vaccines for the  
; prevention and treatment of Alzheimer's Disease  
; FILE REFERENCE: 1151-4167  
; CURRENT APPLICATION NUMBER: US/09/865,294  
; CURRENT FILING DATE: 2001-05-25  
; NUMBER OF SEQ ID NOS: 76  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 66  
; LENGTH: 28  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-865-294-66

Query Match 100.0%; Score 40; DB 10; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.16;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
Db 16 KLVFFAED 23  
|||||||

RESULT 28  
US-09-792-079-5  
; Sequence 5, Application US/09792079  
; Publication No. US20030083277A1  
; GENERAL INFORMATION:  
; APPLICANT: University of Kentucky Research Foundation  
; APPLICANT: Hersh, Louis B.  
; APPLICANT: Mukherjee, Atish  
; TITLE OF INVENTION: Use Of Insulin Degrading Enzyme (IDE) For The Treatment  
Of Alzheimer's  
; TITLE OF INVENTION: Disease Patients  
; FILE REFERENCE: 050229-0261  
; CURRENT APPLICATION NUMBER: US/09/792,079  
; CURRENT FILING DATE: 2001-02-26  
; PRIOR APPLICATION NUMBER: 60/184,826  
; PRIOR FILING DATE: 2000-02-24  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 5  
; LENGTH: 28  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-792-079-5

Query Match 100.0%; Score 40; DB 10; Length 28;

Best Local Similarity 100.0%; Pred. No. 0.16;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 29  
US-10-159-279-5  
; Sequence 5, Application US/10159279  
; Publication No. US20030165481A1  
; GENERAL INFORMATION:  
; APPLICANT: University of Kentucky Research Foundation  
; APPLICANT: Hersh, Louis B.  
; APPLICANT: Mukherjee, Atish  
; TITLE OF INVENTION: Use Of Insulin Degrading Enzyme (IDE) For The Treatment  
Of Alzheimer's  
; TITLE OF INVENTION: Disease Patients  
; FILE REFERENCE: 050229-0298  
; CURRENT APPLICATION NUMBER: US/10/159,279  
; CURRENT FILING DATE: 2002-06-03  
; PRIOR APPLICATION NUMBER: 60/184,826  
; PRIOR FILING DATE: 2000-02-24  
; PRIOR APPLICATION NUMBER: 09/792,079  
; PRIOR FILING DATE: 2001-02-26  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 5  
; LENGTH: 28  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-159-279-5

Query Match 100.0%; Score 40; DB 14; Length 28;  
Best Local Similarity 100.0%; Pred. No. 0.16;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 30  
US-09-861-847-1  
; Sequence 1, Application US/09861847  
; Patent No. US20020077288A1  
; GENERAL INFORMATION:  
; APPLICANT: FRANGIONE, Blas  
; APPLICANT: WISNIEWSKI, Thomas  
; APPLICANT: SIGURDSSON, Einar  
; TITLE OF INVENTION: SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES  
HOMOLOGOUS TO  
; TITLE OF INVENTION: AMYLOID BETA FOR INDUCTION OF AN IMMUNE RESPONSE TO  
AMYLOID BETA AND  
; TITLE OF INVENTION: AMYLOID DEPOSITS  
; FILE REFERENCE: FRANGIONE=2A

; CURRENT APPLICATION NUMBER: US/09/861,847  
; CURRENT FILING DATE: 2001-05-22  
; PRIOR APPLICATION NUMBER: 60/016,233  
; PRIOR FILING DATE: 2000-05-22  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1  
; LENGTH: 30  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-861-847-1

Query Match 100.0%; Score 40; DB 9; Length 30;  
Best Local Similarity 100.0%; Pred. No. 0.17;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | | |  
Db 16 KLVFFAED 23

RESULT 31  
US-10-301-488A-1  
; Sequence 1, Application US/10301488A  
; Publication No. US20030166558A1  
; GENERAL INFORMATION:  
; APPLICANT: FRANGIONE, Blas  
; APPLICANT: WISNIEWSKI, Thomas  
; APPLICANT: SIGURDSSON, Einar  
; TITLE OF INVENTION: SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING  
POLYPEPTIDES AND  
; TITLE OF INVENTION: PEPTIDES HOMOLOGOUS TO AMYLOID BETA, PRION PROTEIN,  
AMYLIN,  
; TITLE OF INVENTION: ALPHA-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION  
OF AN  
; TITLE OF INVENTION: IMMUNE RESPONSE THERETO  
; FILE REFERENCE: 5986/1K434US1  
; CURRENT APPLICATION NUMBER: US/10/301,488A  
; CURRENT FILING DATE: 2002-11-21  
; PRIOR APPLICATION NUMBER: US 60/331,801  
; PRIOR FILING DATE: 2001-11-21  
; NUMBER OF SEQ ID NOS: 55  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1  
; LENGTH: 30  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-301-488A-1

Query Match 100.0%; Score 40; DB 14; Length 30;  
Best Local Similarity 100.0%; Pred. No. 0.17;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy            1 KLVFFAED 8  
              |||||||  
Db            16 KLVFFAED 23

RESULT 32  
US-09-930-915A-295  
; Sequence 295, Application US/09930915A  
; Publication No. US20030138769A1  
; GENERAL INFORMATION:  
; APPLICANT: Birkett, Ashley J.  
; TITLE OF INVENTION: IMMUNOGENIC HBC CHIMER PARTICLES HAVING ENHANCED  
; TITLE OF INVENTION: STABILITY  
; FILE REFERENCE: 4564/83501 ICC-102.2 PCT  
; CURRENT APPLICATION NUMBER: US/09/930,915A  
; CURRENT FILING DATE: 2001-08-15  
; PRIOR APPLICATION NUMBER: 60/226,867  
; PRIOR FILING DATE: 2000-08-22  
; PRIOR APPLICATION NUMBER: 60/225,843  
; PRIOR FILING DATE: 2000-08-16  
; NUMBER OF SEQ ID NOS: 313  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 295  
; LENGTH: 33  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-930-915A-295

Query Match            100.0%; Score 40; DB 10; Length 33;  
Best Local Similarity    100.0%; Pred. No. 0.19;  
Matches    8; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy            1 KLVFFAED 8  
              |||||||  
Db            16 KLVFFAED 23

RESULT 33  
US-10-082-014-84  
; Sequence 84, Application US/10082014  
; Publication No. US20030185858A1  
; GENERAL INFORMATION:  
; APPLICANT: Birkett, Ashley J.  
; TITLE OF INVENTION: IMMUNOGENIC HBC CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE  
; FILE REFERENCE: ICC-130.0 4564/85124  
; CURRENT APPLICATION NUMBER: US/10/082,014  
; CURRENT FILING DATE: 2002-02-22  
; PRIOR APPLICATION NUMBER: 09/930,915  
; PRIOR FILING DATE: 2001-08-15  
; NUMBER OF SEQ ID NOS: 290  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 84  
; LENGTH: 33  
; TYPE: PRT  
; ORGANISM: Alzheimer's disease b-Amyloid  
US-10-082-014-84

Query Match 100.0%; Score 40; DB 14; Length 33;  
Best Local Similarity 100.0%; Pred. No. 0.19;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 34  
US-10-372-076-85  
; Sequence 85, Application US/10372076  
; Publication No. US20030198645A1  
; GENERAL INFORMATION:  
; APPLICANT: Page, Mark  
; APPLICANT: Friede, Martin  
; TITLE OF INVENTION: STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR  
; TITLE OF INVENTION: CHRONIC HEPATITIS  
; FILE REFERENCE: 4564/87179  
; CURRENT APPLICATION NUMBER: US/10/372,076  
; CURRENT FILING DATE: 2003-02-21  
; PRIOR APPLICATION NUMBER: 10/080,299  
; PRIOR FILING DATE: 2002-02-21  
; PRIOR APPLICATION NUMBER: 10/082,014  
; PRIOR FILING DATE: 2002-02-22  
; NUMBER OF SEQ ID NOS: 308  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 85  
; LENGTH: 33  
; TYPE: PRT  
; ORGANISM: Alzheimer's disease b-Amyloid  
US-10-372-076-85

Query Match 100.0%; Score 40; DB 14; Length 33;  
Best Local Similarity 100.0%; Pred. No. 0.19;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 35  
US-09-867-847-3  
; Sequence 3, Application US/09867847  
; Patent No. US20020094335A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xianqi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; TITLE OF INVENTION: AND AMYLOID RELATED DISEASES  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847

; CURRENT FILING DATE: 2001-09-20  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: 09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; NUMBER OF SEQ ID NOS: 65  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 3  
; LENGTH: 35  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides  
; OTHER INFORMATION: or peptidomimetics  
US-09-867-847-3

Query Match 100.0%; Score 40; DB 9; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.2;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 36

US-09-972-475-16

; Sequence 16, Application US/09972475  
; Patent No. US20020098173A1  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/972,475  
; FILING DATE: 04-Oct-2001  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/617,267  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.

; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:  
US-09-972-475-16

Query Match 100.0%; Score 40; DB 9; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.2;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KLVFFAED 8  
| | | | | |  
Db 11 KLVFFAED 18

RESULT 37  
US-10-463-729-16  
; Sequence 16, Application US/10463729  
; Publication No. US20040005307A1  
; GENERAL INFORMATION:  
; APPLICANT: Findeis, Mark A. et al.  
; TITLE OF INVENTION: Modulators of Amyloid Aggregation  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD, LLP  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1875  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/463,729  
; FILING DATE: 17-JUNE-2003  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/617,267C  
; FILING DATE: 14-MAR-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/404,831  
; FILING DATE: 14-MAR-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: USSN 08/475,579  
; FILING DATE: 07-JUN-1995  
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: USSN 08/548,998  
; FILING DATE: 27-OCT-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DeConti, Giulio A.  
; REGISTRATION NUMBER: 31,503  
; REFERENCE/DOCKET NUMBER: PPI-002CP2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)227-5941  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
US-10-463-729-16

Query Match 100.0%; Score 40; DB 15; Length 35;  
Best Local Similarity 100.0%; Pred. No. 0.2;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
      |||||||  
Db 11 KLVFFAED 18

RESULT 38  
US-09-861-847-6  
; Sequence 6, Application US/09861847  
; Patent No. US20020077288A1  
; GENERAL INFORMATION:  
; APPLICANT: FRANGIONE, Blas  
; APPLICANT: WISNIEWSKI, Thomas  
; APPLICANT: SIGURDSSON, Einar  
; TITLE OF INVENTION: SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES  
HOMOLOGOUS TO  
; TITLE OF INVENTION: AMYLOID BETA FOR INDUCTION OF AN IMMUNE RESPONSE TO  
AMYLOID BETA AND  
; TITLE OF INVENTION: AMYLOID DEPOSITS  
; FILE REFERENCE: FRANGIONE=2A  
; CURRENT APPLICATION NUMBER: US/09/861,847  
; CURRENT FILING DATE: 2001-05-22  
; PRIOR APPLICATION NUMBER: 60/016,233  
; PRIOR FILING DATE: 2000-05-22  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6  
; LENGTH: 36  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
; NAME/KEY: misc\_feature  
; OTHER INFORMATION: C-terminal residue 36 may be amidated.  
US-09-861-847-6

Query Match 100.0%; Score 40; DB 9; Length 36;  
Best Local Similarity 100.0%; Pred. No. 0.21;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 22 KLVFFAED 29

RESULT 39

US-09-861-847-11

; Sequence 11, Application US/09861847  
; Patent No. US20020077288A1  
; GENERAL INFORMATION:  
; APPLICANT: FRANGIONE, Blas  
; APPLICANT: WISNIEWSKI, Thomas  
; APPLICANT: SIGURDSSON, Einar  
; TITLE OF INVENTION: SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES  
HOMOLOGOUS TO  
; TITLE OF INVENTION: AMYLOID BETA FOR INDUCTION OF AN IMMUNE RESPONSE TO  
AMYLOID BETA AND  
; TITLE OF INVENTION: AMYLOID DEPOSITS  
; FILE REFERENCE: FRANGIONE=2A  
; CURRENT APPLICATION NUMBER: US/09/861,847  
; CURRENT FILING DATE: 2001-05-22  
; PRIOR APPLICATION NUMBER: 60/016,233  
; PRIOR FILING DATE: 2000-05-22  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 11  
; LENGTH: 36  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic

US-09-861-847-11

Query Match 100.0%; Score 40; DB 9; Length 36;  
Best Local Similarity 100.0%; Pred. No. 0.21;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
|||||||  
Db 16 KLVFFAED 23

RESULT 40

US-10-301-488A-6

; Sequence 6, Application US/10301488A  
; Publication No. US20030166558A1  
; GENERAL INFORMATION:  
; APPLICANT: FRANGIONE, Blas  
; APPLICANT: WISNIEWSKI, Thomas  
; APPLICANT: SIGURDSSON, Einar  
; TITLE OF INVENTION: SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING  
POLYPEPTIDES AND

; TITLE OF INVENTION: PEPTIDES HOMOLOGOUS TO AMYLOID BETA, PRION PROTEIN,  
AMYLIN,  
; TITLE OF INVENTION: ALPHA-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION  
OF AN  
; TITLE OF INVENTION: IMMUNE RESPONSE THERETO  
; FILE REFERENCE: 5986/1K434US1  
; CURRENT APPLICATION NUMBER: US/10/301,488A  
; CURRENT FILING DATE: 2002-11-21  
; PRIOR APPLICATION NUMBER: US 60/331,801  
; PRIOR FILING DATE: 2001-11-21  
; NUMBER OF SEQ ID NOS: 55  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 6  
; LENGTH: 36  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
; FEATURE:  
; NAME/KEY: misc\_feature  
; OTHER INFORMATION: C-terminal residue 36 may be amidated.  
US-10-301-488A-6

Query Match 100.0%; Score 40; DB 14; Length 36;  
Best Local Similarity 100.0%; Pred. No. 0.21;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 KLVFFAED 8  
| | | | | | |  
Db 22 KLVFFAED 29

RESULT 41  
US-10-301-488A-11  
; Sequence 11, Application US/10301488A  
; Publication No. US20030166558A1  
; GENERAL INFORMATION:  
; APPLICANT: FRANGIONE, Blas  
; APPLICANT: WISNIEWSKI, Thomas  
; APPLICANT: SIGURDSSON, Einar  
; TITLE OF INVENTION: SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING  
POLYPEPTIDES AND  
; TITLE OF INVENTION: PEPTIDES HOMOLOGOUS TO AMYLOID BETA, PRION PROTEIN,  
AMYLIN,  
; TITLE OF INVENTION: ALPHA-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION  
OF AN  
; TITLE OF INVENTION: IMMUNE RESPONSE THERETO  
; FILE REFERENCE: 5986/1K434US1  
; CURRENT APPLICATION NUMBER: US/10/301,488A  
; CURRENT FILING DATE: 2002-11-21  
; PRIOR APPLICATION NUMBER: US 60/331,801  
; PRIOR FILING DATE: 2001-11-21  
; NUMBER OF SEQ ID NOS: 55  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 11  
; LENGTH: 36  
; TYPE: PRT

; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-301-488A-11

Query Match 100.0%; Score 40; DB 14; Length 36;  
Best Local Similarity 100.0%; Pred. No. 0.21;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KLVFFAED 8  
| | | | |  
Db 16 KLVFFAED 23

RESULT 42  
US-10-051-496-5  
; Sequence 5, Application US/10051496  
; Publication No. US20020182660A1  
; GENERAL INFORMATION:  
; APPLICANT: Kei-Lai L. Fong  
; TITLE OF INVENTION: N- and C-Terminus Specific Immunoassays for  
Full Length Beta-Amyloid Peptide - Abeta(1-40),  
Abeta(1-39),  
Abeta(1-41), Abeta(1-42) and Abeta (1-43)  
; NUMBER OF SEQUENCES: 5  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Kei-Lai L. Fong  
; STREET: 1004 West 8th Avenue  
; CITY: King of Prussia  
; STATE: Pennsylvania  
; COUNTRY: USA  
; ZIP: 19406  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.50 inch, 1.44MB storage  
; COMPUTER: IBM PC Compatibles  
; OPERATING SYSTEM: Windows  
; SOFTWARE: MS No. US20020182660Alepad  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/051,496  
; FILING DATE: 18-Jan-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/784,854A  
; FILING DATE: 16-Feb-2001  
; APPLICATION NUMBER: 60/183,407  
; FILING DATE: 18-February-2000  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Koenig, C. Frederick III  
; REGISTRATION NUMBER: 29,662  
; REFERENCE/DOCKET NUMBER: PBI-PT001.1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (215) 568-6400  
; TELEFAX: (215) 568-6499  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 39 Amino Acid  
; TYPE: Amino Acid

;           TOPOLOGY: Linear  
;           MOLECULE TYPE: Protein  
;  
;           FEATURE:  
;            NAME/KEY:   Signal Sequence  
;            LOCATION:   1-39  
;            IDENTIFICATION METHOD:   Similarity to other sequences, hydro-  
phobic  
;  
;           OTHER INFORMATION:  
;           PUBLICATION INFORMATION:  
;            AUTHORS:  
;            TITLE:  
;            JOURNAL:  
;            VOLUME:  
;            ISSUE:  
;            PAGES:  
;            DATE:  
;            RELEVANT RESIDUES IN SEQ ID NO:   5:FROM 1-39  
;           SEQUENCE DESCRIPTION: SEQ ID NO: 5:  
US-10-051-496-5

Query Match               100.0%; Score 40; DB 13; Length 39;  
Best Local Similarity   100.0%; Pred. No. 0.23;  
Matches   8; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy            1 KLVFFAED 8  
              |||||||  
Db            16 KLVFFAED 23

RESULT 43

US-10-190-548A-5

; Sequence 5, Application US/10190548A  
; Publication No. US20030109435A1  
; GENERAL INFORMATION:  
; APPLICANT: Griswold Prenner, Irene  
; APPLICANT: Wright, Sarah  
; APPLICANT: Yednock, Theodore  
; APPLICANT: Rydel, Russell  
; TITLE OF INVENTION: Methods of Inhibiting Amyloid Toxicity  
; FILE REFERENCE: 08576.0030-00  
; CURRENT APPLICATION NUMBER: US/10/190,548A  
; CURRENT FILING DATE: 2002-12-09  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 5  
; LENGTH: 39  
; TYPE: PRT  
; ORGANISM: homo sapiens  
US-10-190-548A-5

Query Match               100.0%; Score 40; DB 14; Length 39;  
Best Local Similarity   100.0%; Pred. No. 0.23;  
Matches   8; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy            1 KLVFFAED 8  
              |||||||  
Db            16 KLVFFAED 23

RESULT 44  
US-09-861-847-7  
; Sequence 7, Application US/09861847  
; Patent No. US20020077288A1  
; GENERAL INFORMATION:  
; APPLICANT: FRANGIONE, Blas  
; APPLICANT: WISNIEWSKI, Thomas  
; APPLICANT: SIGURDSSON, Einar  
; TITLE OF INVENTION: SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES  
HOMOLOGOUS TO  
; TITLE OF INVENTION: AMYLOID BETA FOR INDUCTION OF AN IMMUNE RESPONSE TO  
AMYLOID BETA AND  
; TITLE OF INVENTION: AMYLOID DEPOSITS  
; FILE REFERENCE: FRANGIONE=2A  
; CURRENT APPLICATION NUMBER: US/09/861,847  
; CURRENT FILING DATE: 2001-05-22  
; PRIOR APPLICATION NUMBER: 60/016,233  
; PRIOR FILING DATE: 2000-05-22  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 7  
; LENGTH: 40  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
; NAME/KEY: misc\_feature  
; OTHER INFORMATION: Amino acid residues 1-6 can either be absent or present  
as Lys or  
; OTHER INFORMATION: Asp to form, in combination with residues 7-10, a N-  
terminal  
; OTHER INFORMATION: polylysine or polyaspartate segment of 4-10 residues in  
length.  
; NAME/KEY: misc\_feature  
; OTHER INFORMATION: The C-terminal Ala residue may be amidated.  
US-09-861-847-7

Query Match 100.0%; Score 40; DB 9; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.23;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 KLVFFAED 8  
| | | | | | | |  
Db 26 KLVFFAED 33

RESULT 45  
US-09-861-847-8  
; Sequence 8, Application US/09861847  
; Patent No. US20020077288A1  
; GENERAL INFORMATION:  
; APPLICANT: FRANGIONE, Blas  
; APPLICANT: WISNIEWSKI, Thomas  
; APPLICANT: SIGURDSSON, Einar

; TITLE OF INVENTION: SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES  
HOMOLOGOUS TO  
; TITLE OF INVENTION: AMYLOID BETA FOR INDUCTION OF AN IMMUNE RESPONSE TO  
AMYLOID BETA AND  
; TITLE OF INVENTION: AMYLOID DEPOSITS  
; FILE REFERENCE: FRANGIONE=2A  
; CURRENT APPLICATION NUMBER: US/09/861,847  
; CURRENT FILING DATE: 2001-05-22  
; PRIOR APPLICATION NUMBER: 60/016,233  
; PRIOR FILING DATE: 2000-05-22  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 8  
; LENGTH: 40  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
; NAME/KEY: misc\_feature  
; OTHER INFORMATION: Amino acid residues 35-40 can either be absent or present  
as Lys  
; OTHER INFORMATION: or Asp to form, in combination with residues 31-34, a C-  
terminal  
; OTHER INFORMATION: polylysine or polyaspartate segment of 4-10 residues in  
length.  
US-09-861-847-8

Query Match 100.0%; Score 40; DB 9; Length 40;  
Best Local Similarity 100.0%; Pred. No. 0.23;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 1 KLVFFAED 8  
| | | | | | | |  
Db 16 KLVFFAED 23

#### RESULT 46

US-09-867-847-2

; Sequence 2, Application US/09867847  
; Patent No. US20020094335A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalifour, Robert  
; APPLICANT: Hebert, Lise  
; APPLICANT: Kong, Xianqi  
; APPLICANT: Gervais, Francine  
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S  
; TITLE OF INVENTION: AND AMYLOID RELATED DISEASES  
; FILE REFERENCE: 14445-501 CIP  
; CURRENT APPLICATION NUMBER: US/09/867,847  
; CURRENT FILING DATE: 2001-09-20  
; PRIOR APPLICATION NUMBER: 60/168,594  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: 09/724,842  
; PRIOR FILING DATE: 2000-11-28  
; NUMBER OF SEQ ID NOS: 65  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2